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People with type 2 diabetes mellitus (T2DM) have normal to high bone mineral 
densities, but counterintuitively have greater fracture risks than people without T2DM, 
even after accounting for potential confounders like BMI and falls. Therefore, T2DM 
may alter aspects of the quality of bone, independently of bone mass, through 
metabolic or biochemical mechanisms as a result of a T2DM disease state. The main 
objective of this research was to elucidate the material factors that increase fragility in 
T2DM by characterizing the material properties, microarchitecture, and mechanics of 
bone from subjects with and without T2DM. The tissue material properties of bone 
from two clinical populations and from a rodent model of T2DM were evaluated, and 
the microarchitecture and and mechanics were evaluated for one of the clinical 
populations. In the rodent model of T2DM, mice with T2DM had more mineralized 
tissue, more mature collagen, and less heterogenous mineral properties compared to 
non-DM littermate controls, all of which are consistent with an older tissue that has 
undergone less remodeling. Tissue properties of the iliac crest from post-menopausal 
women varied with different stages of glycemic control, from normal glucose 
tolerance, impaired glucose tolerance, and overt T2DM. Glycemic derangement was 
associated with increased mineralization, decreased collagen maturity, and atypical 
 mineral maturation, all of which can alter the mechanics of bone. Finally, femoral 
neck cancellous bone from men with T2DM had increased mineralization, a less 
mature mineral, more numerous trabeculae, and greater accumulation of non-
enzymatically-formed collagen crosslinks compared to men without T2DM. The 
mechanical properties of the T2DM specimens reflected these alterations: stiffness and 
strength were greater in the T2DM specimens because of the greater mineral content 
and improved microarchitecture. Regression modeling of post-yield toughness 
demonstrated a significant deleterious impact of mineral maturity and non-enzymatic 
crosslinks once the improvement in microarchitecture was mathematically accounted 
for. Together, these results indicate a beneficial effect of T2DM on cancellous 
microarchitecture, but a deleterious effect of T2DM on the collagen matrix and 
mineral maturation. In conclusion, this work aids in the understanding of how bone 
becomes more fragile with T2DM, and this work is clinically relevant because it 
demonstrates that different populations of T2DM patients may have distinctly 
different bone fragilities as a result of varying tissue composition and 
microarchitecture. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 T2DM and Fracture Risk 
Diabetes mellitus is an increasingly prevalent disease, and each year the economic and 
healthcare burden of diabetes grows. According to the Center of Disease Control’s 
2017 statistics, 12% of Americans have diabetes and the prevalence increases to 25% 
for Americans over the age of 65. Of people with diabetes, 90-95% have type 2 
diabetes mellitus (T2DM), which is also known as adult-onset diabetes or non-insulin 
dependent diabetes.(1) People with T2DM, on average, have twice the medical 
expenditures per year as those without T2DM(1) and a 10 year shorter expected 
lifespan.(2) Cardiovascular disease is responsible for ~70% of T2DM-related mortality, 
and other serious health complications that are common include stroke, retinopathy, 
nephropathy, renal disease, cardiovascular disease, extremity numbness, and loss of 
limb.(1,3)  
In addition to these complications, people with T2DM also have an increased 
risk of bone fracture compared to people without T2DM,(4–7) which can have devasting 
consequences for life expectancy and risk of future fractures.(8,9) A recent retrospective 
study showed that one-year survival probability was just 68% for people with T2DM 
versus 87% for people without T2DM.(9) The higher fracture incidence for people with 
T2DM is well-established;(4–7) however, the underlying causes for T2DM-related 
fragility fractures are not fully understood. 
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One of the main confounding factors is that people with T2DM have normal to 
high bone mineral density (BMD) measured by bone densitometry (DEXA),(10–12) 
which is typically associated with reduced fragility fracture risk. For a given BMD, 
however, people with T2DM have a greater fracture risk than those without T2DM.(7) 
The 10-year hip fracture risk for both men and women is greater for those with T2DM 
compared to those without T2DM, regardless of BMD, and the risk increases further 
for those with T2DM on insulin (Figure 1.1-1).  
 
 
 
Figure 1.1-1: 10-Year hip fracture risk versus femoral neck BMD T-score for women 
(left) and men (right) without T2DM, with T2DM and non on insulin treatment, and 
with T2DM and on insulin treatment. Figure credit: adapted from Schwartz, A. V. et 
al. JAMA. (2011).  
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The greater fracture risk for people with T2DM that is not fully accounted by 
the quantity of bone (i.e., BMD) indicates that other factors influence bone fragility. 
These other factors are collectively referred to as bone quality and include tissue 
material properties, microarchitecture, and accumulation of microdamage (Figure 
1.1-2).  
Figure 1.1-2: Bone quality is the summation of other factors that influence bone's 
ability to resist fracture that are not bone mass.  
 4 
 
 T2DM can alter tissue material properties and architecture by several 
mechanisms, including 1) hyperglycemia, 2) hyperinsulinemia, and 3) oxidative stress. 
Hyperglycemia, the condition of having elevated blood sugar, is hypothesized to affect 
bone in two main ways. The first is through disruption and suppression of bone 
remodeling processes, and the second is through the formation and accumulation of 
advanced glycation endproducts (AGEs). In contrast to hyperglycemia, insulin is an 
anabolic agent, and hyperinsulinemia is hypothesized to be, in part, responsible for the 
greater BMD observed in people with T2DM.(13) Oxidative stress, which is the 
imbalance of reactive oxygen species and antioxidants,(14) is hypothesized to be the 
pathogenic factor that leads to T2DM, first by causing insulin resistance and β-cell 
disfunction, then by impairing glucose tolerance.(15) Similar to hyperglycemia, 
oxidative stress can lead to the accumulation of AGEs, and it has also been implicated 
in vascular tissue damage associated with T2DM.(15) The extent to which the 
deleterious effects on bone of hyperglycemia and oxidative stress are balanced by the 
beneficial effects on bone of hyperinsulinemia is unknown, and it is possible that the 
effects vary with T2DM severity.  
Changes in bone quality with T2DM as a result of hyperglycemia, 
hyperinsulinemia, or oxidative stress are believed to manifest first at the molecular 
level in bone.(16–18) The hierarchical structure of bone enables these molecular changes 
to subsequently affect macroscopic mechanical properties.  
1.2 Bone Quality and the Hierarchical Composite Structure of Bone 
Bone is a hierarchical composite structure comprised of imperfect hydroxyapatite 
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(HA), type 1 collagen, water, and non-collagenous proteins that aggregate into a 
vascularized network.(19) The organic matrix is laid down first, then it undergoes 
mineralization. Because bone is a hierarchical structure, small changes at the 
molecular-level can have drastic effects at larger length scales. Moreover, because 
bone is a composite structure, macroscale changes may be a result of bone quality 
alterations in the organic matrix or in the inorganic mineral. Figure 1.2-1 shows the 
hierarchical organization of bone and its constituent organic and inorganic materials.  
 
 
Bone is ~30 wt% organic matrix, 90% of which is type 1 collagen.(20) The 
organic matrix has highly ordered secondary and tertiary structures that are governed 
by the alignment of collagen molecules. Osteoblasts secrete tropocollagen, a right-
handed triple helical molecule around 300 nm in length and 1.6 nm in diameter 
(Figure 1.2-2Error! Reference source not found.).(21,22) Approximately one-third of 
Figure 1.2-1: The hierarchical structure of bone from its constituent materials at the 
nanoscale (right) to the whole bone at the macroscale (left). Figure credit: adapted 
from Hunt, H. B. et al. Clin. Rev. Bone. Miner. Metab. (2016). 
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the amino acids in type 1 collagen are glycine, which allows the individual collagen 
chains to compactly align and hydrogen bond within the helix; one-sixth of the amino 
acids are either proline or hydroxyproline; and the remaining residues are naturally 
occurring amino acids such as lysine and arginine, which are particularly important in 
post-translational processes that assemble higher level structures.(20,23,24)  
 
Figure 1.2-2: Triple helix structure of collagen molecule (left), staggered array of 
collagen molecules (right). Figure credit: adapted from Streeter, I. et al. Soft Matter. 
(2011). 
 
 
Post-translational modifications to the osteoblast-secreted collagen molecules 
stabilize bone’s organic matrix by chemically crosslinking adjacent molecules. 
Crosslink formation is initialized at the non-helical termini via enzymatic reactions of 
lysyl oxidase with telopeptide lysine and hydroxylysine residues (Lys and Hyl). First, 
lysyl oxidase deaminates the residues of Lys or Hyl producing allysine or 
hydroxyallysine, then two nearby allysine or hydroxyallysine residues undergo a 
condensation reaction that connects the two collagen molecules together with a 
divalent crosslink.(20) Over time, the divalent crosslink that connects the telopeptide 
ends of two collagen molecules matures into a trivalent crosslink by reacting with the 
helical portion of a third collagen molecule. The locations of the residues in immature 
 7 
 
divalent and mature trivalent crosslinks are highly controlled and occur at specific 
amino acid sequences.(20) 
 The enzymatically controlled crosslinking described above allows for higher-
ordered assembly of the organic matrix. Specifically, five collagen molecules arrange 
into fibrils that consist of a quarter-staggered array with a D-period of 67 nm (Figure 
1.2-2), and these fibrils further assemble into larger fibers. The 67 nm D-period is 
maintained, such that gap channels occur throughout a fiber.(20,21,25)  
In addition to enzymatic crosslinks that further stabilize the collagen matrix, 
non-enzymatic crosslinking can also occur. Non-enzymatic glycation (NEG), also 
known as the Maillard reaction, is the reaction of an amino group with a sugar (e.g., 
glucose, ribose).(26) The reaction between an amino group (typically on Lys or Arg) 
and a sugar and an creates a Schiff base, which then undergoes spontaneous Amadori 
rearrangement to a more stable ketosamine. Finally, a dehydration of the ketosamine 
into reductones or to other short-chain hydrolytic fission products produces AGEs 
(Figure 1.2-3).(16,27)  
AGEs manifest as additional crosslinks in the collagen matrix; however, unlike 
the formation of enzymatic crosslinks, the location and number of AGEs are not 
controlled. It is therefore possible for AGEs to form between two adjacent collagen 
molecules or within a single collagen molecule;(28) however, it is currently unknown if 
AGEs can take the place of enzymatic crosslinks. In addition, there are hundreds of 
different AGEs, which complicates understanding of how they function and form.(26)  
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Mineralization of the organic matrix begins in the gap regions of fibrils 
approximately 5-10 days after the secretion of the matrix by osteoblasts.(29) The 
mineral in bone is nominally HA, which has the chemical formula Ca₁₀(PO₄)₆(OH)₂; 
however, biologic HA is non-stoichiometric and poorly crystalline. As a result of its 
large surface area, biological HA easily incorporates other ions like Mg2+, Na+, F-, and 
CO3
2- that are present in the surrounding extracellular fluid.(30) 
HA is nucleated in an apatitic core located in the gap regions of the quarter-
staggered collagen and along the fibrils. A hydration layer surrounds the apatitic core 
and allows for the necessary ion exchange for crystals to grow and mature.(30) Once 
the crystal reaches its final size, typically 95% of the theoretical maximum for the 
space in the collagen matrix, the hydration layer diminishes leaving just the HA. The 
resulting HA crystals are platelet-shaped (1-7 nm thick, 10-80 nm wide, and 15-200 
Figure 1.2-3: States of the non-enzymatic glycation reaction, or Maillard reaction. 
Note: The triple helix collagen molecules are not drawn to scale. CML = 
carboxymethllysine. Figure credit: adapted from Oliveira, E. J. Bras. Patol. e Med. 
Lab. (2013). 
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nm long) and arrange themselves parallel to one other with their crystallographic c-
axis aligned with the collagen’s longitudinal direction.(30) 
As bundles of fibrils join to create fibers, the structural organization of the 
tissue at this level is either lamellar or woven bone. Lamellar bone is the predominant 
structure in mature bone, and it is characterized by highly ordered layers, or lamellae, 
of bone approximately 3 μm thick.(31) The fibers within a lamellae have a primary 
orientation, but the orientation from one layer to the next.(31–33) Unlike lamellar bone, 
woven bone is poorly oriented and can be loosely packed.(32) Woven bone can be laid 
down very quickly and, consequently, is found in fracture callouses and embryonic 
bone.(31)  
 Lamellar bone comprises the cortical and cancellous structures from the micro-
scale up to the millimeter-scale. In cortical bone, the lamellae have a cylindrical motif 
that surrounds osteons. In cancellous bone, the lamellae are organized in “packets” 
that layer into a porous network.(32) Cortical bone is more dense and is found along the 
outer surfaces of bones, while cancellous bone is has large, marrow-filled cavities and 
is found at the ends of long bones and in the center of vertebrae.(32)  
1.3 Microarchitecture, Remodeling, and Microdamage 
The microarchitectures of cortical and cancellous differ in terms of organization and 
porosity. Cortical bone is characterized by average cortical thickness, cortical porosity, 
cross-sectional area, and cortical area fraction.(34) Cancellous bone, on the other hand, 
is characterized by bone volume fraction, trabecular thickness, trabecular separation, 
 10 
 
trabecular number, degree of anisotropy, connective density, and plate-like or rod-
like.(34)  
 The microarchitecture of bone is highly influenced by the extent of 
remodeling, the process of old bone being replaced with new bone.(35) During 
remodeling, old, damaged tissue is removed by osteoclasts, and then bone-forming 
cells called osteoblasts are recruited to lay down the organic matrix (Figure 1.3-1).(36)  
 
Bone is constantly remodeling, and the adult skeleton turnover rate can reach 
10% each year.(37) A mismatch in bone resorption and bone formation rates within the 
remodeling process can lead to bone loss. For example, incomplete refilling of cavities 
that have been resorbed by osteoclasts leads to net bone loss over time.(35) Moreover, 
bone loss over time can change the structure of cancellous bone from plate-like to rod-
Figure 1.3-1: The cells and features of the bone remodeling process. Figure credit: 
Seeman et al. N. Engl. J. Med. (2006). 
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like, which will affect the mechanical behavior of the tissue.(38,39) 
Formation of microdamage catalyzes the remodeling process. Specifically, 
when the osteocyte network within bone tissue is damaged and osteocyte apoptosis 
occurs, osteoclast resorption is signaled and quickly begins at the damage location.(40) 
Microdamage accumulates in both the cortical and cancellous compartments 
with age.(41) Two main types of damage have been identified: crack-like and 
diffuse.(42) Crack-like damage indicates less energy needed to propagate a crack and is 
consistent with a more brittle material. Diffuse-like damage, on the other hand, is 
consistent with a more ductile material.(42)  
1.4 Bone Quality and its Relation to Mechanical Performance 
Bone fracture is inherently a biomechanical event;(43) therefore, the importance of 
bone quality measures (i.e., tissue material properties, microarchitecture, 
microdamage) lies in the ability of these measures to explain the mechanical 
performance of bone.  
 Bone derives its strength and stiffness from the inorganic mineral and its 
toughness and plasticity from the surrounding organic matrix.(44–46) Thus, alterations in 
the organic matrix can manifest differently than alterations in the mineral. Inhibiting 
the formation of mature enzymatic crosslinks from immature crosslink in rats resulted 
in a decrease in energy to failure, but did not change the stiffness.(47) Conversely, 
vitamin D deficient rats had reduced tissue mineral content, which corresponded to a 
reduction in stiffness and strength, yet there were minimal changes to the collagen.(48) 
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In addition to the degree of mineralization of bone, the extent of ion 
substitution, size variation, and heterogeneity of the mineral have specific implications 
for the functionality of the bone. In osteoporosis and aging, both of which are 
associated with a high fracture risk, crystal size is greater and the distribution width of 
crystal sizes is more narrow.(49) Larger than optimal crystals are hypothesized to affect 
bone’s ability to respond to a load; however, these parameters have not yet been 
directly correlated. Moreover, the less heterogeneous crystallinity is hypothesized to 
decrease the fracture resistance of bone.(49)  
 The accumulation of AGEs is implicated for the decreased fracture resistance 
in aged bone as well as with T2DM.(50–52) Greater accumulation of tissue AGEs in 
bone from subjects with T2DM compared to controls has been reported,(53,54) and in 
general, more AGE crosslinks within the collagen matrix leads to a stronger, stiffer 
bone.(55) Just as with increased mineral content, the increase in stiffness and strength 
due to AGE accumulation can come at the cost bone’s overall toughness.(44–46)  
1.5 Current Status of Research/Literature Review 
The effects of T2DM on bone have been studied in animal models,(53,56,57) in vitro,(58–
61) in cross-sectional studies,(62–68) in vivo,(67) and recently ex vivo in a clinical 
population of patients with osteoarthritis undergoing total hip arthroplasty.(69) While 
all contribute to the understanding of the effects of T2DM on bone as a whole, 
dissimilar methods make the results of each study difficult to compare. Moreover, no 
direct link between alterations in bone quality and decreased mechanical performance 
has been formed. 
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 Animal models of T2DM point to an accumulation of AGEs, altered collagen 
crosslink profiles, and reduced energy absorption capabilities compared to 
controls.(53,56,70) In a rodent model for T2DM, the T2DM rats became diabetic around 
12 months of age which coincided with a decrease in energy absorption and maximum 
load and an increase in the AGE pentosidine in the T2DM rats versus age-matched 
controls (Figure 1.5-1: Fasting blood glucose (upper left), pentosidine (lower left), 
Figure 1.5-1: Fasting blood glucose (upper left), pentosidine (lower left), energy 
absorption (upper right), and maximum load (lower right) for T2DM WBN/kob rats 
versus Wistar controls. * indicates p < 0.05. Figure credit: adapted from Saito et al. 
Osteoporo. Int. (2006). 
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energy absorption (upper right), and maximum load (lower right) for T2DM 
WBN/kob rats versus Wistar controls. * indicates p < 0.05. Figure credit: adapted 
from Saito et al. Osteoporo. Int. (2006).Figure 1.5-1). 
In vitro studies provide the bulk of evidence of AGE accumulation and altered 
remodeling processes in hyperglycemic conditions. Incubating human and bovine 
tissue in highly concentrated ribose and glucose solutions (at least 100x greater than 
physiologic conditions) have been used to study aging and T2DM, albeit much 
accelerated system. These studies demonstrated that AGE accumulation in cancellous 
and cortical bone and that tissue with higher AGE content was associated with 
decreased energy absorption capabilities.(58–61) Additionally, in vitro studies in AGE-
modified collagen compared to non-AGE modified collagen report decreased 
osteoblast proliferation and differentiation(71–73) and decreased osteoclast 
differentiation,(74) which all point to a decrease in bone turnover.  
In cross-sectional studies of people with and without T2DM, people with 
T2DM had lower bone formation markers(62–67) and bone resorption markers than 
those without T2DM, (65–67) and these findings were corroborated by 
histomorphometric analyses.(68)  
To date, only one in vivo study has been conducted in people with and without 
T2DM. Using a handheld microindentation instrument known as an OsteoProbe 
Reference Point Indenter (RPI), the researchers indented tibial bone with a known 
force and correlated the displacement of the probe tip with a calibration block of 
plastic to calculate a bone material strength index (BMSi). Men and women with 
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T2DM had greater BMSi compared to those without T2DM, and the BMSi was 
inversely correlated with 10-year HbA1c.(67) The indentation distance of the 
OsteoProbe has not been validated with standard mechanical testing outcomes, thus 
how these results relate to stiffness, strength, and toughness is unknown.(75) Despite 
this limitation, this study demonstrates that worsening glycemic control is associated 
with mechanical performance at the tissue-level. 
A recent ex vivo study that used explants of femoral head tissue from people 
with and without T2DM undergoing total hip arthroplasty analyzed serum AGEs, 
fluorescent tissue AGEs, microarchitecture, and mechanical performance.(69) The 
microarchitecture of the cortical and cancellous tissue used in this study did not differ 
between groups, nor did tissue fluorescent AGEs. Creep indentation distance 
measured with cyclic RPI in cortical tissue was greater in the T2DM group compared 
to the non-DM group, but no differences in stiffness, strength, or post-yield properties 
were observed in cancellous bone.(69) The lack of difference in mechanical properties 
between groups was likely due to the similarities of microarchitecture between the 
groups, especially in the cancellous tissue where mechanical performance is 
dominated by BV/TV. Moreover, the characterization of tissue material properties was 
limited in this study to fluorescent AGEs, so insight into how T2DM affects the 
organic and inorganic constituents of bone is incomplete. Nevertheless, this study adds 
to the understanding of bone composition, microarchitecture, and mechanics in people 
with T2DM.  
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1.6 Research Objectives 
The objective of this work was to characterize the tissue material properties, 
microarchitecture, and mechanical performance of tissue from subjects with and 
without T2DM. The main hypothesis is that the presence of excess glucose in the 
blood due to hyperglycemia will alter bone’s structure and composition which will in 
turn deleteriously affect mechanical performance. 
The contributions of this work to the broader understanding of T2DM and 
bone fragility are: 1) this work elucidates the material factors that increase fragility in 
T2DM through the characterization of material properties, microarchitecture, and 
mechanics of type 2 diabetic bone compared to non-diabetic bone, and 2) this work 
relates the observed material changes to the pathophysiology of T2DM. 
1.7 Dissertation Overview and Organization 
Chapter 1, the Introduction, details the greater fracture risk in people with T2DM 
compared to those without T2DM, which motivates the bulk of this dissertation. The 
proposed mechanisms for how T2DM can change bone quality are briefly described. 
The constituent materials that make bone a composite material and the complex 
hierarchical structure of bone that spans several length scales are discussed in detail, 
and how these features can affect bone mechanical performance is also considered. A 
brief summary of the current state of relevant literature is given, followed by a 
statement of research objectives for this work. 
Chapter 2 covers techniques available to study bone quality from geometric, 
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compositional, and mechanical frameworks. Many of the techniques described are 
utilized in subsequent chapters. This chapter was published as the following paper:(76) 
Hunt, H. B. & Donnelly, E. Bone Quality Assessment Techniques: Geometric, 
Compositional, and Mechanical Characterization from Macroscale to 
Nanoscale. Clin. Rev. Bone Miner. Metab. 14, 133–149 (2016). 
Chapter 3 investigates the tissue material properties and AGE content in the KK-Ay 
mouse model of T2DM compared to littermate controls. Fourier transform infrared 
imaging, high-performance liquid chromatography, and fluorescence 
spectrophotometry were used to characterize the tissue material properties. This 
chapter was published as the following paper:(70) 
Hunt, H. B., Pearl, J. C., Diaz, D. R., King, K. B. & Donnelly, E. Bone Tissue 
Collagen Maturity and Mineral Content Increase With Sustained 
Hyperglycemia in the KK-Ay Murine Model of Type 2 Diabetes. J. Bone 
Miner. Res. 33, 921–929 (2017). 
Chapter 4 is a clinical study characterizing the tissue material properties in cortical and 
cancellous tissue from women with varying levels of glucose derangement. Post-
menopausal women were recruited and assigned to the following groups: normal 
glucose tolerance, impaired glucose tolerance, and T2DM. This study is the first to 
capture the intermediate impaired glucose tolerance group. This chapter is the basis for 
the following paper in preparation: 
Hunt, H. B., Miller, N. A., Hemmerling, K.J., Koga, M., Lopez, K. A., 
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Moseley, K. F. & Donnelly, E. Bone tissue composition in post-menopausal 
women varies with glycemic control from normal glucose tolerance to type 2 
diabetes mellitus. J. Bone Miner. Res. (2019). 
Chapter 5 is a clinical study characterizing the tissue material properties, 
microarchitecture, and mechanical performance of cancellous bone from men with and 
without T2DM. This study was the first to characterize the mineral and collagen 
components of tissue from humans with T2DM and the first to report significant 
differences in tissue AGE accumulation in human tissue between humans with and 
without T2DM. This chapter is the basis for the following paper that has been 
submitted and is in review:(77) 
Hunt, H. B. et al. Altered tissue composition, microarchitecture, and 
mechanical performance in cancellous bone from men with type 2 diabetes 
mellitus. J. Bone Miner. Res. (2018). 
Chapter 6 summarizes and discusses the key results of Chapters 2-5 and proposes 
directions for future research.  
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CHAPTER 2 
 
BONE QUALITY ASSESSMENT TECHNIQUES: GEOMETRIC, 
COMPOSITIONAL, AND MECHANICAL CHARACTERIZATION FROM 
MACROSCALE TO NANOSCALE 
 
2.1 Introduction 
Measurements of areal bone mineral density (aBMD) assessed by dual-energy x-ray 
absorptiometry (DEXA) have historically been the standard for fracture risk 
prediction. However, the quantity of bone measured by aBMD incompletely describes 
fracture risk.(1) The ability of bone to resist fracture is influenced by the mass of the 
bone; its spatial distribution, including geometry and microarchitecture; and its 
material properties. Geometric characteristics include macroscopic features such as the 
cross-sectional properties of the whole bone, as well as smaller scale features such as 
the trabecular architecture. Tissue material properties include elastic modulus, 
strength, and fracture toughness, which are influenced by the composition and 
organization of the mineral and matrix components, as well as the presence of 
microdamage. These geometric, compositional, and material factors contribute to the 
“quality” of bone, and by extension to fracture resistance, independently of bone 
quantity. Therefore, for the purpose of this review, we define bone quality as the 
geometric and material factors that contribute to fracture resistance independently of 
aBMD.  
Measurement techniques that evaluate bone quality to supplement DEXA-
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assessed aBMD are sought to improve prediction, and thereby eventual prevention, of 
fragility fractures across diseased and aging populations.(2) However, the ability to 
improve assessment of bone’s resistance to fracture from DEXA-assessed aBMD 
alone is complicated by the fact that the most direct assessment of fracture resistance, 
ex vivo destructive mechanical testing, cannot be performed in vivo. 
This review covers commonly used bone quality measurement techniques, 
with an emphasis on the newest or most recently improved techniques, as well as those 
that are used in vivo. In particular, we compare the methods available for assessment 
of the geometric, compositional, and mechanical properties that contribute to bone 
quality; we detail their outcome measures; and we offer examples of how each 
technique is used currently or can be used in the future. Furthermore, each section is 
organized in descending order of the length scale of each assessment. Figure 2.1-1 
positions each characterization method in terms of bone’s hierarchical structure, and 
Table 2.1-1 summarizes important features of each characterization technique. 
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Figure 2.1-1: The five levels associated with bone quality measurements are depicted 
on a logarithmic scale of the hierarchical structure of bone. Along the top from left to 
right, representative images of bone using the imaging techniques of HRpQCT 
(adapted with permission from (134)), qBEI (adapted with permission from (135)), FTIRI 
of crystallinity (adapted with permission from (136)), and AFM (adapted with 
permission from (137)) are shown. The field of view of the representative images 
corresponds with the scale bar. Along the bottom, each characterization technique is 
categorized as geometric, compositional, or mechanical and is depicted by a bar 
showing the approximate range of resolutions currently achievable. Abbreviations: 
AFM = atomic force microscopy; FTIR = Fourier transform infrared; HPLC = high-
performance liquid chromatography; HRMRI = high-resolution magnetic resonance 
imaging; HRpQCT = high-resolution peripheral quantitative computed tomography; 
Micro-CT = micro-computed tomography; NMR = nuclear magnetic resonance 
imaging; qBEI = quantitative backscattered electron imaging; QCT = quantitative 
computed tomography; RPI = reference point indentation; SAXS = small-angle x-ray 
scattering; SEM = scanning electron microscopy; TGA = thermogravimetric analysis; 
XRD = x-ray diffraction. 
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Table 2.1-1: Summary of important features of each characterization method, categorized by geometric, compositional, or 
mechanical. Geometric and compositional abbreviations: BMD = bone mineral density; BMDD = bone mineral density 
distribution; BV/TV = bone volume fraction; Ct.D = cortical density; Ct.Po = cortical porosity; Ct.Th = cortical thickness; Tb.A = 
trabecular anisotropy; Tb.Conn = trabecular connectivity; Tb.D = trabecular density; Tb.N = trabecular number; Tb.Th = trabecular 
thickness; Tb.Sp = trabecular separation. Mechanical abbreviations: BMSi = bone material strength index; CID = creep indentation 
distance; ID = indentation distance. 
 
 Length 
scale of 
analysis  
Destructive? 
Testing 
environment 
Research 
phase 
Compositional 
component(s) 
evaluated 
Spatially 
resolved?  
Outcome 
variables 
Geometric 
Characterization 
              
Magnetic 
resonance 
imaging 
100's μm 
to m 
No in vivo, ex 
vivo 
Broad 
clinical use 
water Yes BV/TV; 
Tb.D; Tb.Th; 
Tb.Sp; Tb.N; 
Tb.Conn; 
Tb.A; Ct.D; 
Ct.Th; Ct.Po 
Quantitative 
computed 
tomography  
100's μm No in vivo, ex 
vivo 
Broad 
clinical use 
mineral Yes BMD; bone 
geometry; 
Ct.Th 
High-resolution 
peripheral 
quantitative 
computed 
tomography  
10's μm 
to mm 
No in vivo Clinical 
research 
mineral Yes BV/TV; Ct.D; 
Tb.D; Tb.Th; 
Tb.Sp; Tb.N 
Micro-computed 
tomography  
50 nm to 
mm 
No in vivo on 
small 
animals, ex 
Translation
al research 
mineral Yes BV/TV; 
Tb.D; Tb.Th; 
Tb.Sp; Tb.N; 
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vivo Tb.Conn; 
Tb.A; Ct.D; 
Ct.Th; Ct.Po, 
quantification 
of 
microdamage
, osteocyte 
lacunae  
Atomic force 
microscopy 
Å to μm No; polished 
surface 
required 
ex vivo Basic 
research 
mineral, matrix Yes surface 
topology; 
stiffness 
mapping 
X-ray diffraction Å to nm  Yes; 
powdering 
of non-
crystalline 
samples 
ex vivo Basic 
research 
mineral No degree of 
mineralizatio
n; crystal size 
and 
perfection; 
atomic 
spacing 
Small-angle x-ray 
scattering 
Å to nm  No ex vivo Basic 
research 
mineral, matrix Yes crystal shape, 
thickness, 
orientation 
Compositional 
Characterization 
              
Nuclear magnetic 
resonance  
100's μm No in vivo, ex 
vivo 
Basic 
research 
mineral, matrix, 
water 
No BMD; water 
content  
Fourier transform 
infrared 
spectroscopy 
μm to 
mm 
Yes; sample 
homogenizat
ion or 
embedding 
ex vivo Translation
al research 
mineral, matrix Yes mineral:matri
x; 
carbonate:ph
osphate; 
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required collagen 
maturity; 
crystallinity; 
tissue 
maturity 
Raman 
spectroscopy 
μm to 
mm 
No; polished 
surface 
required 
in vivo, ex 
vivo 
Translation
al research 
mineral, matrix Yes mineral:matri
x; 
carbonate:ph
osphate; 
collagen 
maturity; 
crystallinity 
Scanning electron 
microscopy: 
secondary 
electrons  
nm to 
mm 
Yes; 
conductive 
coating 
required 
ex vivo Basic 
research 
mineral, matrix Yes surface 
topology 
Scanning electron 
microscopy: 
quantitative 
backscattered 
electron imaging 
nm to 
mm 
No; polished 
surface 
required 
ex vivo Basic 
research 
mineral Yes BMDD 
High-performance 
liquid 
chromatography 
Å to nm  Yes ex vivo Basic 
research 
matrix No collagen 
crosslinks; 
bone 
turnover 
markers; 
amino acid 
composition 
Thermal 
gravimetric 
Å to nm  Yes ex vivo Basic 
research 
mineral, matrix, 
water 
No ash fraction  
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analysis  
Mechanical 
Characterization 
              
Whole-bone 
testing 
mm to m Yes ex vivo Basic 
research 
mineral, matrix, 
water 
No structural 
stiffness, 
strength, 
toughness 
Apparent-level 
cortical and 
cancellous testing 
μm to 
cm 
Yes ex vivo Basic 
research 
mineral, matrix, 
water 
No apparent-level 
stiffness, 
strength, 
toughness 
Tissue-level 
cortical and 
trabecular testing 
100's μm 
to mm 
Yes ex vivo Basic 
research 
mineral, matrix, 
water 
No tissue-level 
stiffness, 
strength, 
toughness 
Microindentation 100's μm No; polished 
surface 
required 
ex vivo Basic 
research 
mineral, matrix, 
water 
Yes hardness 
Reference point 
indentation 
100's μm No in vivo, ex 
vivo 
Translation
al research 
mineral, matrix, 
water 
Yes BMSi; ID; 
maximum 
force; energy 
dissipation; 
CID; loading 
slope; 
unloading 
slope 
Nanoindentation μm No; polished 
surface 
required 
ex vivo Basic 
research 
mineral, matrix, 
water 
Yes hardness; 
unloading 
modulus 
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2.2 Geometric Characterization 
The organization and distribution of cortical and cancellous bone vary throughout the 
skeleton and with each bone’s function. By evaluating the geometric properties of 
cortical and cancellous bone at a variety of length scales (Figure 2.1-1), their influence 
on bone quality at larger length scales can be assessed. Because cancellous bone is 
generally more sensitive to pathologic changes than cortical bone due to its relatively 
greater metabolic activity, cancellous sites are highly clinically significant for diseased 
or aging populations. The length scale required to characterize cancellous bone 
geometry is typically smaller than that for cortical bone; thus, while many of the 
techniques described here focus on cancellous bone structure, they can also be used to 
characterize similarly sized, or larger, features in cortical bone. In addition, the 
research question drives the selection of the technique used to characterize geometric 
features: for example, if the research question addresses cortical thickness, then 
techniques that characterize millimeter-scale features in bone are adequate, and 
techniques capable of characterizing trabecular architecture (micron-scale features) 
may be unnecessary. 
Therefore, identification of the key length scale or feature size of interest is 
critical to selection of the appropriate technique for characterization of geometric 
features of bone. At the micron- to nanometer-scale, bone is composed of a complex 
hierarchical structure of lamellae and mineralized collagen fibers that can be probed 
with advanced materials characterization techniques, including atomic force 
microscopy, x-ray diffraction, and x-ray scattering. The micron to millimeter scale 
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tissue structures can be characterized with micro-computed tomographic techniques. 
Finally, the macroscopic structures can be characterized with clinical imaging 
modalities such as computed tomography and MRI. Key advantages of many of the 
techniques discussed in the following sections include the ability to 1) generate true 
volumetric bone densities (reported in g/cm3), as opposed to aBMD calculated via 
DEXA, and 2) make multiple measurements within the same individual over time, 
allowing for longitudinal assessment of bone geometry and microarchitecture with 
aging or treatment.  
2.2.1 High-Resolution Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) is a widely available, nonionizing clinical 
modality used to image the water in skeletal tissues in vivo. MRI utilizes a large 
magnet to align the magnetic poles of the protons in the tissue being imaged, and then 
a radio frequency signal specific to hydrogen is added. Upon removing the radio wave, 
the magnetic vector associated with each proton relaxes and causes another radio wave 
to be emitted. The emitted radio wave can subsequently be analyzed for the time 
required for the proton to relax after the initial radio wave signal, as well as for the 
time required for the axial spin to return to its resting state. Because these two 
characteristic times vary for different types of tissue (e.g., bone, fat, marrow), a tissue-
specific image can be created.(3) 
While standard clinical MRI techniques do not resolve trabecular bone, high-
resolution MRI (HR-MRI) techniques can provide 3-D information on trabecular bone 
at peripheral sites (e.g., the radius, tibia, and calcaneus) with a resolution on the order 
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of trabecular dimensions (in-plane resolution: ~110 μm, slice thickness: ~300 μm).(4–7) 
MR imaging measures the water in marrow cavities; thus, trabecular architecture is 
derived from the negative MR image. Recent advancements allow for imaging of the 
proximal femur, a major site of clinical interest, though the signal-to-noise ratio (SNR) 
and the resolution (in plane resolution: ~250 μm, slice thickness: ~500 μm) are lower 
than those at peripheral sites.(5) The outcomes from MRI are bone volume fraction 
(BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular 
number (Tb.N), trabecular anisotropy and connectivity, cortical thickness (Ct.Th), and 
cortical porosity (Ct.Po).(5,8) 
MRI studies show promise for monitoring osteoporosis treatment(9) and 
predicting fracture risk clinically.(10) MRI scans can also be used to generate 3-D bone 
geometry for finite element analysis (FEA) models, a numerical method that can be 
used to computationally predict a bone’s mechanical response to loading (see review 
by Hernandez, this issue). An FEA study using 3-D reconstructions of bone from MRI 
and micro-computed tomography images found stiffness to strongly correlate between 
the two imaging modalities, suggesting MRI-based models are suitable predictors of 
mechanical performance.(11) Some of the main drawbacks of MRI include limited 
ability to resolve trabeculae, low SNR, and high cost; however, the former two issues 
are being addressed with improved data collection and processing methods.(12) 
2.2.2 Quantitative Computed Tomographic Imaging 
Quantitative computed tomography (QCT) assesses 3-D bone geometry and 
volumetric bone mineral density (vBMD) in vivo. vBMD measurements differ from 
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aBMD measurements in that vBMD measures a true volumetric density (g/cm3), while 
aBMD is the mass of bone mineral within the 2-D scan area (g/cm2).  
In QCT, x-ray radiation is directed at an object of interest, and the attenuation 
of the x-rays as they interact with the object is recorded by a detector opposite the 
radiation source. The x-ray source and detector rotate around the object, and 
tomographic algorithms create a 3-D image reconstruction. Inclusion of a mineral 
standard or phantom in the scans allows for calculation of vBMD.  
Cortical and cancellous bone compartments can be distinguished using QCT 
(Figure 2.1-1). The resolution of standard clinical QCT (in-plane resolution: ~500 μm) 
is sufficient to measure cortical thickness and volume; however, it is insufficient to 
characterize trabecular microarchitecture, as the thickness of individual trabeculae 
range from 50 to 300 μm.(13) QCT is particularly useful for imaging clinically relevant 
sites such as the spine and hip, though cortical volume measurements of the spine may 
include some subcortical bone.(13–15) 
Peripheral QCT (pQCT) imaging is a subset of QCT that allows QCT 
measurements to be taken at appendicular sites.(13) pQCT offers finer resolution (in 
plane resolution: ~200 to 500 μm) than QCT, but delivers higher effective radiation 
doses to patients and thus is limited to use on the peripheral sites,(16) where the 
effective radiation dose is relatively low. For example, a QCT scan on an axial site 
delivers an effective radiation dose on the order of 5 mSv, while a pQCT scan of a 
peripheral site delivers an effective radiation dose less than 0.01 mSv.(17) 
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2.2.3 High-Resolution QCT (HRpQCT) 
High-resolution peripheral quantitative computed tomography (HRpQCT) allows for 
in vivo measurement of vBMD and resolution of cortical and trabecular features. The 
principle of image generation is similar to that of QCT systems, and the use of a 
calibration phantom allows conversion of x-ray attenuation to bone density. Similar to 
pQCT, HRpQCT can distinguish between cortical and cancellous bone regions; 
however, the resolution of HRpQCT is higher and can more accurately measure 
cancellous bone morphology. Sites available for HRpQCT assessment include the 
distal radius, distal tibia, hand, and fingers. Direct outcome measurements from 
HRpQCT include cortical bone density, trabecular bone density, total bone density, 
and mean cortical thickness. Using post-scanning algorithms, calculations of Tb.Th, 
Tb.Sp, and Tb.N are possible.(18)  
The newest commercial HRpQCT system (XtremeCT II, Scanco Medical, 
Brüttisellen, Switzerland) features a nominal isotropic pixel size as small as 17 μm; 
however, most of the published literature reports the use of a nominal isotropic pixel 
size between 82 μm and 270 μm.(19) At a resolution of 82 μm, cortical and trabecular 
bone are distinguishable, allowing for separate vBMD measurements of cortical and 
trabecular regions; however, trabecular thickness-independent algorithms are 
necessary to compute trabecular microarchitectural parameters,(19) and cortical pore 
size may be below scan resolution.(20) Moreover, partial volume effects may arise in 
trabecular microarchitecture measurements because trabecular parameters (e.g., 
thickness and separation) are on the order of the scan’s spatial resolution.  
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The clinical applicability of HRpQCT is exemplified in studies showing 
microarchitectural differences between postmenopausal and premenopausal women as 
well as osteoporotic and osteopenic women,(19) between type 2 diabetic and non-
diabetic patients,(21) and between risedronate- and placebo-treated menopausal 
women.(22) Another major benefit of HRpQCT is the ability to generate patient-
specific FEA models of bone to assess its mechanical performance in different loading 
conditions. For example, stiffness and failure load derived from HRpQCT-based 
micro-FEA data from the radius and tibia were correlated with vertebral and non-
vertebral fractures.(23)  
The effective radiation dose per HRpQCT scan is around 3 μSv, orders of 
magnitude lower than that delivered by QCT and pQCT scans.(24) Recent reviews 
highlight the promise for clinical use of HRpQCT.(24,25) Disadvantages of this 
technique include 1) the availability of HRpQCT systems is currently limited to 
academic medical centers, and 2) the relatively few anatomic sites that can be imaged.  
2.2.4 Micro-Computed Tomography (Micro-CT) 
Micro-computed tomography (micro-CT) is used to characterize 3-D bone geometry 
and trabecular microarchitecture of biopsies or other excised tissues ex vivo or key 
skeletal regions of interest of small animals in vivo. Nominal resolution of micro-CT 
ranges from 1 to 100 μm, but recent advances have increased the nominal isotropic 
resolution for ex vivo analyses to 50 nm (Zeiss Xradia 800 Ultra, Zeiss, Oberkochen, 
Germany). Similar to QCT and HRpQCT, tomographic algorithms generate micro-CT 
3-D images, but the attenuation data is collected in a slightly different manner: 
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desktop micro-CT scanners designed for ex vivo specimens often have a rotational 
specimen stage and a stationary x-ray source and detector, while scanners designed for 
in vivo small animal scans have a stationary stage and a rotational source-detector 
gantry.  
From 3-D micro-CT data reconstructions, trabecular microarchitecture is 
characterized through outcomes such as BV/TV, Tb.Th, Tb.Sp, Tb.N, trabecular 
connectivity and anisotropy measurements, and tissue mineral density (TMD) (g/cm3). 
TMD has the same units as vBMD, but, unlike vBMD, the volume of interest for 
TMD excludes voids and soft tissue; TMD therefore represents the density of the bone 
material itself, whereas vBMD may include porosity. In addition, measures of cortical 
porosity and thickness can also be calculated; however, adequate scan resolution 
should be carefully considered to achieve accurate cortical porosity measurements.(26)  
In small animals, micro-CT can be used to monitor skeletal morphology over 
time,(27) and in human biopsies, it can determine the effects of a drug therapy(28) or a 
disease condition on bone morphology.(29) Quantification of microdamage(30,31) and 
osteocyte lacunae in human biopsies or animal models is also possible, though 
isotropic resolutions less than 1 μm may be required, necessitating the use of a high-
resolution desktop scanner or synchrotron source.(32)  
The primary advantages of this technique include the ability to characterize the 
details of trabecular architecture, microdamage, and even the osteocyte network; 
however, finer resolutions come at a cost of longer scan durations and greater 
radiation exposure. In addition, the specimen sizes that can be scanned ex vivo at the 
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highest resolutions are limited (~100 mm diameter, 140 mm length). 
2.2.5 Atomic Force Microscopy (AFM) 
Atomic force microscopy (AFM) measures the force deflections that arise when a 
cantilever beam with an atomically sharp tip is scanned over a sample’s surface. 
Collection of topographic images with a sub-nanometer spatial resolution are 
possible.(33) In addition to imaging topography, AFMs can be used to manipulate 
sample surfaces (e.g., functionalization) and measure forces (e.g., stiffness mapping). 
AFM has been used to document collagen fibril alignment and structure, 
including the 67 nm quarter-stagger fibril alignment,(34) as well as bone’s sub-fibrillar 
structure.(35) It is also possible to image mineral platelets and the topology of fractured 
specimens.(36) Technological improvements now allow for high-speed AFM (HS-
AFM) which maintains the nanometer resolution, but scans complete within seconds 
rather than minutes.(37) HS-AFM can therefore be used to measure dynamic processes 
including surface functionalization and diffusion.  
One major advantage of AFM over other imaging techniques is the ability to 
image and probe samples in saline or other liquids, thereby maintaining the sample 
near biological conditions. Furthermore, AFM maintains a sub-nanometer resolution 
without the preparative steps like fixation, staining, metal coating, and critical point 
drying that are required for other imaging techniques like transmission electron 
microscopy (TEM). Disadvantages of AFM include a small scan area (scan area: 
hundreds of μm by hundreds of μm, height amplitude limit: 10 to 20 μm) and image 
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distortion of some topological features such as overhangs and steep edges.  
2.2.6 X-ray Diffraction and Scattering  
X-ray Diffraction (XRD) 
For ex vivo studies, x-ray diffraction (XRD) is the gold standard for characterizing the 
structure of bone mineral. In XRD, an incident beam of x-rays on a sample results in a 
diffracted ray with variations in intensity due to constructive and destructive 
interference from planes of atoms within the sample. The x-ray source and the detector 
are rotated through a range of angles, and the resulting data is processed to determine 
atomic spacing and structure. The primary outcomes of this technique are the spacings 
between various atomic planes; crystallite size can also be estimated from the plane 
spacing data. 
The first XRD analysis of bone nearly a century ago established the mineral as 
hydroxyapatite.(38) Since then, XRD studies have increased in versatility, leading to 
important insights including the degree of mineralization and crystallinity as functions 
of tissue and animal age,(39) the effect of crystallinity changes on mineral strain,(40) and 
the effects of impurity substitution (e.g., fluoride, strontium, magnesium) into the 
hydroxyapatite lattice.(41)  
The key advantage of XRD is that it provides detailed information on the 
structure of bone mineral crystals. Because sample homogenization is necessary and 
powdering non-crystalline samples is standard, XRD is typically destructive, despite 
the diffraction process itself being nondestructive.(42)  
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Small-angle X-ray Scattering (SAXS) 
Small-angle x-ray scattering (SAXS) is a complementary technique to standard XRD 
that does not require homogenization of samples. In SAXS, the scattered rays from an 
incident x-ray beam are measured instead of the diffracted rays as in XRD. Outcome 
measurements from SAXS include crystal shape, average crystal thickness, and crystal 
orientation.(43) 
The advent of synchrotrons, which produce high energy, monochromatic x-
rays, allowed SAXS characterization of bone tissue. The use of in situ synchrotron 
imaging has enabled a 3-D reconstruction of a trabecula with complete ultrastructural 
details,(44) analysis of the internal stresses of cortical bone during a compressive 
load,(45) studying the load transfer between the mineral and organic matrix of bone at 
the nanoscale,(46) and evaluating strained microdamage at a resolution of 30 nm.(47) 
These studies show promise for translating structural measurements directly into 
mechanical property characterizations.  
Key advantages of SAXS include the ability to image non-crystalline samples 
with minimal sample preparation, which allows for detailed insights into bone’s 
nanoscale structure, variations in tissue mineral density, and damage accumulation. 
However, SAXS suffers from a lower SNR than XRD; thus, a synchrotron source is 
required for these measurements. 
2.3 Compositional Characterization 
The nanoscale building blocks of bone are an organic matrix, composed mainly of 
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type 1 collagen, a hydroxyapatite-like mineral, and water. In general, the collagen 
matrix provides bone’s ductility, the mineral provides bone’s stiffness and strength,(48) 
and the water provides bone’s viscoelastic, or time-dependent, behavior.(49) Because 
toughness, which characterizes a bone’s ability to absorb energy before failure (see 
review by Burr, this issue), arises from the combination of ductility and strength, the 
collagen, mineral, and water components of bone are critical to fracture resistance. 
Therefore, characterization of the mineral, matrix, and water components of bone 
lends insight into bone quality and their contribution to structural integrity of whole 
bones.(50,51) 
2.3.1 Nuclear Magnetic Resonance (NMR) 
Nuclear magnetic resonance (NMR), also called magnetic resonance spectroscopy or 
nuclear paramagnetic resonance, operates using the same principles as MRI. Whereas 
MRI is typically used to image the water in a tissue, NMR can be used to measure 
other isotopes. NMR uses the responses of isotopes to an external magnetic field to 
generate compositional information about the sample being scanned. The response of 
a particular isotope to an external magnetic field is unique and depends on the 
isotope’s molecular environment, and the parameter used to describe an isotope’s 
response is called chemical shift. The two isotopes used to study bone with NMR are 
1H and 31P. Although the feasibility of measuring cortical and cancellous tibial bone 
BMD has been demonstrated in vivo using 31P,(52) a low SNR remains a key challenge 
for this isotope.(53) Therefore, here we focus primarily on 1H, or proton, NMR.  
Proton NMR is used to characterize the water content in bone. Water in bone 
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plays roles in transporting ions during mineralization, damping during mechanical 
loading, and regulating bone formation via fluid flow-mediated mechanotransduction. 
The water in bone falls into two main categories: bound and unbound. Bound water 
exists in Ca2+ coordination sites on the mineral and is associated with collagen fibrils. 
Unbound water, or bulk water, exists in the pores of the Haversian system and is used 
as an inverse measure of bone density.(54) 
Both varieties of water in bone are distinguishable through proton NMR.(55) In 
a study investigating water content, aging, and mechanical properties ex vivo, bound 
water increased with age while unbound water correlated to porosity. Additionally, 
both bound and unbound water influenced mechanical properties.(56) The important 
roles of water in bone and the push towards its use in clinical measurements is 
described in a recent review.(55) Advances in NMR technology in the past several 
decades have also enabled ultrafast Magic Angle Spinning (MAS) NMR on solid bone 
samples.(57,58) Ultrafast MAS NMR has the potential help further elucidate the 
complex structure and order of bone’s hierarchical system beyond standard NMR 
measurements of water content and location. 
Two main advantages of NMR are 1) the ability to scan in vivo without 
subjecting the patient to ionizing radiation, and 2) the technique is nondestructive, 
allowing repeated measurements on the same patient or sample. The principal 
disadvantage is the low SNR of isotopes other than 1H, which limits NMR’s versatility 
for specimens, like biological tissues, that have high water content.  
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2.3.2 Vibrational Spectroscopy and Imaging 
Infrared (IR) spectroscopy and Raman spectroscopy can be used to determine the 
chemical signature of a sample. Both techniques rely on the characteristic fingerprints 
of molecular bond vibrations from a material’s constituents. When coupled to a 
microscope and an array detector, both of these techniques can be used in an imaging 
mode to assess material composition in a spatially resolved fashion.(59) 
In general, strong molecular bond vibrations in the IR spectrum correspond to 
weak bond vibrations in the Raman spectrum, and vice-versa. The differences in the 
strength of vibrational modes between IR and Raman arises from complex molecular 
symmetry, but typically a change in dipole moment indicates an IR active-mode, and a 
change in polarizability indicates a Raman active-mode. In bone, both IR and Raman 
spectroscopy can differentiate the molecular signals of the organic matrix components 
(collagen, proteoglycans, lipids, etc.) from the signals arising from the constituents of 
the hydroxyapatite (phosphate, carbonate).  
FTIR Spectroscopy and Imaging 
Fourier transform infrared spectroscopy (FTIR) is used primarily in transmission or 
absorption mode and requires a thin sample (thickness: ~2 μm). When characteristic 
frequencies of an incident infrared beam are absorbed by molecular bonds in the 
sample, the resulting interferogram is Fast Fourier Transformed into a spectrum in the 
frequency domain. The peaks in the resulting FTIR spectrum are analyzed to identify 
molecular species, qualitatively determine the amount of specific components, and 
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provide information on the stoichiometry of a particular molecular species.  
The outcome measurements from a typical FTIR spectrum of bone include the 
mineral to matrix ratio, indicating the extent of mineralization of the organic matrix; 
the carbonate to phosphate ratio, indicating the extent to which carbonate has been 
substituted into hydroxyapatite; the collagen maturity, indicating the relative crosslink 
proportion of mature trivalent crosslinks to immature divalent crosslinks; the 
crystallinity, a measure of crystal size and perfection; and acid phosphate content, a 
measure of tissue maturity.(60,61) Furthermore, spatial mapping and information about 
tissue heterogeneity is possible through FTIR imaging (FTIRI) which allows for 
characterization of the above parameters across a region of interest with a spatial 
resolution around 6 μm2.  
FTIR and FTIRI were used to detect differences in the quantity and quality of 
mineral in diseased Schmid metaphyseal chondrodysplasia bone compared to non-
diseased bone,(62) in collagen maturity between bone from rats treated with a 
lathyrogen and from untreated controls,(63) and in heterogeneity of bisphosphonate 
treated postmenopausal women with fractures compared to non-fracture controls.(64) 
Together, these studies exemplify the power of FTIR and FTIRI in evaluating the 
mineral, organic matrix, and the relationship between the two.  
Advantages of FTIR include spatial mapping with FTIRI, concurrent mineral 
and matrix evaluation, high sensitivity, and a high SNR relative to Raman allowing for 
faster data collection. A disadvantage of FTIR spectroscopy or imaging is that sample 
dehydration is required because water dominates the absorption spectrum in the 
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infrared; thus, analysis of biological tissues in their native hydrated states is precluded. 
In addition, PMMA embedding and microtoming of thin sections (thickness: ~2 μm) is 
required for FTIRI. Finally, a disadvantage of FTIRI includes a coarser resolution than 
related techniques (FTIRI: ~6 μm, Raman imaging: ~1 μm). 
Raman Spectroscopy and Imaging 
Raman spectroscopy uses the inelastic scattering of incident light on a sample to detect 
changes in polarizability of molecules. The outcome variables for Raman spectroscopy 
are similar to those of FTIR, with the exceptions of crystallinity and acid phosphate.(65) 
Crystallinity in Raman spectroscopy is measured as the inverse of the full-width at 
half-maximum (FWHM) of the 959 cm-1 phosphate peak which is related to the length 
of the mineral crystallite c-axis.(66)  
Within the past decade, in vivo Raman capabilities have been realized.(67) 
Using spatially offset Raman spectroscopy (SORS), millimeter depths human tibial 
and finger tissue have been scanned.(68) A comprehensive analysis of the feasibility 
and promise of Raman in a clinical setting is described by Hanlon et al.(69) 
Raman imaging offers several advantages relative to FTIRI, including a finer 
spatial resolution (~1 μm); the ability to scan thick, hydrated specimens, which allows 
for more versatile use in biological samples; and in vivo capabilities. The key 
drawback of Raman is its relatively low SNR, which substantially increases scan times 
relative to FTIR. 
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2.3.3 Scanning Electron Microscopy (EM) 
SEM: Secondary Electrons  
In scanning electron microscopy (SEM) an electron beam is rastered across a sample 
surface to determine topographical and compositional information with a resolution of 
tens of nanometers.(70) As the electrons from the beam contact the sample surface, 
energy from the incident electron is transferred to an atom in the sample. When this 
extra energy in the atom is released, a secondary electron is emitted and subsequently 
detected. Because the primary outcome of this technique is a detailed 2-D image of the 
specimen surface, secondary outcomes can include parameters quantifying formation 
and resorption areas in bone undergoing remodeling.(71,72) 
SEM imaging has been used to demonstrate collagen fiber orientation and fiber 
deformation from an excised cortical bone specimen undergoing bending.(73) 
Furthermore, SEM and energy dispersive x-ray analysis, which allows for analysis of 
the elemental composition of a specimen, were used in concert to monitor the effect of 
bisphosphonate treatment on mineral content and quality of fracture healing in rats,(74) 
These studies demonstrate the capability of SEM to characterize both the organic and 
mineral components of bone. SEM images also can show the formation and resorption 
regions associated with bone remodeling.(75) 
An advantage of SEM is that it allows higher resolution than standard 
histology by optical microscopy, and thin sections need not be microtomed. With the 
exception of environmental SEM, SEM requires a conductive sample to avoid 
 53 
 
charging effects at the surface, so samples are typically coated with a thin conductive 
layer prior to imaging. 
SEM: Quantitative Backscattered Electron Imaging (qBEI) 
In addition to the signal measured from secondary electrons, SEM imaging also 
produces a backscattered electron signal which is used to generate a quantitative 
backscattered electron image (qBEI). As an electron beam is rastered across a sample, 
some of the incident electrons collide with atoms in the sample causing the electrons 
to be scattered backwards. The amount of backscattering an electron exhibits is 
proportional to the atomic number Z of the atom with which it collides; therefore, 
higher atomic numbered atoms will generate a higher backscattering signal. This is 
also called Z contrast.  
Of the constituents in bone (organic matrix: C, O, H, N, P; mineral: Ca, O, H, 
P, Mg), calcium has the highest Z number (Z = 20). Calcium dominates qBEI image 
contrast, and it indicates different stages of mineralization in a tissue. The main 
outcome measurement for qBEI is bone mineral density distribution (BMDD) which 
details the degree of mineralization spatially across a region of interest.(76) Unlike 
standard in vivo BMD measurements, BMDD measurements using qBEI require bone 
tissue to be embedded in a plastic resin and imaged using an SEM. Surface topography 
greatly affects backscattering; thus, highly polished samples are required.  
BMDD measurements using qBEI can be calibrated against a calcium standard 
to determine calcium weight in clinical biopsies.(76) qBEI is a particularly useful 
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technique when the mineral component of bone is expected to deleteriously affect 
bone quality, for example in patients with osteogenesis imperfecta(76) or in fragility 
fracture patients with acute or chronic illnesses.(77) Additionally, qBEI can 
characterize BMDD of multiple trabecular or cortical regions quickly at a resolution 
around 1 μm.(78) A key limitation of qBEI for clinical use is the need for a plastic 
embedded and polished biopsy.  
2.3.4 High-Performance Liquid Chromatography (HPLC) 
High-performance liquid chromatography (HPLC) is an analytical chemistry 
technique used to identify and quantify compounds in a liquid sample. HPLC works 
by pumping a sample through a column containing porous solid beads of known size 
and composition. Based on the physical and chemical interactions of the sample 
components with the column beads, each component elutes from the column at a 
signature rate, and the concentration of each component is measured precisely with a 
detector at the eluting end. Typical HPLC outcomes for bone quality are collagen 
crosslinks, bone turnover markers, and the amino acid composition.  
The collagen crosslinks formed through enzymatic and non-enzymatic 
pathways have different effects on bone quality. Enzymatic crosslinks form through 
the action of lysyl oxidase and undergo a maturation process from an immature 
divalent crosslink to a mature trivalent crosslink. Enzymatic collagen crosslinks that 
have been measured using HPLC include the immature crosslinks of 
dehydrodihydroxynorleucine (DHLNL) and dehydrohydroxylysinonorleucine 
(HLNL), and the mature crosslinks of hydroxylysyl pyridinoline (HP) and lysyl 
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pyridinoline (LP).(79) Enzymatic crosslinks in humans stabilize around 10-15 years of 
age,(79) and in general are associated with advantageous mechanical stabilization of the 
collagen matrix and as precursors to mineralization.(80) The specific crosslinks HP and 
LP are also used as markers for bone turnover.(81) HPLC measurements of non-
enzymatic crosslinks include glycation endproducts like pentosidine which has been 
implicated in reduced bone quality in patients with osteoporosis or type 2 diabetes,(82) 
and in normal aging.(83)  
Important benefits of HPLC are the precise measurement of concentrations of 
molecular components as low as [picomol] and the ability to measure many 
components in one test. HPLC is destructive and requires sample homogenization, 
specialized equipment, and technical expertise. Future improvements will aim for 
higher selectivity of components, decreased throughput time, and lowered cost.  
2.3.5 Thermal Gravimetric Analysis (TGA) 
Thermal gravimetric analysis (TGA) characterizes the mass of organic and inorganic 
constituents in a sample by monitoring the sample’s weight change with increasing 
temperature. For bone, samples are first dried at 110 °C to remove water. Continued 
heating between 200 and 600 °C causes the organic components to decompose until 
they are eliminated completely by combustion.(84) The remaining material after heating 
to 600 °C is called the ash weight, which consists only of the inorganic 
hydroxyapatite-like mineral in bone. The primary outcome is the ash fraction, which is 
obtained by dividing the ash weight by the initial dried sample weight.  
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TGA is the gold standard for determination of the mineral fraction in bone 
tissue; however, the primary drawback is that it is a destructive technique, leaving 
behind only the mineral component after combustion. 
2.4 Mechanical Characterization 
A fragility fracture is a mechanical event in a biological system.(85) Bone’s resistance 
to fracture depends on many properties and their interactions including: 1) stiffness, 
the ability to resist elastic/reversible deformation; 2) strength, the ability to resist 
plastic/permanent deformation; 3) toughness, the ability to absorb energy during 
deformation; and 4) fracture toughness, the ability to prevent cracks from initiating 
and progressing. These properties also change with repetitive loading over time, a 
process known as fatigue, which is a complex process beyond the scope of this 
review.(86,87) Although a discussion of fracture toughness testing is beyond the scope 
of this review, several reviews are available regarding fracture toughness of bone at 
multiple length scales.(88–90)  
Mechanical properties can be assessed at different levels of the bone structural 
hierarchy (Figure 2.1-1). In specifying a length scale at which to perform a mechanical 
test, influences from larger length scales can be removed, so that the test includes 
mechanical influences from the properties at and below the testing scale. For example, 
if a cancellous core from the proximal femur (mm length scale) is mechanically tested, 
the whole bone size and shape do not influence the test outcomes, and instead, the 
smaller scale properties (e.g., microarchitecture, composition, bone volume fraction) 
affecting the test outcome variables are included. Furthermore, the influence of 
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heterogeneity and flaws on the outcomes of a mechanical test are highly dependent on 
the size of the tested sample. More specifically, a small structural or compositional 
flaw will have a larger effect on a tissue-level mechanical test than the same flaw 
would have on a whole-bone mechanical test.  
The following section details common types of mechanical testing, their 
outcome variables, and the length scale assessed by each test. Though not discussed in 
detail here, bone tissue handling and storage conditions (e.g., number of freeze-thaw 
cycles, tissue fixation, hydration) prior to mechanical testing may strongly influence 
the test’s outcome variables and should be carefully controlled.(91,92) 
2.4.1 Whole-bone Testing  
Macroscale mechanical testing of whole bones is destructive and therefore only 
possible in studies using animal models or cadaveric tissue. In general, whole-bone 
testing involves stabilizing the bone of interest, applying a load (or displacement), and 
measuring the resulting deformation. The standard bones used for whole-bone testing 
are long bones and vertebrae, and typical loading modes include compression, tension, 
and bending.(93) For small animal studies, femoral bending tests are often performed 
because the diaphyseal cross-section is approximately elliptical, which simplifies 
subsequent mechanical analyses,(88,91) although other long bones and vertebrae can be 
tested depending on the research question. Outcome variables for a quasi-static load 
on a whole bone include a force-displacement curve, structural stiffness, structural 
strength, and toughness.(94)  
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Mechanical testing of vertebrae from ovariectomized macaques treated with 
ibandronate showed significant increases in strength and stiffness with drug 
treatment,(95) and testing of femora from rats with type 2 diabetes showed decreased 
strength, stiffness, and energy absorption arising from alterations of the collagen 
matrix.(96) These studies exemplify the utility of using whole-bone testing to study the 
effects of drug therapy and disease on the structural properties of bone. Drawbacks of 
whole-bone testing are that it is inherently destructive, and that this level of analysis is 
unable to decouple the structural and compositional factors that influence structural 
properties.  
2.4.2 Apparent-level Bulk Cortical and Cancellous Bone Testing  
Using regularly-shaped specimens of bulk cortical and cancellous tissue (width: mm to 
cm, length: mm to cm), mechanical tests allow determination of material properties of 
each tissue type including apparent-level stiffness, strength, and toughness. At this 
level of structural hierarchy, the effects of porosity are included in these 
measurements; thus, the outcomes are apparent-level properties. Testing at a smaller 
length scales is necessary to isolate tissue-level properties (see Tissue-level Cortical 
and Trabecular Testing).  
Bulk tissue testing shows the mechanical properties of cancellous bone to be 
highly dependent on bone volume fraction, and, similarly, it shows the mechanical 
properties of cortical bone to be highly dependent on cortical porosity(97,98) Mechanical 
properties of both types of bone vary with anatomic site and loading direction,(99,100) 
which demonstrates the utility of separating mechanical tests by bulk tissue type and 
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site. Similar to whole bone testing, bulk cortical and cancellous bone testing has 
proven useful in elucidating the effects of drug therapy, disease, and aging in animal 
and human studies.(101–104) A disadvantage of using this level of mechanical testing is 
the necessity for uniformly machined specimens.  
2.4.3 Tissue-level Cortical and Trabecular Testing 
Performing mechanical testing on the scale of cortical microbeams or individual 
trabeculae further removes the effect of geometry and structure from mechanical 
property measurements. Typical dimensions of tissue-level mechanical testing are 
hundreds of microns in width and height, and hundreds to thousands of microns in 
length. Due to the technical challenges of testing small specimens, micro-tensile or 
microbeam bending are favored over micro-compression tests.  
Micro-tensile testing of single trabeculae in human vertebral bone revealed 
large differences in ultimate strain between trabeculae, even within a single donor, 
thus highlighting the variations in tissue at small scales.(105) Disadvantages of tissue-
level testing are the complexity of sample preparation and test design. Also, 
machining regular prismatic specimens can introduce damage or other testing artifacts, 
and these limitations should be considered when interpreting tissue-level outcomes. 
In addition to tissue-level mechanical testing, tissue-level material properties 
can also be estimated from whole-bone or apparent-level tests by normalizing the 
property by the sample’s geometry, as determined by micro-CT or other means. 
Estimation of tissue material properties from whole-bone structural properties relies 
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on many underlying assumptions, including assuming material homogeneity and a 
prismatic cross-section, which are not appropriate for whole bones.(91,94) Material 
properties estimated from whole-bone testing are poorly correlated with material 
properties assessed directly;(106) thus, material properties should be assessed directly 
with one of the techniques described below. 
2.4.4 Indentation Testing 
In an indentation, or hardness, test, the sample is subjected to a single, static force by a 
small tip, and the resulting indentation depth and size are recorded. In bone, 
indentation testing can be performed at several length scales, and it gives information 
regarding the resistance of bone tissue to plastic/permanent deformation.  
For all length scales of indentation testing, tissue hydration, tip morphology, 
surface roughness, loading rate, and sample orientation must be carefully 
controlled.(107) Embedding samples in resin and polishing the surface can attenuate 
variability in outcome measures, though dehydration is known to increase 
hardness.(108) 
Microindentation 
In a microindentation test, the sample is subjected to a static load, and the resulting 
geometry of the indentation impression after load removal is used to calculate 
hardness. Hardness is defined as the force applied divided by the area of the residual 
indentation, which characterizes the material’s resistance to plastic deformation.(109) 
Microindentation allows for hardness testing at the length scales of individual 
 61 
 
trabeculae and osteons of bone.  
In one of the foundational studies involving microindentation of bone, 
microhardness correlated with degree of mineralization.(109) More recently, hardness 
differences along the three orthogonal directions of parallel-fibered bone were 
observed, indicating the sensitivity of microindentation to local microstructure.(110) 
Furthermore, microindentation hardness values can distinguish between severely 
damaged bone and intact bone,(111) and it has also been used to characterize aged and 
osteoporotic bone.(107) 
Key advantages of microindentation are the simplicity of the technique and the 
ability to quickly map microhardness across a sample. The main disadvantage is that 
microindentation has a single outcome measurement, hardness.  
Reference Point Indentation 
Within the past decade, a new type of indentation testing known as reference point 
indentation (RPI) was developed. RPI measures bone material properties on a scale 
similar to that of microindentation ex vivo. There are two main RPI devices, the 
OsteoProbe (Active Life Scientific, Santa Barbara, CA) and the BioDent (Active Life 
Scientific, Santa Barbara, CA), which operate under different mechanical loading 
conditions resulting in dissimilar outcome measurements.  
The in vivo OsteoProbe utilizes a single indent with three phases: 1) a linear 
preload which passes through soft tissue; 2) a quick impact; and 3) unloading as the 
probe is removed manually. The outcome variable from the OsteoProbe is called bone 
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material strength index (BMSi) which is calculated as 100 times the indentation 
distance increase (IDI) of a calibration block of poly (methyl-methacrylate) divided by 
the IDI from the preload to the final load. Typical testing includes five or more indents 
spaced 2 mm apart. This testing practice accounts for bone’s heterogeneity and avoids 
measurement interference from previous indentations.(112) In contrast to the single 
impact-based OsteoProbe, the BioDent features a cyclic indentation technique with 
customizable parameters in preconditioning, maximum indentation force, and cycle 
number. The output measurement is a force-indentation distance curve with each cycle 
presented on the same plot in real-time, and the outcome parameters achievable for 
each cycle include: 1) maximum indentation distance; 2) maximum force reached; 3) 
energy dissipation (energy under the force-displacement curve); 4) creep indentation 
distance; 5) loading slope; and 6) unloading slope. Furthermore, the variance between 
cycles of each of these parameters can also be calculated.(113,114) 
The physical meaning of the outcome variables of the OsteoProbe and the 
BioDent are still under debate.(114,115) The impact loading conditions from the 
OsteoProbe are dissimilar to the relatively slow loading rates of a traditional 
microhardness test. In addition, the deformation geometry is not measured; thus, a 
hardness value cannot be determined from OsteoProbe tests. Furthermore, the name 
BMSi is itself potentially a source of confusion, as it is not a rigorous measurement of 
strength and has not been correlated with strength from other standard testing 
modalities.(114) It has been proposed that the OsteoProbe measures cracking of lamellar 
bone at the periosteal surface of the tibia, and as such, the closest analog of BMSi 
would be tissue toughness; however, the correlation between BMSi and tissue-level 
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toughness has also not yet been demonstrated.(116) Similar to the OsteoProbe, efforts to 
correlate BioDent outcomes to standard mechanical properties have been 
inconclusive.(114) The BioDent is most similar to a creep or low-cycle fatigue test,(116) 
but differences in the RPI technology versus standard mechanical testing procedures 
complicate direct comparisons of outcomes. Furthermore, the outcome measurements 
from each device were found to be weakly related to each other, if at all, in human 
cadaveric tibiae.(117) 
Empirical evidence for the clinical utility of these techniques is bolstered by 
several studies using both the OsteoProbe and the BioDent. Studies using the 
OsteoProbe showed differences in BMSi between patient populations, including a 
decrease in BMSi in type 2 diabetic patients compared to non-diabetic patients,(118) as 
well as an increase in BMSi of glucocorticoid treated- compared to non-treated 
patients.(119) Using the BioDent, the maximum indentation distance and indentation 
distance increase between the first and last cycle were higher in femoral fracture 
patients than in non-fracture controls, suggesting the BioDent can distinguish a 
clinical fracture population.(120)  
Key advantages of these techniques include the ability, for the first time, to 
directly measure mechanical properties of bone tissue in vivo. However, the outcome 
variables await rigorous validation, and standardization of RPI techniques between 
studies is lacking, complicating comparisons of RPI data across studies.  
Nanoindentation 
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As in a microhardness test, in a nanoindentation test, a tip is loaded into and unloaded 
from the material of interest to probe the material properties of the sample. However, 
nanoindentation tests provide more information about the material behavior through 
the use of depth-sensing transducers. In nanoindentation, when force is applied to the 
nanoindenter tip, the tip displacement is continuously measured to produce a force-
displacement curve. Hardness, representing the average pressure under load, is 
calculated as the maximum load divided by the indentation contact area; and the 
reduced modulus, which includes contributions from both the sample and the indenter, 
is calculated from the slope of the unloading portion of the force-displacement 
curve.(121) The elastic modulus of the sample, representing its resistance to 
elastic/reversible deformation, can be calculated from the reduced modulus, the 
Poisson’s ratio of the sample, and the material properties of the indenter. 
In bone, nanoindentation has a spatial contact resolution around 1 μm which 
allows for characterization of the lower levels of bone’s hierarchical structure 
including lamellar and interlamellar regions.(122) Also, new instruments combine the 
imaging capability of an AFM with the mechanical testing capability of an indenter, 
thereby allowing for precise control over indentation location (within tenths of nm) 
and surface morphology.(123) Nanoindentation can be performed in a grid pattern 
resulting in a stiffness map,(124,125) and it can also be coupled to a Raman spectrometer 
such that mechanical and compositional information are collected simultaneously (TI 
950 TriboIndenter, Hysitron, Minneapolis, MN). 
When nanoindentation was used in conjunction with second harmonic 
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generation imaging on trabecular bone tissue, lamellar bone was harder and had more 
aligned collagen as compared to interlamellar bone.(126) Several validation studies of 
anisotropic elastic moduli with acoustic microscopy or tensile testing provide support 
for the translation of nanoindentation measurements to the macroscale.(127,128) These 
studies taken together demonstrate the feasibility of incorporating nanoindentation 
measurements of different sites into larger-scale models.  
The capability for dynamic load- and displacement-control during 
nanoindentation allow acquisition of full force-displacement curves at μm-scale and 
even sub-μm-scale resolution. Nanoindentation also offers modulus mapping 
capabilities, and it can be coupled with simultaneous compositional testing like Raman 
spectroscopy, giving this technique versatility.(129) A drawback of nanoindentation is 
that its spatial resolution is effectively limited by specimen surface roughness; thus, 
careful sample preparation (e.g., surface polishing) is required for surface irregularities 
to be small in comparison to the indentation size.(130)  
2.5 Summary and Discussion 
Direct assessment of bone’s resistance to fracture involves destructive mechanical 
testing, which is infeasible for clinical fracture risk evaluation. Although surrogate 
measures of fracture risk such as DEXA-assessed aBMD are clinically useful, they 
have important limitations as predictors of fracture risk,(131) and bone quality 
measurements can provide complementary information. Here we have reviewed 
techniques available to assess the geometric and material factors that contribute to 
bone quality across multiple length scales (Figure 2.1-1) along with some of their key 
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outcomes and characteristics (Table 2.1-1).  
The techniques we review for geometric characterization include imaging 
technologies spanning length scales from nanometer to meter. These techniques share 
some common trade-offs, including 1) the size of the sample to be scanned versus the 
time required to complete a scan, which applies to MRI, all CT-based imaging 
modalities, and AFM imaging; 2) the scan resolution versus the radiation dose, which 
applies to in vivo characterization techniques that use x-ray sources, including QCT 
and HRpQCT; and 3) the clinical relevance of a site versus the amount of soft tissue 
that can interfere with scanning, which applies to MRI, QCT, and HRpQCT. These 
three trade-offs have attenuated over the past several decades and are expected to 
improve with future technological advances.  
The techniques we review for compositional characterization characterize the 
collagen, mineral, and water components of bone spanning length scales from 
nanometer to meter. Of the methods reviewed, NMR and Raman offer in vivo 
capabilities. The remaining techniques require a biopsy, of which FTIR, Raman, SEM, 
and qBEI require special sample preparation and/or mounting; and HPLC and TGA 
are destructive. Despite many compositional characterization methods not being 
particularly well suited for clinical use, they offer powerful insights into the effects of 
diseases, aging, and drug therapies on bone composition that are typically not 
obtainable through noninvasive means. In clinical studies, these techniques can be 
performed on biopsies from a small subset of patients to provide detailed information 
on bone quality that cannot currently be assessed noninvasively. 
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Finally, we review the types of mechanical testing available for 
characterization of the mechanical properties of bone at different levels of structural 
hierarchy. The contributions of cancellous and cortical bone to whole-bone structural 
performance, as well as the variations in tissue-level properties, further demonstrate 
the importance of geometry and composition to bone’s mechanical properties. 
Mechanical testing remains the gold standard for assessment of bone stiffness, 
strength, toughness, and fracture resistance in cadaveric or animal models. In human 
clinical studies, bone geometry derived from a noninvasive imaging modality can be 
used in conjunction with finite element analysis (FEA) validated from cadaveric 
studies to simulate mechanical testing and predict mechanical properties of clinical 
populations.(132) 
Thus, although no single technique can completely characterize bone quality, 
many of the techniques discussed here can be synergistically combined to generate a 
more comprehensive understanding of bone geometry, composition, and mechanical 
properties. Useful combinations of characterization methods include HR-MRI or 
HRpQCT used with FEA modeling, which allows for non-invasive prediction of the 
effects of drug treatment on structural properties in human clinical studies, as well as 
nanoindentation and Raman spectroscopy, which allows simultaneous examination of 
the relationship between of compositional and mechanical properties in studies in 
which biopsies are available.(21,133) Finally, advancements in techniques like Raman 
imaging and RPI, which were previously feasible only in a laboratory setting, are now 
enabling their transition into in vivo use. These types of in vivo characterization are 
expected to make previously unobtainable patient-specific information on bone quality 
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available in the clinic.  
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CHAPTER 3 
BONE TISSUE COLLAGEN MATURITY AND MINERAL CONTENT 
INCREASE WITH SUSTAINED HYPERGLYCEMIA IN THE KK-AY MURINE 
MODEL OF TYPE 2 DIABETES 
 
3.1 Introduction 
Type 2 diabetes mellitus (T2DM) increases fracture risk for a given bone mineral 
density (BMD),(1,2) and the greater fracture risk for patients with T2DM persists after 
adjustment for age, body mass index (BMI), and physical activity.(3) Additionally, 
T2DM-related fractures are underpredicted by current clinical fracture risk assessment 
tools that rely heavily on BMD, such as FRAX.(2) Taken together, these findings 
suggest T2DM degrades bone quality independently of BMD, which motivates further 
assessment of bone tissue properties from patients with T2DM.  
The precise mechanisms responsible for the putative alterations in bone quality 
that increase T2DM-related fractures are unknown; however, changes in the post-
translational modifications of collagen due to hyperglycemia have been suggested as a 
contributing factor. Post-translational modifications of collagen include 1) 
crosslinking through enzymatically-mediated processes and 2) the formation of a 
heterogenous group of reaction products collectively known as advanced glycation 
endproducts (AGEs) through non-enzymatically-induced processes. Enzymatic 
crosslinking is controlled by the action of lysyl oxidase and results in the formation of 
trivalent crosslinks such as hydroxylysylpyridinoline (HP, also referred to as 
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pyridinoline) and lysylpyridinoline (LP, also referred to as deoxypyridinoline).(4) Non-
enzymatically-induced AGEs, on the other hand, form through the reaction of 
extracellular reducing sugars (e.g., glucose, ribose, fructose) with free amino groups in 
proteins and can result in non-enzymatic crosslinks, as well as other non-crosslinking 
AGEs (e.g., carboxymethyl-lysine).(5) 
Whereas enzymatic crosslinks strengthen and stabilize the collagen matrix,(6) 
AGEs decrease energy absorption and embrittle bone tissue in animal models,(7) and in 
glycated/ribosylated human(8) and bovine tissue in vitro.(9) Rodent models supply 
direct evidence that T2DM impairs whole-bone fracture resistance, and the skeletal 
phenotypes of rodents with T2DM are typically characterized by substantial 
reductions in maximum load and inconsistently by reductions in energy to failure and 
BMD (summarized in (10)). For example, spontaneously diabetic WBN/Kob rats 
exhibited reduced maximum load and work-to-fracture with no change in BMD 
compared to controls, and these weakening and embrittlement processes were 
accompanied by concomitant decreases in enzymatic collagen crosslinks and increases 
in non-enzymatic collagen crosslinks.(11)  
Additionally, AGEs impair bone remodeling processes. In AGE-modified 
collagen, osteoblastic growth and differentiation were disrupted,(12,13) and apoptosis 
increased.(14) Observations of reduced bone formation in T2DM patients compared to 
non-DM controls are also supported by analysis of histomorphometric data(15) and 
biochemical markers of bone formation.(16–18)  
A promising model to study T2DM is the KK-Ay mouse, and to date, 
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compositional skeletal characteristics of the KK-Ay mice have not been evaluated.(19) 
Mice from the KK strain exhibit insulin insensitivity and glucose intolerance,(20,21) yet 
they are neither glucosuric nor hyperglycemic.(20,22,23) The addition of the Ay mutation 
to the KK mouse induces obesity and a distinguishing yellow coat, and KK-Ay mice 
exhibit overt glucosuria and hyperglycemia around eight weeks of age.(22,23) When 
tested in three-point bending, the tibiae of KK-Ay mice had a lower ultimate load 
compared to controls,(24) which may parallel the impaired structural integrity observed 
in humans.  
Prior studies of the skeletal properties of KK-Ay mice compared to controls 
consistently report reduced trabecular BMD,(24–26) whereas the findings for cortical 
vBMD, total aBMD, and bone formation/resorption markers are less consistent. In two 
studies comparing KK-Ay mice to C57BL/6 controls, one study reported a decrease in 
cortical area, thickness, and vBMD with a concomitant decrease in osteoblastogenesis 
and osteoclastogenesis,(24) and in contrast, the other study reported an increase in 
cortical thickness and vBMD with an upregulation of osteoblast- and osteoclast-
related gene expression.(25) While skeletal morphology(24–27) and collagen 
crosslinks(11,27–29) have been characterized in T2DM bone, compositional data beyond 
ash weight(30–32) and mineral:matrix ratio (using Raman spectroscopy)(27,32) are limited. 
These results underscore the need for compartment-specific (i.e., trabecular, cortical) 
and whole-bone compositional assays of T2DM bone tissue. 
Therefore, the objective of this work was to compare the spatially-resolved 
compositional properties and collagen crosslinks of bone tissue from KK-Ay mice 
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with overt T2DM (Ay/a) to their non-overt T2DM siblings (a/a). We hypothesized that 
hyperglycemia would increase tissue-level non-enzymatic crosslinking (due to AGE 
accumulation) and would increase tissue mineral content and collagen maturity (due to 
reduced bone turnover) in the Ay/a mice compared to the a/a controls.  
3.2 Materials and Methods 
3.2.1 Obese Mouse Model of T2DM 
Male KK.Cg-Ay/J mice were purchased from The Jackson Laboratory at eight weeks 
of age (002468, Bar Harbor, ME), raised in ventilated cages at 20-22 °C with a 14-
hour light-dark cycle, and given free access to standard irradiated chow (2920x, 
Harlan Laboratories, Inc., Indianapolis, IN). The yellow heterozygous Ay/a mice were 
used to model T2DM and their black homozygous a/a littermates were used as 
controls.  
The femora used here were the non-operative controls from a study of the 
effects of T2DM on osteoarthritis progression.(33) At 12 weeks of age, mice within 
each group (Ay/a: n = 14, a/a: n = 8) were anesthetized and chosen at random to 
undergo either a destabilization medial meniscus (DMM) or sham procedure on the 
left distal femora.(34) The right femora used in the current study were not operated or 
otherwise treated. Body masses at the time of surgery were recorded. A minimum of 
three blood glucose measurements were performed via tail nick test (Precision Xtra 
Blood Glucose Test Strips, Abbott Diabetes Care Inc., Alameda, CA), with three of 
the measurement time points at 8 weeks of age (at purchase from Jackson), 12 weeks 
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of age (at DMM surgery), and 20 weeks of age (at euthanasia). A lifetime-average 
blood glucose level (average of all blood glucose measurements for each mouse) 
greater than 300 mg/dl confirmed hyperglycemic status of the Ay/a mice and 
euglycemic status of the a/a mice.(19) For a subset of the mice (Ay/a: n = 4, a/a: n = 4), 
fasting blood glucose measurements were taken. Because fasting blood glucose in 
mice may not be representative of steady-state conditions,(35) the blood glucose 
measurements of these mice were excluded from mean blood glucose calculations for 
each group. No other treatments were applied to these mice throughout the study. 
Mice were euthanized with carbon dioxide at 20 weeks of age, and the femora were 
dissected. The stifle joints (including the distal half of each femur) were allocated to 
osteoarthritis analyses,(33) and the proximal halves of the femora were allocated to 
bone tissue compositional analyses for the current study. The proximal femora were 
wrapped in saline-soaked gauze and frozen at -20 °C. All animal care and procedures 
were performed at the University of Colorado School of Medicine with the approval of 
the Institutional Animal Care and Use Committee. 
3.2.2 Fourier Transform Infrared Imaging 
Fourier transform infrared (FTIR) imaging was used to evaluate bone tissue 
compositional properties in a spatially resolved fashion. The proximal femora were 
thawed, dehydrated in graded organic solvents, and embedded in poly(methyl 
methacrylate) (PMMA). For each of the femora, three non-consecutive, 1-µm-thick 
longitudinal sections spaced a minimum of 10 µm apart were cut near the midplane of 
the femur with a microtome (SM2500, Leica Biosystems, Nussloch, Germany) and 
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placed on BaF2 windows (Spectral Systems, Hopewell Junction, NY).  
FTIR images were collected at two levels of structural hierarchy: 1) a whole-
proximal-femur image was generated at 25 µm spatial resolution, and 2) tissue-
specific cortical and trabecular regions of interest (ROIs) (size: 400 µm x 500 µm) 
were generated at 6.25 µm spatial resolution. For each section, a single whole-
proximal-femur image, in addition to three cortical and three trabecular ROIs (Figure 
S1), were collected over the spectral range 800-2000 cm-1 at a spectral resolution of 4 
cm-1 using an infrared imaging system (Spotlight 400, Perkin-Elmer Instruments, 
Waltham, MA). Subsequently, chemical imaging software (ISys, Malvern Instruments, 
Worcestershire, UK) was used to remove the background, baseline, and subtract the 
PMMA spectral contribution from the bone spectra.(36) For five proximal femora, soft 
tissue on the femoral head was present at the time of PMMA embedding. This soft 
tissue was excluded from FTIR image analysis with a spectral mask. 
For each image, the infrared spectrum at each pixel was analyzed to determine 
the following parameters: mineral:matrix ratio, carbonate:phosphate ratio, collagen 
maturity, and mineral crystallinity.(37) The mineral:matrix ratio (area ratio of the 
phosphate 1-3 and amide I peaks) characterizes tissue mineral content;(38,39) the 
carbonate:phosphate ratio (area ratio of the carbonate 2 and phosphate 1-3 peaks) 
characterizes the extent to which carbonate substitutes into the mineral lattice;(40) 
collagen maturity (the intensity ratio of 1660 cm-1 and 1690 cm-1) is related to the ratio 
of mature, non-reducible collagen crosslinks to immature, reducible collagen 
crosslinks;(41) and the mineral crystallinity (intensity ratio of 1030 cm-1 and 1020 cm-1) 
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is related to crystal size and perfection assessed by x-ray diffraction.(42) Two outcome 
measurements were obtained for each FTIR parameter from each image: the mean 
value of all pixels and the distribution width (calculated as the full-width at half-
maximum (FWHM) of the Gaussian curve fit to the distribution of pixels, Fig. 2) to 
assess compositional heterogeneity. Thus, eight outcomes were assessed separately for 
cortical, trabecular, and whole-proximal-femur ROIs: 1) mean mineral:matrix ratio, 2) 
mean carbonate:phosphate ratio, 3) mean collagen maturity, 4) mean crystallinity, 5) 
mineral:matrix ratio FWHM, 6) carbonate:phosphate ratio FWHM, 7) collagen 
maturity FWHM, and 8) crystallinity FWHM.  
3.2.3 High-performance Liquid Chromatography 
High-performance liquid chromatography (HPLC) was used to quantify the AGE 
pentosidine in the whole proximal femur. The enzymatic crosslinks HP and LP were 
quantified as secondary outcomes.  
Following completion of FTIR imaging, the proximal femora were de-
embedded from PMMA through agitation in methyl acetate for three days, with a 
solution change every 24 hours. After de-embedding, the femora were agitated in 
100% acetone (24 h), 100% ethanol (24 h), and isopropyl ether (3x, 15 min). After 
rinsing with DI water, the femora were lyophilized then hydrolyzed in 6 N HCl at 110 
°C for 18 h. The hydrolysates were dried in a vacuum centrifuge (Speed Vac SC110A, 
Savant, Farmingdale, NY) then re-suspended in an internal standard solution 
containing 10 nM pyridoxine and 2.4 μM homoarginine; 30 μl of internal standard 
solution was added for every mg of dried bone. The re-suspended samples were 
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filtered, then diluted 1:5 with 10% acetonitrile (v/v) and 0.5% heptafluorobutyric acid 
(v/v).  
Samples were injected into the column and separated using two isocratic 
steps.(29,43) A calibrator containing all three crosslinks (pentosidine, HP, LP) was 
serially diluted 1:2 five times to create a linear calibration curve. The pentosidine 
standard was purchased from Case Western Reserve University (Cleveland, OH), and 
the HP and LP standards were purchased from Quidel (8004, Quidel, Athens, OH). 
Separations were performed with a Gemini-NX C-18 column (Phenomenex, Torrance, 
CA) connected to a programmable HPLC system (Model 126, Beckman Coulter, Inc., 
Fullerton, CA). 32 Karat Workstation software (v. 5.0, Beckman Coulter, Inc., Brea, 
CA) was used to control the autosampler, pump, and fluorimeter (Model FP1520, 
Jasco, Easton, MD). Data analysis was performed using 32 Karat Workstation 
software and MATLAB (2012a, The MathWorks, Inc., Natick, MA).  
Pentosidine, HP, and LP concentrations were normalized by collagen 
concentration as determined by hydroxyproline concentration. For the hydroxyproline 
measurements, an aliquot of the diluted sample from the crosslink analysis was further 
diluted 1:50 with 6 μM homoarginine in 0.1 M borate buffer (pH 11.4), derivatized 
using 6 mM 9-fluorenylmethyl chloroformate for 40 minutes, and extracted using 
pentane. Pentane extraction removes excess FMOC-Cl reagent, FMOC-OH reaction 
product, and acetone. Three extractions were performed, then 25% (v/v) acetonitrile in 
0.25 M boric acid (pH 5.5) was added. The separation of amino acids was run using 
the same column and system as the crosslink separations using the injection sequence 
  
95 
 
described by Bank et al.(44) Five serial 1:2 dilutions of purified hydroxyproline 
(Sigma-Aldrich, St. Louis, MO) and 6 μM homoarginine in 0.1 M borate buffer (pH 
11.4) were used to make a linear calibration curve for hydroxyproline. Collagen 
concentration was determined from the constant ratio of hydroxyproline in fibrillar 
collagen (300 mol hydroxyproline per mol collagen). 
The final outcomes for HPLC included concentrations for pentosidine, HP, and 
LP. The ratio of HP to LP (HP:LP), the total concentration of mature enzymatic 
crosslinks (HP+LP), and the ratio of pentosidine to mature enzymatic crosslinks 
(Pentosidine:HP+LP) were also examined.  
3.2.4 Statistical Analysis 
Mouse characteristics (body mass, lifetime-average non-fasting blood glucose) and 
collagen crosslinks (pentosidine, HP, LP) were assessed for normality and 
homogeneity of variances, and a two-tailed Student’s t-test was performed to assess 
differences between groups. A significance level of 0.05 was used for all analyses. 
 For the eight FTIR outcome variables, cortical, trabecular, and whole-
proximal-femur regions were analyzed separately. For each region, a linear mixed 
model was used to assess the relationship between genotype (Ay/a, a/a) while 
accounting for the multiple sections analyzed per mouse (3 sections/femur) and for 
repeated measurements made within each section (3 trabecular ROIs and 3 cortical 
ROIs). To test if the increased mass of the Ay/a mice vs. controls had an effect on the 
FTIR outcome variables, subsequent linear mixed models that included the fixed 
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effect of body mass were analyzed. Pairwise differences between groups were 
assessed with Tukey post-hoc tests. The reported percent differences for FTIR 
parameters were calculated from the raw data, while the p-values were determined by 
the linear mixed models.  
The relationships of lifetime-average blood glucose with all FTIR imaging and 
HPLC outcomes were analyzed to elucidate the effects of hyperglycemia on tissue 
material properties. Cortical, trabecular, and whole-proximal-femur FTIR ROIs were 
regressed separately with lifetime-average blood glucose to highlight potential region-
specific effects of hyperglycemia. Because AGE accumulation may also affect bone 
turnover, the relationships of pentosidine and the proximal femur FTIR outcomes were 
also investigated. The HPLC measurements of collagen crosslinks were performed on 
the homogenized whole proximal femur, so region-specific (i.e., cortical, trabecular) 
correlations were not assessed between pentosidine and the FTIR imaging outcomes. 
For all regressions, Ay/a and a/a data were pooled because the relationships did not 
differ between groups (p > 0.05). 
3.3 Results 
3.3.1 Mouse Characteristics 
The Ay/a mice experienced hyperglycemia for a minimum duration of 12 weeks and 
were heavier than their a/a littermate controls. In Ay/a mice relative to controls, the 
lifetime-average non-fasting blood glucose was 83% higher (mean ± SD, Ay/a: 426.5 ± 
49.2 mg/dL vs. a/a: 234.5 ± 5.1 mg/dL, p << 0.001), and body mass at time of DMM 
  
97 
 
surgery was 16% higher (Ay/a: 36.7 ± 3.8 g vs. a/a: 31.5 ± 2.6 g, p = 0.0024). 
Furthermore, hyperglycemia in the Ay/a mice was confirmed over the 12-week study 
period. The non-fasting blood glucose of the Ay/a mice was 67% greater than the a/a 
mice at 8 weeks of age (Ay/a: 346.2 ± 130.6 mg/dL vs. a/a: 207.6 ± 18.5 mg/dL, p < 
0.001), 114% greater at 12 weeks of age (at DMM surgery): (Ay/a: 413.3 ± 93.2 
mg/dL vs. a/a: 193.0 ± 11.8 mg/dL, p < 0.001), and 76% greater at 20 weeks of age (at 
euthanasia): (Ay/a: 456.8 ± 76.3 mg/dL vs. a/a: 258.5 ± 41.7 mg/dL, p < 0.001).  
3.3.2 FTIR Imaging: Parameter Distribution Means and Widths 
Bone tissue from the Ay/a mice exhibited greater mean collagen maturity and mineral 
content, and narrower distribution widths of carbonate:phosphate ratio and 
crystallinity compared to the a/a mice.  
Compared to a/a controls, mean collagen maturity was greater in the Ay/a mice 
in cortical bone (+12%, p = 0.0285; Figure 3.3-1A, Figure 3.3-2A), trabecular bone 
(+8%, p = 0.0399; Figure 3.3-1A, Figure 3.3-2C), and in the whole proximal femur 
(+7%, p = 0.0499; Figure 3.3-1A, Figure 3.3-2B). In the whole proximal femur, the 
mean mineral:matrix ratio was greater in Ay/a mice compared to controls (+12%, p = 
0.0233; Figure 3.3-1A, Figure 3.3-2B) and trended towards being greater in cortical 
bone (+8%, p = 0.0790; Figure 3.3-1A). Body mass had a significant positive effect on 
the mean mineral:matrix ratio in cortical bone (p < 0.001); however, no observed 
effect of body mass on mean mineral:matrix ratio was observed in the trabecular or 
whole proximal femur regions or in the mean collagen maturity of cortical, trabecular, 
and whole proximal femur regions. The mean carbonate:phosphate ratio and mean 
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crystallinity were similar between Ay/a and a/a mice across all regions. Distributions 
were narrower in the Ay/a mice compared to controls for carbonate:phosphate ratio (-
19%, p = 0.0078; Figure 3.3-1B, Figure 3.3-3A) and crystallinity (-24%, p = 0.0099; 
Figure 3.3-1B, Figure 3.3-3B) in the whole proximal femora. The distribution widths 
were similar for all other parameters.  
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Figure 3.3-1: FTIR parameter distribution means (A) and widths (B) for cortical, 
trabecular, and whole-proximal-femur regions by group. Bar heights indicate the 
parameter means, and error bars denote the 95% confidence interval. * indicates 
p<0.05 and # p<0.10, after adjustment for repeated measures in the linear mixed 
models. 
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Figure 3.3-2: Representative images of selected FTIR parameters in a/a and Ay/a 
mouse bone for A) cortical collagen maturity, B) whole proximal femur collagen 
maturity, C) trabecular collagen maturity, and D) whole proximal femur 
mineral:matrix ratio. Scale bars indicate 50 μm in cortical and trabecular images and 
500 μm in whole-proximal-femur images. 
Figure 3.3-3: Representative images of selected FTIR parameters and corresponding 
pixel histograms in a/a and Ay/a specimens for A) whole proximal femur 
carbonate:phosphate ratio, and B) whole proximal femur crystallinity. Scale bars on 
FTIR images indicate 500 μm. The red curve on each pixel histograms indicates the 
Gaussian distribution fit, and the white horizontal bar with arrows indicates the full 
width at half maximum (FWHM). 
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3.3.3 HPLC Collagen Crosslinks  
 
The concentrations of pentosidine, HP, and LP and the parameters HP:LP, HP+LP, 
and Pentosidine:HP+LP in the whole proximal femur were similar between groups 
(Table 3.3-1).  
Table 3.3-1: Concentrations of collagen crosslinks determined with HPLC and 
selected collagen crosslink ratios. HP = hydroxylysyl pyridinoline, LP = lysyl 
pyridinoline. p-value represents Student’s t-test between Ay/a and a/a groups. 
  
Outcome a/a 
(mean ± SD) 
Ay/a 
(mean ± SD) 
p 
Pentosidine (mmol/mol 
collagen) 
2.12 ± 1.04 2.48 ± 1.48 0.6300 
HP (mol/mol collagen) 0.59 ± 0.30 0.68 ± 0.28 0.5586 
LP (mol/mol collagen) 0.24 ± 0.09 0.24 ± 0.13 0.5380 
HP:LP 2.50 ± 0.79 2.95 ± 0.83 0.8788 
 
HP+LP 0.82 ± 0.36 2.42 ± 1.48 0.7055 
Pentosidine:HP+LP 2.68 ± 1.00 2.75 ± 1.04 0.5597 
 
 
Association of Blood Glucose with Collagen Crosslinks and Tissue Material 
Properties  
When relationships between lifetime-average blood glucose and FTIR imaging 
parameters were examined, these parameters were correlated in trabecular and whole-
proximal-femur ROIs, but not in cortical ROIs. In the trabecular ROIs, lifetime-
average blood glucose correlated with 1) carbonate:phosphate ratio FWHM and 2) 
collagen maturity FWHM, and 3) trended towards a correlation with mean collagen 
maturity (Table 3.3-2). In the whole-proximal-femur ROIs, lifetime-average blood 
glucose correlated with 1) mean collagen maturity, 2) carbonate:phosphate ratio 
FWHM, and 3) crystallinity FWHM, and 4) trended towards a correlation with 
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mineral:matrix ratio FWHM (Table 3.3-2). 
Lifetime-average blood glucose did not correlate with the concentrations of 
pentosidine, HP, and LP assessed by HPLC, or with HP:LP, HP+LP, or 
Pentosidine:HP+LP (Table 3.3-2). The concentration of pentosidine did not correlate 
with any whole-proximal-femur FTIR imaging parameters; however, pentosidine 
correlated with 1) HP, 2) LP, and 3) HP+LP (Table 3.3-2). 
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Table 3.3-2: Correlations between lifetime-average blood glucose and pentosidine with FTIR imaging parameters and HPLC-
determined collagen crosslinks. FWHM = full-width at half-maximum, HP = hydroxylysyl pyridinoline, LP = lysyl pyridinoline. 
Bold values indicate p < 0.05. 
 Lifetime-Average Blood Glucose (mg/dL) Pentosidine (mmol/mol collagen) 
Outcome Correlation 
Coefficient (r) 
R2 p Correlation 
Coefficient (r) 
R2 p 
FTIR Imaging       
Trabecular       
Mean Collagen 
Maturity 
0.503 0.253 0.0669 N/A N/A N/A 
Carbonate:Phosphate 
Ratio FWHM 
0.626 0.392 0.0166 N/A N/A N/A 
Collagen Maturity 
FWHM 
0.552 0.305 0.0407 N/A N/A N/A 
hole Proximal 
Femur 
            
Mean Collagen 
Maturity 
0.600 0.361 0.0300 0.238 0.057 0.3116 
ineral:Matrix Ratio 
FWHM 
0.568 0.322 0.0685 0.040 0.002 0.8755 
Carbonate:Phosphate 
Ratio FWHM 
-0.656 0.430 0.0150 0.048 0.002 0.8406 
Crystallinity FWHM  -0.763 0.582 0.0024 0.032 0.001 0.8928 
HPLC              
Pentosidine 0.233 0.054 0.4441 N/A N/A N/A 
HP 0.242 0.059 0.3906 0.597 0.357 0.0042 
LP  0.339 0.115 0.2573 0.877 0.769 0.0006 
HP:LP 0.003 0.000 0.9931 0.241 0.058 0.2920 
HP+LP  0.293 0.086 0.3312 0.715 0.511 0.0003 
Pentosidine:HP+LP 0.166 0.027 0.5888 N/A N/A N/A 
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3.4 Discussion  
In this study, we assessed the effects of hyperglycemia on bone tissue AGEs and 
material properties in the KK-Ay murine model of T2DM. The blood glucose levels 
and body masses of the KK-Ay mice in this study are comparable to previously 
reported values,(21,23) and confirm the KK-Ay mice to be hyperglycemic and obese. 
The control mice were euglycemic and overweight. 
Our data reveal that bone tissue from Ay/a mice has 1) increased collagen 
maturity, 2) increased mineral content, and 3) less heterogeneous mineral properties 
compared to control a/a mice. Specifically, the greater mean collagen maturity, 
assessed with FTIR imaging observed in Ay/a vs. a/a bone tissue, demonstrates a 
higher ratio of mature enzymatic crosslinks to immature crosslinks, which is 
consistent with older, more mature tissue.(41) The greater mean mineral:matrix ratio 
observed in Ay/a vs. a/a bone tissue similarly points to an increased tissue age (i.e., 
time since tissue formation), as older tissue will have a greater mineral content.(45) The 
narrower distribution widths of the carbonate:phosphate ratio and crystallinity of Ay/a 
vs. a/a whole proximal femoral bone tissue suggest the Ay/a mice had less bone 
turnover.(46) 
Several key mechanisms can modulate tissue properties in murine bone, even 
at cortical sites that lack a robust intra cortical remodeling process. The observed 
alterations in mean mineral content may arise from 1) differing rates of periosteal 
expansion and endosteal resorption(47) or 2) direct osteocytic regulation.(48) In healthy 
tissue, changes in collagen maturity typically reflect turnover; however, the alterations 
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in this parameter observed in the KK-Ay mice could alternatively arise from an 
accelerated rate of conversion from divalent to trivalent enzymatic crosslinks. In the 
absence of double-labels for new bone formation, the current study design precludes 
discernment of the precise mechanism(s) responsible for the observed changes in 
tissue properties. Furthermore, prior findings regarding the balance of formation and 
resorption markers in KK-Ay mice are in conflict: some studies report decreased bone 
turnover markers,(24) while others report upregulation of bone turnover-related gene 
expression.(25) Together, these findings indicate complex, compartment-dependent 
effects of hyperglycemia in the KK-Ay mouse model. 
Previous studies of the KK-Ay mouse(25,26) and other rodent models of 
T2DM(27,32) point to a larger effect of T2DM on BMD in trabecular bone compared to 
cortical bone and the whole bone. In this study, a greater mean collagen maturity was 
observed in the bone tissue of Ay/a mice vs. the a/a mice in all compartments 
examined (trabecular, cortical, and whole proximal femur), but no differences in 
mineral properties were observed in the trabecular compartment. It is likely that two 
key factors affected our ability to detect subtle differences in mineral properties in 
trabecular bone: 1) the small analysis area of trabecular compartments (i.e., the 
number of bone pixels vs. non-bone pixels per ROI) and 2) the inherent variability of 
the distribution width, particularly in the carbonate:phosphate ratio.  
The regressions of FTIR imaging parameters with mean blood glucose support 
the interpretation that the Ay/a tissue is older with less turnover and that the reduced 
turnover is in part due to hyperglycemia. Mean collagen maturity in trabecular bone 
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and the whole proximal femur increased with worsening hyperglycemia (R2 = 0.253, p 
= 0.0669; R2 = 0.600, p = 0.0300, respectively), and the carbonate:phosphate ratio and 
crystallinity distribution widths in the whole proximal femur narrowed with increasing 
hyperglycemia (R2 = 0.430, p = 0.0150; R2 = 0.600, p = 0.0300, respectively) (Table 
3.3-2). Together, these results indicate that the Ay/a bone tissue is older, consistent 
with the observations of disrupted and/or reduced remodeling processes in T2DM.(15–
18) 
One potential explanation for the greater mineral content observed in the Ay/a 
vs. a/a mice is body mass. Because the Ay/a mice were heavier than the a/a controls, 
the greater tissue mineral content observed in the Ay/a mice may reflect an adaptive 
response. When body mass was added as a factor in the linear mixed models for the 
mean mineral:matrix ratio and collagen maturity parameters, body mass had a 
significant positive effect on mean mineral:matrix ratio in the cortical compartment (p 
< 0.001). Thus, it is likely that body mass is a contributing factor for the increased 
mineral content in the Ay/a vs. a/a mice; however, the lack of an effect of body mass 
with respect to the collagen maturity indicates body mass alone does not describe the 
observed changes to the collagen in the Ay/a mice.  
AGE accumulation in the whole proximal femur assessed by pentosidine 
concentration did not increase with hyperglycemia in Ay/a mice, as demonstrated by 
the lack of correlation between lifetime-average blood glucose and pentosidine 
concentration in the whole proximal femur (Table 3.3-2). Although bone tissue 
ribosylated and glycated at supra-physiological concentrations in vitro is characterized 
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by increased total AGEs and pentosidine,(8,9,49,50) evidence of AGE accumulation due 
to T2DM in vivo is currently inconclusive. Specifically, bone tissue pentosidine 
concentration increased in T2DM rats compared to non-DM controls;(11) however, no 
difference in pentosidine concentration was found in a study of human bone from 
T2DM and non-DM patients.(28) 
There are several factors that may explain the similar levels of pentosidine 
between Ay/a and a/a mice. First, pentosidine is just one of hundreds of AGE species, 
and while HPLC measurement of pentosidine concentration is accepted as a sensitive 
assay of this crosslink, it has not yet known if tissue pentosidine concentration is a 
representative measurement of all tissue AGE species.(51) Second, cortical and 
trabecular bone differentially accumulate AGEs, but the differences show inconsistent 
trends. Human trabecular bone accumulated more fluorescent AGEs than cortical bone 
during in vitro glycation and ribosylation,(49,50) but cortical bone accumulated more 
pentosidine than trabecular bone in in vivo studies of type 1 diabetic(52) and non-
diabetic women and men.(53) In the current study of the proximal femur, the masses of 
the murine trabecular and cortical diaphyseal tissue alone were too small to generate 
detectable signals for HPLC. Consequently, the whole proximal femora were 
homogenized for HPLC analyses, thereby preventing analysis of compartment-specific 
pentosidine accumulation. Because of this limitation, a difference in pentosidine 
concentration between genotypes in trabecular or cortical bone, which may have been 
detected in a compartment-specific assay, could have been masked in the 
homogenized assay by equal (or opposite) concentrations across genotypes in the other 
compartment. Third, the formation of AGEs like pentosidine can take weeks to form 
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in vivo.(54) It is possible that the 20-week lifespan of these mice was not long enough 
to accumulate more pentosidine in the Ay/a mice compared to a/a mice, even in 
hyperglycemic conditions. To our knowledge, no study monitoring the progression of 
AGE accumulation with aging in mice has been performed; however, pentosidine 
concentrations in T2DM rats did not differ from non-DM rats until 12 months of 
age.(11) 
The concentrations of the enzymatic crosslinks HP and LP were similar 
between groups which indicates that the concentration of mature pyridinoline 
crosslinks in the whole proximal femur remained constant with hyperglycemia. These 
results are consistent with data from a T2DM rodent model(11) and T2DM human 
tissue.(28,29) Although concentrations of immature crosslinks were not assessed 
directly, the effects of hyperglycemia on their concentrations can be inferred. Because 
collagen maturity (as measured with FTIR) increased, and HP and LP (as measured 
with HPLC) did not change in the Ay/a vs. a/a mice, the observed increase in collagen 
maturity may be due to a decrease in enzymatic crosslinking. This effect is consistent 
with a decrease in immature enzymatic crosslinking observed in T2DM rats.(11)  
There are several limitations and strengths to note for interpreting our findings. 
First, non-fasting blood glucose measurements were only available for approximately 
two-thirds of the mice use in this study (Ay/a: n = 10/14, a/a: n = 4/8). Due to the 
yellow coat color of the mice with the Ay allele, we can be confident in the mouse 
genotype; however, directly evaluating the glycemic control to the extent of tissue 
material changes was not possible for every mouse. Second, the lack of double-labels 
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for bone formation prevented identification of the mechanism responsible for the 
changes in the observed tissue properties. In particular, because onset of T2DM in the 
Ay/a mice occurred prior to attainment of skeletal maturity, the contribution of any 
differences in periosteal expansion and endosteal resorption between groups to the 
observed compositional differences could not be assessed. Third, the small masses of 
metaphyseal trabecular tissue and diaphyseal cortical tissue in these specimens 
precluded separate HPLC analyses of trabecular and cortical bone, and the whole 
proximal femora were homogenized. Thus, the crosslinks measured by HPLC are a 
mixture of both cortical and trabecular crosslinks. Because the proximal femora were 
mostly cortical bone by mass (exemplified in Figure 3.3-1B, Figure 3.3-1D, Figure 
3.3-2A, Figure 3.3-2B), it is likely that the measured pentosidine concentration was 
dominated by pentosidine from cortical tissue. On the other hand, a negligible 
contribution of pentosidine from trabecular tissue cannot be guaranteed. The inability 
to differentiate pentosidine concentrations in the trabecular and cortical compartments 
is a major limitation of this assay because AGEs differentially accumulate in a 
compartment-dependent manner.(49,50,52,53) However, the HPLC analysis of the 
homogenized tissue provides insight into collagen crosslinking at the level of the 
whole proximal femur, and the results of these analyses can be directly compared to 
the whole-proximal-femur region FTIR parameters. Lastly, we note that the 
concentrations of HP and LP found in our study are slightly higher than previously 
reported values;(55) however, our ratio of HP to LP is well within established ranges.(55) 
Although the femora were carefully cleaned of soft tissue prior to hydrolysis for 
HPLC analysis, it is possible that small contributions of soft tissue were included in 
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the HPLC collagen crosslink assessments which could increase HP and LP 
concentrations.(55) Nevertheless, the data presented here contribute to the 
understanding of bone material property changes in T2DM due to hyperglycemia.  
This work is the first to characterize the compositional characteristics of bone 
in the KK-Ay mouse. Our study showed spatially-resolved changes in tissue-level 
material properties due to hyperglycemia in the KK-Ay mouse, and the findings of 
increased mean collagen maturity and mineral content in the KK-Ay mice compared 
to controls is consistent with previous documentation of reduced bone turnover with 
T2DM. Overt T2DM manifests in KK-Ay mice around eight weeks of age as a result 
of insulin resistance, thus the KK-Ay mouse exhibits an essential feature of T2DM in 
humans. In summary, the observed changes in the tissue material properties of KK-Ay 
mice contribute to an evolving understanding of alterations in bone quality with 
T2DM.  
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3.7 Supplemental 
Figure 3.6-S3.6-1: Representative optical image of proximal femur with 
cortical and trabecular regions of interest noted. 
  
119 
 
CHAPTER 4 
BONE TISSUE COMPOSITION IN POST-MENOPAUSAL WOMEN VARIES 
WITH GLYCEMIC CONTROL 
 
4.1 Introduction  
Hip fracture is a devastating event, especially for older adults, and can lead to a lower 
quality of life, higher medical costs, and an increased risk of mortality.(1–4) The risk of 
experiencing a fragility fracture increases substantially for people with type 2 diabetes 
mellitus (T2DM),(5–8) despite people with T2DM having normal or high bone mineral 
density (BMD), which conventionally signifies skeletal integrity.(9–11) The increase in 
fracture risk while maintaining bone mass indicates that the T2DM disease state 
adversely affects bone quality, thereby leading to decreased skeletal performance.(12–14) 
 Interestingly, people with impaired glucose tolerance (IGT) do not share the 
significantly greater fracture risk as those with overt T2DM. In the Health Aging and 
Body Composition study, men and women with T2DM and normal BMD had a 64% 
increased risk of fracture (relative risk [RR] and 95% confidence interval [CI], 1.64, 
1.07-2.51) while those with IGT did not have a significant increased risk.(15) Similar 
findings were observed in the Rotterdam study: people with overt T2DM and IGT had 
higher BMD than non-diabetic controls; however, only the T2DM group had a greater 
fracture risk.(10) Taken together, these findings suggest that the transition from IGT to 
T2DM, while maintaining BMD, has deleterious effects on bone quality that contribute 
to the observed greater fracture risk in people with T2DM.  
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 The mechanism by which the transition from normal glucose tolerance (NGT) to 
IGT to overt T2DM changes bone quality is currently unknown. Current hypotheses, 
however, include impaired bone remodeling and accumulation of advanced glycation 
endproducts (AGEs), both of which can alter tissue composition. In cross-sectional 
studies of people with and without T2DM, people with T2DM had lower bone 
formation markers(16–21) and bone resorption markers than those without T2DM,(19–21) 
and these findings were corroborated by histomorphometric analyses.(22) The effects of 
altered bone remodeling on tissue composition has been extensively demonstrated, 
particularly through studies of osteoporosis and bisphosphonate treatments.(23,24) In 
addition, high sugar conditions in vitro and ex vivo lead to the formation and 
accumulation of non-enzymatic crosslinks (a.k.a. AGEs) in bone,(25–28) which inherently 
changes the crosslink profile of the tissue and can have downstream effects on the tissue 
mechanics. For example, an animal model of T2DM found that the onset of T2DM 
coincided with the accumulation of AGEs, decreased concentrations of enzymatically 
formed crosslinks, and decreased energy absorption capabilities.(29) Furthermore, there 
is evidence that AGE-modified tissue can decrease osteoblast and osteoclast 
function,(30–33) thus potentially creating a positive feedback cycle of greater AGE 
accumulation and decreased tissue remodeling.  
 To understand how progressive glycemic derangement affects bone tissue 
composition, we used Fourier transform infrared (FTIR) imaging to spatially analyze 
cortical and cancellous bone from women with normal glucose tolerance, impaired 
glucose tolerance, and overt type 2 diabetes mellitus. The goal of this research is to 
elucidate how progressive glycemic derangement changes bone tissue composition. 
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4.2 Methods 
4.2.1 Study Cohort 
Post-menopausal women between the ages of 50 and 80 years were sequentially 
recruited and allocated to three groups: 1) normal glucose tolerance (NGT, n = 32), 
defined as a 2-hour 75 g oral glucose tolerance test (OGTT) less than 140 mg/dL; 2) 
impaired glucose tolerance (IGT, n = 25), defined has OGTT greater than 140 but less 
than 199 mg/dL; and 3) T2DM (n = 23), defined as participants with an existing T2DM 
diagnosis and on insulin therapy. Women with a T2DM diagnosis but not on insulin 
therapy were excluded from the T2DM group in order to capture the effects of T2DM 
among the population with the greatest fracture risk.(11) In addition, women with 
nephropathy were excluded from this study to remove potential confounding effects. 
The participant characteristics are shown in Table 4.3-1. 
All participants gave informed consent, and all procedures were approved by the 
Johns Hopkins Medicine Internal Review Board. The participants came for a total of 
five visits: 1) Initial screening to assess medical history and administer OGTT to 
determine glycemic control; 2) Secondary screening to administer blood and urine 
analyses; 3) Baseline visit to instruct participants how to administer demeclocycline 
double-labeling and how to prepare for bone biopsy; 4) Iliac crest bone biopsy visit; and 
5) Final visit to remove sutures and address follow-up questions. Participants were 
compensated for each visit.  
  
122 
 
4.2.2 Fourier Transform Infrared Imaging 
The compositional properties of cortical and trabecular iliac crest bone tissue were 
evaluated using Fourier transform infrared (FTIR) imaging. The transiliac crest biopsies 
were dehydrated using organic solvents, embedded in poly(methyl methacrylate) 
(PMMA), longitudinally microtomed into 1-μm-thick sections (SM2500, Leica 
Biosystems, Nussloch, Germany), and placed on BaF2 windows (Spectral Systems, 
Hopewell Junction, NY). Three sections were taken per biopsy at a minimum of 10 μm 
of longitudinal distance apart. 
For each section, three cortical and three trabecular regions of interest (ROIs) of 
400 μm x 500 μm were collected at a spatial resolution of 6.25 μm. FTIR images for 
each ROI were generated over the spectral range 800-2000 cm-1 at a spectral resolution 
of 4 cm-1 using an infrared imaging system (Spotlight 400, Perkin-Elmer Instruments, 
Waltham, MA). Chemical imaging software (ISys, Malvern Instruments, 
Worcestershire, UK) was used to baseline the spectra, remove the PMMA contribution 
from the bone spectra (as described in (34)), and exclude any non-bone pixels.  
For each FTIR image of the cortical and trabecular ROIs, the spectrum at each 
bone tissue pixel was analyzed to determine the following parameters: 1) collagen 
maturity (XLR), which is the intensity ratio of 1660 cm-1 to 1690 cm-1 and is related to 
the ratio of pyridinoline to divalent crosslinks; (35,36) 2) mineral:matrix ratio (M:M), 
which is the area ratio of the phosphate 1-3 peak (916-1180 cm-1) to amide I peak 
(1596-1712 cm-1) and characterizes tissue mineral content;(37,38) 3) crystallinity (XST), 
which is the intensity ratio of 1030 cm-1 to 1020 cm-1 and is related to hydroxyapatite 
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crystal size and stoichiometric perfection;(39) 4) carbonate:phosphate ratio (C:P), which 
is the area ratio of the carbonate 2 peak (852-890 cm-1) to phosphate 1-3 peak (916-
1180 cm-1) and characterizes carbonate substitution into hydroxyapatite;(40,41) and 5) and 
acid phosphate content (AP), which is the intensity ratio of 1127 cm-1 to 1096 cm-1 and 
characterizes acid phosphate substitution into stoichiometric hydroxyapatite.(41,42) Next, 
a histogram of the pixels values for each FTIR parameter of an ROI was generated and 
a normal distribution was fit to the data. The full-width at half-maximum (FWHM), an 
indication of parameter heterogeneity, was then calculated from the normal distribution 
(see reference 11 for an example).  
For the FTIR compositional parameters evaluated on each ROI (XLR, M:M, 
XST, C:P, AP), the following outcome variables were calculated: 1) the mean value of 
the parameter distribution; 2) the parameter FWHM; 3) the parameter “head” value, 
which is the 5th percentile of the parameter data; and 4) the parameter “tail” value, 
which is the 95th percentile of the parameter data.  
4.2.3 Statistical Analyses 
Differences across groups for participant characteristics were determined by a Kruskal-
Wallis H test for continuous variables and by a Chi-square test for nominal variables. 
Bivariate linear regressions were performed with each of the cortical and trabecular 
FTIR parameter averages of each sample with 1) T2DM duration (for the T2DM group 
only), 2) HbA1c, and 3) bone turnover markers. For HbA1c and bone turnover markers, 
all three groups were included in the regression first, then the NGT group was removed 
and the regression analyzed again to determine relationships among just deranged 
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glycemic control. Regressions were considered to be significant if p < 0.05 was 
achieved as well as R2 > 0.10. 
Cortical and trabecular outcome variables were analyzed separately. Linear 
mixed effects models were used to assess the relationship between group (NGT, IGT, 
T2DM) and each FTIR imaging outcome variable while controlling for the repeated 
measurements made per biopsy (3 sections/biopsy) and per section (3 cortical and 3 
trabecular ROIs/section). Pairwise differences between groups were assessed with 
Tukey post-hoc tests. Percent differences of the FTIR imaging outcome variables 
between groups were calculated from the raw data, while the corresponding reported p-
values were determined by the linear mixed effects models. A significance level of 0.05 
was used for all analyses.  
4.3 Results 
4.3.1 Study Cohort 
Thirty-five women were included in the NGT group, 26 in the IGT group, and 25 in the 
T2DM group. The ages were similar among groups. As expected, the HbA1c confirmed 
T2DM status in the T2DM group (> 6.5%), and the HbA1c of the T2DM group was 
significantly higher than the NGT and IGT groups (Table 4.3-1). BMI in the IGT and 
T2DM groups was 16% and 23% greater than that of the NGT group, respectively (both 
p < 0.05), and did not differ between the IGT and T2DM groups (Table 4.3-1). There 
were more white women in the NGT group than the T2DM group and more black 
women in the T2DM group than the NGT group (Table 4.3-1). The characteristics of 
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the participating women were otherwise not different among groups. 
Serum and urinary analyses revealed a 39% greater parathyroid hormone (PTH) 
concentration in the IGT versus NGT group, and a 20% and 21% greater alkaline 
phosphatase (ALP) concentration in the T2DM group versus the NGT an IGT groups, 
respectively (all p < 0.05) (Table 4.3-1). 25-hyrdoxyvitamin D, creatinine, calcium, 
phosphorous, eGFR, sclerostin, and pentosidine were not different between groups 
(Table 4.3-1). In terms of bone turnover markers, there was a 25% and 24% lower 
P1NP concentration in the T2DM group versus the NGT and IGT groups, respectively; 
a 31% decrease in CTx concentration in the T2DM versus the NGT group; and a 25% 
decrease in ucOC concentration in the T2DM versus the NGT group (all p < 0.05) 
(Table 4.3-1). 
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Table 4.3-1: Participant characteristics by group. Values shown are mean ± std unless otherwise noted. Statistical significance 
determined by Kruskal-Wallis H test or Chi-square test at a significance level of 0.05. † indicates difference between NGT and IGT 
groups; ‡ indicates difference between NGT and T2DM groups; ҂ indicates difference between IGT and T2DM groups. 
Abbreviations: NGT = normal glucose tolerance group; IGT = impaired glucose tolerance group; T2DM = type 2 diabetes mellitus 
group; OGTT = oral glucose tolerance test; eGFR = estimated glomerular filtration rate; CTx = carboxy-terminal telopeptide of 
type 1 collagen; P1NP = amino-terminal propeptide of type 1 collagen; ucOC = undercarboxylated osteocalcin; n/a = not 
applicable.  
 
 
Characteristics NGT IGT T2DM Sig. Key 
n 35 26 25 
 
Anthropometric  
    
Age (years)  64.8 ± 6.8 64.4 ± 5.4 63.8 ± 6.2 
 
Weight (kg) 76.4 ± 14.6 94.0 ± 22.9 94.3 ± 16.4 † ‡ 
Height (cm) 160.8 ± 6.7 165.6 ± 6.5 160.9 ± 5.9 † ҂ 
BMI (kg/m2) 29.6 ± 5.6 34.3 ± 8.4 36.5 ± 6.9 † ‡ 
Race/ethnicity 
    
White, n (%) 27 (77) 13 (50) 6 (24) ‡ 
Black, n (%) 8 (23) 11 (42) 17 (68) ‡ 
Asian, n (%) 0 (0) 1 (4) 0 (0) 
 
Hispanic, n (%) 0 (0) 0 (0) 0 (0) 
 
Other, n (%) 0 (0) 1 (4) 2 (8) 
 
T2DM Status 
    
T2DM dx duration (years) n/a n/a 14.5 ± 8.4 n/a 
OGTT (mg/dL) 95.5 ± 18.2 163.5 ± 29.8 n/a † 
HbA1c (%) 5.76 ± 0.26 6.03 ± 0.42 9.13 ± 2.16 ‡ ҂ 
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T2DM-related Drugs 
    
Insulin, n (%) 0 (0) 0 (0) 25 (100) ‡ ҂ 
Metformin, n (%) 0 (0) 0 (0) 14 (56) ‡ ҂ 
Sulfonylurea, n (%) 0 (0) 0 (0) 2 (8) 
 
Serum and Urinary Parameters 
    
25-hydroxyvitamin D (ng/mL) 33.46 ± 9.41 33.23 ± 10.11 30.64 ± 7.31 
 
Creatinine (mg/dL) 0.81 ± 0.16 0.87 ± 0.20 0.84 ± 0.16 
 
Calcium (mg/dL) 9.44 ± 0.30 9.51 ± 0.42 9.44 ± 0.39 
 
Phosphorous (mg/dL) 3.65 ± 0.49 3.48 ± 0.51 3.57 ± 0.66 
 
Alkaline phosphatase (U/L) 73.57 ± 17.95 72.96 ± 19.84 88.08 ± 24.09 ‡ ҂ 
Parathyroid Hormone (pg/mL) 28.77 ± 13.00 39.93 ± 17.59 33.48 ± 16.66 † 
eGFR (mL/min/1.73 m2) 80.49 ± 16.29 80.81 ± 13.46 80.08 ± 15.99 
 
P1NP (ng/mL) 58.78 ± 23.65 57.83 ± 18.62 44.20 ± 14.07 ‡ ҂ 
CTx (ng/mL) 0.32 ± 0.18 0.31 ± 0.22 0.22 ± 0.11 ‡ 
Sclerostin (pmol/L) 238.34 ± 98.96 224.50 ± 68.44 229.95 ± 101.36 
 
Pentosidine (nmol/L) 56.25 ± 15.94 51.49 ± 13.54 53.89 ± 13.80 
 
ucOC (ng/mL) 3.53 ± 2.00 3.15 ± 2.13 2.66 ± 2.37 ‡ 
Other Supplements 
    
Calcium, n (%) 8 (23) 6 (23) 3 (12) 
 
Vitamin D, n (%) 13 (37) 11 (42) 11 (44) 
 
Multi-vitamin, n (%) 15 (43) 10 (38) 4 (16) 
 
Statin, n (%) 8 (23) 9 (35) 12 (48) 
 
Acetylsalicylic acid (aspirin), n 
(%) 
15 (43) 7 (27) 12 (48) 
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4.3.2 Composition of cortical tissue evaluated with FTIR imaging 
In the cortical tissue, the mineral:matrix mean was 7% greater in the T2DM group 
compared to the NGT group, which indicates greater tissue mineral content in the 
T2DM specimens (p < 0.05) (Figure 4.3-1A, Figure 4.3-2A). Also in the cortical 
tissue, the mineral:matrix distribution was 10% narrower in the T2DM versus NGT 
group (p < 0.05) (Figure 4.3-2A) and trended towards a narrower distribution in the 
T2DM versus IGT group (-9%, p = 0.06). The cortical mineral:matrix head value was 
10% greater in the T2DM versus NGT group (p < 0.5) (Figure 4.3-1E, Figure 
4.3-2A), and the cortical mineral:matrix tail value trended towards a greater value in 
the T2DM versus NGT group (+6%, p = 0.07) (Figure 4.3-1G, Figure 4.3-2A). 
Representative FTIR images and distributions for cortical mineral:matrix ROIs in the 
NGT and T2DM groups are shown in Figure 4.3-2A. 
 The cortical crystallinity mean and head value did not differ between groups 
(Figure 4.3-1A, Figure 4.3-1E, Figure 4.3-2A); however, in the T2DM versus NGT 
group, the cortical crystallinity distribution width was 16% wider (p < 0.05) (Figure 
4.3-1C, Figure 4.3-2B) and the cortical crystallinity tail value was 2% greater (p < 
0.05) (Figure 4.3-1G, Figure 4.3-2B). Representative FTIR images and distributions 
for cortical crystallinity ROIs in the NGT and T2DM groups are shown in Figure 
4.3-2B. 
 The cortical acid phosphate content distribution width was 14% narrower in 
the T2DM versus NGT group and 14% narrower in the T2DM versus IGT group (both 
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p < 0.05) (Figure 4.3-1C, Figure 4.3-2C). All other cortical acid phosphate content 
outcome variables did not differ between groups (Figure 4.3-1A, Figure 4.3-1E, 
Figure 4.3-1G). Representative FTIR images and distributions for cortical acid 
phosphate content ROIs in the NGT and T2DM groups are shown in Figure 4.3-2C. 
 None of the cortical collagen maturity and carbonate:phosphate parameters 
differed among groups (Figure 4.3-1A, Figure 4.3-1C, Figure 4.3-1E, Figure 
4.3-1G).  
4.3.3 Composition of trabecular tissue evaluated with FTIR imaging 
There were subtle differences in trabecular collagen maturity outcomes that were not 
observed in the cortical collagen maturity outcomes. In the T2DM versus NGT group, 
the trabecular collagen maturity mean trended towards a lower value (-5%, p = 0.05) 
(Figure 4.3-1B, Figure 4.3-2D), the trabecular collagen maturity head value trended 
towards a lower value (-3%; p = 0.07) (Figure 4.3-1F, Figure 4.3-2D), and the 
trabecular collagen maturity tail value was lower (-9%, p < 0.05) (Figure 4.3-1H, 
Figure 4.3-2D). Additionally, the trabecular collagen maturity distribution width 
trended towards a narrower width in the T2DM versus IGT group (-18%; p = 0.09) 
(Figure 4.3-1D, Figure 4.3-2D). Representative FTIR images and distributions for 
trabecular collagen maturity ROIs in the NGT and T2DM groups are shown in Figure 
4.3-2D. 
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Figure 4.3-1: FTIR results for (A) cortical parameter means, (B) trabecular parameter 
means, (C) cortical distribution widths, (D) trabecular distribution widths, (E) cortical 
parameter 5th percentile values, (F) trabecular parameter 5th percentile values, (G) 
cortical  parameter 95th percentile values, and (H) trabecular parameter 95th percentile 
values. Bars denote the raw mean values of each parameter ± standard deviation, while 
the significance levels were determined from linear mixed models. Abbreviations: 
NGT = normal glucose tolerance; IGT = impaired glucose tolerance; T2DM = type 2 
diabetes mellitus; FWHM = full-width at half-maximum. * p < 0.05, # p < 0.10. 
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Figure 4.3-2: Representative FTIR images and parameter distributions of NGT and T2DM 
ROIs for (A) cortical mineral:matrix, (B) cortical crystallinity, (C) cortical acid phosphate 
content, (D) trabecular collagen maturity, (E) trabecular mineral:matrix, (F) trabecular 
crystallinity, and (G) trabecular acid phosphate content. On the parameter histograms, the 
Gaussian fit to the data is shown in red, the FWHM is shown with a yellow horizontal 
double arrow, and the 5th percentile and 95th percentile values are shown with dark blue 
vertical lines. Scale bar in each FTIR image is 50 μm, Abbreviations: NGT = normal 
glucose tolerance; T2DM = type 2 diabetes mellitus; full-width at half-maximum = FWHM; 
ROI = region of interest. 
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Similar findings were observed with mineral:matrix, crystallinity, and acid 
phosphate content in the trabecular tissue as in the cortical tissue. Specifically, the 
trabecular mineral:matrix mean and head value trended towards greater values in the 
T2DM group than the NGT group (mean: +4%, p = 0.09, head: +7%, p = 0.09) 
(Figure 4.3-1, Figure 4.3-2E, Figure 4.3-1F, Figure 4.3-2E), while the mineral:matrix 
distribution width and the mineral:matrix tail value did not differ between groups 
(Figure 4.3-1D, Figure 4.3-2H). Representative FTIR images and distributions for 
trabecular mineral:matrix ROIs in the NGT and T2DM groups are shown in Figure 
4.3-2E. 
 The trabecular crystallinity distribution width was 14% greater (p < 0.05) 
Figure 4.3-1D, Figure 4.3-2F) and the trabecular crystallinity tail value trended 
towards a greater value in the T2DM group compared to the NGT group +1%, p = 
0.09) (Figure 4.3-1H, Figure 4.3-2F). The trabecular crystallinity mean and head 
value did not differ between groups (Figure 4.3-1B, Figure 4.3-1F). Representative 
FTIR images and distributions for trabecular crystallinity ROIs in the NGT and T2DM 
groups are shown in Figure 4.3-2F. 
 Again similar to the cortical tissue findings, the trabecular acid phosphate 
content distribution width was 11% narrower in the T2DM versus NGT group and 
10% narrower in the T2DM versus IGT group (both p < 0.05) (Figure 4.3-1D, Figure 
4.3-2G), and all other cortical acid phosphate content outcome variables did not differ 
between groups (Figure 4.3-1B, Figure 4.3-1F, Figure 4.3-1H). Representative FTIR 
images and distributions for trabecular acid phosphate content ROIs in the NGT and 
T2DM groups are shown in Figure 4.3-2. 
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 The trabecular carbonate:phosphate trended towards a wider distribution width 
in the IGT group versus the NGT group (+11%, p = 0.08) (Figure 4.3-1D). All other 
trabecular carbonate:phosphate variable outcomes did not differ between groups 
(Figure 4.3-1B, Figure 4.3-1F, Figure 4.3-1H). 
4.3.4 Association of tissue composition with T2DM duration and HbA1c 
T2DM duration (T2DM group only) and OGTT level (NGT and IGT groups only) 
were not associated with mean or distribution width FTIR outcomes. HbA1c and 
cortical acid phosphate content distribution width were correlated only when the IGT 
and T2DM groups were pooled and the NGT group was excluded (R2 = 0.172, p < 
0.05). T2DM duration and HbA1c were not correlated; however, OGTT level and 
HbA1c were correlated (R2 = 0.146, p < 0.05).  
4.3.5 Association of tissue composition with bone turnover markers 
When all three groups were included in the regression, mean and distribution with 
FTIR outcomes for cortical and trabecular bone were not associated with P1NP, PTH, 
ucOC, or CTx with the exception of cortical carbonate:phosphate distribution width 
and CTx (R2 = 0.142, p < 0.05). Similarly, serum pentosidine was not correlated with 
any FTIR parameter outcomes when all three groups were included. Several 
parameters were significantly associated (p < 0.05), but the correlation coefficient was 
weak (R2 < 0.10).  
When just the IGT and T2DM groups were included in the regression analysis, 
there were several significant associations. Cortical and trabecular mean collagen 
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maturity were correlated with CTx (c-XLR: R2 = 0.224, t-XLR: R2 = 0.136, both p < 
0.05) (Figure 4.3-3A), as was cortical mean acid phosphate content (c-AP: R2 = 0.219, 
p < 0.05) (Figure 4.3-3E). The distribution widths of cortical and trabecular collagen 
maturity were correlated with CTx (c-XLR: R2 = 0.262, t-XLR: R2 = 0.171, both p < 
0.05) (Figure 4.3-3B), in addition to the distribution widths of cortical and trabecular 
carbonate:phosphate ratio (c-C:P: R2 = 0.262, t-C:P: R2 = 0.115, both p < 0.05) 
(Figure 4.3-3D). P1NP was only correlated with the distribution width of trabecular 
collagen maturity (t-XLR: R2 = 0.181, p < 0.05) (Figure 4.3-3C). PTH, ucOC, and 
pentosidine were not correlated with any FTIR parameter when only the IGT and 
T2DM groups were included in the regression.  
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Figure 4.3-3: Regression models of the IGT and T2DM groups for (A) cortical and 
trabecular mean collagen maturity vs. CTx; (B) cortical mean acid phosphate content 
vs. CTx; (C) cortical and trabecular collagen maturity distribution width vs. CTx; (D) 
cortical and trabecular carbonate:phosphate ratio distribution width vs. CTX; and (E) 
trabecular collagen maturity distribution width vs. P1NP. Orange indicates the IGT 
group, red indicates the T2DM group, circles indicate cortical tissue, triangles indicate 
trabecular tissue, solid black lines indicate the regression fit for the cortical samples, 
and dotted black line indicate the regression fit for the trabecular samples. Each circle 
or triangle is the arithmetic mean of all FTIR ROIs for that parameter. 
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4.4 Discussion 
In this study, we assessed the compositional changes due to progressive glucose 
intolerance (normal glucose tolerance to impaired glucose tolerance to overt type 2 
diabetes mellitus) on cortical and trabecular bone tissue using FTIR imaging.  
Our data show compositional alterations in cortical and trabecular tissue from 
normal glucose tolerance to overt T2DM. In the cortical and trabecular tissue, we 
observed the following group-wise differences in the T2DM group compared to the 
NGT group: 1) greater tissue mineral content; 2) less heterogeneous mineral content; 
3) less heterogenous acid phosphate substitution; 4) more heterogeneous crystallinity; 
and in the trabecular compartment only, 5) trends towards less mature and less 
heterogeneous collagen maturity. Moreover, our bone turnover marker data show 
lower bone resorption and formation that decreases with worsening glycemic 
derangement. 
The P1NP concentration in the T2DM group was lower than both the NGT and 
IGT groups (T2DM vs. NGT: -25%; T2DM vs. IGT: -24%), which indicates that bone 
formation is decreased in the progression from IGT to T2DM, but not in progression 
from NGT to IGT. The CTx and ucOC concentrations were also lower in the T2DM 
versus the NGT group (CTx: -31%; ucOC: -25%), which indicates lower bone 
resorption in the progression from NGT to T2DM, but not in the progression from 
NGT to IGT or from IGT to T2DM. Nevertheless, these findings support prior studies 
that demonstrated decreased bone turnover with T2DM compared to non-diabetic 
controls.(16–21)  
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Our first main group-wise finding is that the cortical and trabecular tissue of 
the T2DM group had greater mineral content (assessed by mineral:matrix) compared 
to the NGT group. This is indicative of older tissue (i.e., time since tissue formation) 
because older tissue has a higher mineral content than younger tissue.(43) The greater 
average mineral content is distinctly illustrated in the representative FTIR images in 
Figure 4.3-2A and Figure 4.3-2E, as the T2DM tissue has more numerous high values 
of mineral:matrix (shown in red) and less numerous low values of mineral:matrix 
(shown in blue) compared to the NGT tissue. Additionally, the greater mineral:matrix 
head and tail values in the cortical tissue indicate a shift of the whole mineral:matrix 
distribution to the right (e.g., a shift to higher mineral:matrix values) (Figure 4.3-2A) 
and corroborates the greater mineral:matrix mean result in the cortical tissue in the 
T2DM versus NGT group (Figure 4.3-1A). In the trabecular tissue, the head value 
only was borderline greater in the T2DM versus NGT group, which suggests that the 
higher average mineral content in the T2DM group is likely due to less numerous low 
mineral:matrix values. Our results are in agreement with prior reports that found 
subjects with T2DM had greater mineral content than subjects without T2DM in 
femoral neck trabecular tissue.(44,45)  
While our study did not directly evaluate the energy absorption capabilities of 
tissue from patients with and without T2DM, the observed greater mineral content 
may help explain the increased fracture rates among patients with T2DM. In general, a 
more mineralized tissue is stiffer and stronger than a less mineralized tissue;(46) but 
this increase in strength is accompanied by a reduction of the tissue’s ability to absorb 
energy before failure (i.e., reduced toughness).(46,47) For example, a rodent model of 
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aging found increased mineral content to be associated with reduced ductility, as the 
greater degree of mineralization purportedly impaired collagen fiber mobility (i.e., 
reduced ductility and toughness).(48) In our study, it is likely that the greater mineral 
content in cortical and trabecular tissue in the T2DM versus NGT group deleteriously 
affects the deformability of the collagen matrix, leading to impaired fracture resistance 
at the whole-bone level.  
Our second main group-wise finding is that the distribution widths of 
mineral:matrix values in cortical and trabecular tissue were narrower in the T2DM 
group than the NGT group (Figure 4.3-2A, Figure 4.3-2E), which indicates a less 
heterogenous distribution of mineral content in T2DM tissue compared to NGT or 
IGT tissue (Figure 4.3-1C, Figure 4.3-2A). The heterogeneity of bone tissue at 
multiple length scales has direct implications for the mechanical performance of the 
tissue.(49,50) Specifically, more narrow distributions of mineral content in diseased 
versus control bone has been linked to decreased bone turnover and has been 
documented in patients with osteoporosis(51) and patients receiving bisphosphonate 
treatment for osteoporosis.(24) Therefore, in our study, the narrower distributions of 
mineral content in the T2DM group compared to the NGT group may similarly point 
to decreased bone turnover with T2DM.  
Our third main group-wise finding is that the distribution widths of acid 
phosphate content in cortical and trabecular bone were narrower in the T2DM group 
compared to both the NGT and IGT groups (Figure 4.3-1C, Figure 4.3-1D), which 
indicates that the T2DM group has less heterogenous acid phosphate content than the 
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NGT and IGT groups. Newly mineralized, young tissue has a high acid phosphate 
content, while more mature, older tissue has a lower acid phosphate content.(42) As 
such, the narrower distribution of acid phosphate content indicates the T2DM group 
has a narrower range of tissue ages than the NGT and IGT groups, which, like the 
mineral:matrix results, is consistent with a lower-turnover tissue.  
Our fourth main group-wise finding is that the distribution widths of mineral 
crystallinity in cortical and trabecular tissue were wider in the T2DM group compared 
to the NGT group (Figure 4.3-1C, Figure 4.3-1D), which indicates a more 
heterogenous mineral crystallinity in the T2DM specimens. In addition, the tail 
crystallinity values were greater in the T2DM group than the NGT group for both 
cortical and trabecular tissue, but the head crystallinity values were similar among 
groups, which suggests that the wider crystallinity distributions were due to more 
numerous high crystallinity values, not more numerous low crystallinity values 
(Figure 4.3-2C, Figure 4.3-2D, Figure 4.3-2E, Figure 4.3-2F, Figure 4.3-2G, Figure 
4.3-2H). Because the crystallinity parameter determined from FTIR spectra measures 
a combination of both mineral crystal size and stoichiometry perfection,(39) a more 
heterogenous crystallinity can arise from greater variations in size, perfection, or both. 
However, the lower heterogeneity of acid phosphate content points to more 
stoichiometric mineral in the T2DM group compared to the NGT group (Figure 
4.3-1C, Figure 4.3-1D); therefore, we can infer that the greater overall crystallinity 
heterogeneity is due to, or mostly due to, a greater crystal size heterogeneity. In 
general, longer, more mature crystals increase tissue stiffness and strength, but 
decrease energy absorption capabilities.(52) In this light, the evidence of more 
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numerous high crystallinity values in the T2DM tissue versus the NGT tissue may 
signify that the T2DM tissue would be less resistant to fracture. 
Our final main group-wise finding is that the trabecular collagen maturity 
mean, distribution width, head value, and tail value were borderline lower in the 
T2DM versus the NGT group (Figure 4.3-1B, Figure 4.3-1D, Figure 4.3-1F, Figure 
4.3-1H), which suggests the collagen in the T2DM group is less mature and less 
heterogenous. The more narrow trabecular collagen maturity distribution width in the 
T2DM versus NGT group is due to a decrease in head value (-3%) and a larger 
decrease in tail value (-5%), resulting in the distribution narrowing and shifting left to 
lower collagen maturity values (Figure 4.3-2D). Collagen maturity calculated from 
FTIR spectra is a ratio of mature trivalent pyridinoline crosslinks to immature divalent 
crosslinks, hence the observed decrease in collagen maturity in the T2DM versus NGT 
group may arise from a decrease in mature crosslinks, an increase in immature 
crosslinks, or both. 
Even though the precise concentrations of enzymatic crosslinks cannot be 
measured with FTIR spectroscopy, a change in collagen maturity can result in vastly 
altered mechanical behavior. For example, inhibiting lysyl oxidase in rats resulted in a 
decrease in the concentration of mature collagen crosslinks by ~45% and a decrease in 
femoral bending strength by 26% compared to controls.(53) In addition, lysyl 
hydroxylases regulate the organization of enzymatic crosslinks in type 1 collagen, and 
there is growing evidence that disrupted lysyl hydroxylase action can have 
downstream effects on subsequent mineralization processes.(54)  
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Taken together, these data point to complex effects in the mineral and collagen 
matrix properties of tissue from patients with T2DM compared to those with normal or 
impaired glucose control. The greater mean mineral content and less heterogenous 
mineral content, acid phosphate content, and collagen maturity in the T2DM group 
compared to the NGT group are consistent with an older tissue that has experienced 
lower bone turnover.(55) In contrast, the lower mean collagen maturity and more 
heterogeneous mineral crystallinity are consistent with a younger tissue.  
The correlations between bone turnover markers and compositional properties 
also signify complicated effects with glycemic derangement, and the regression 
analyses of CTx and P1NP with FTIR compositional parameters in the IGT and 
T2DM groups allowed for a more focused analysis in women with some level of 
glucose derangement. In the IGT and T2DM pooled data, the mean and distribution 
width of collagen maturity increased with an increase in resorption marker CTx 
concentration in cortical and trabecular regions (Figure 4.3-3A, Figure 4.3-3B), and 
the distribution width of collagen maturity increased with an increase in the formation 
marker P1NP concentration in trabecular bone (Figure 4.3-3C). Conventionally, 
increases in bone resorption and formation lead to a younger tissue on average that is 
more heterogeneous overall;(24) therefore, the wider collagen maturity distribution 
widths with higher turnover is in line with convention, but the increased collagen 
maturity with higher turnover is not. The relationship between mean acid phosphate 
content in cortical tissue and CTx concentration is also inconsistent with conventional 
thought. That is, higher values of CTx, which signifies more bone resorption, should 
correspond to mineral with lower acid phosphate content (because acid phosphate 
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content is high in young tissue), but the opposite was observed (Figure 4.3-3E).  
There are several possible explanations the apparent tissue-age and bone 
turnover inconsistencies within the FTIR compositional properties in patients with 
T2DM. First, the maturation of collagen from divalent to trivalent crosslinks can be 
inhibited by secondary mineralization processes, which would result in a less mature 
collagen but a more mature mineral.(54) On the other hand, upregulation of one isoform 
of lysyl hydroxylase, LH2, can lead to disrupted mineralization processes such as the 
location of hydroxyapatite nucleation, which would result in altered mineral properties 
without altered collagen properties.(54) In either of these two scenarios, the maturation 
of the collagen matrix and the maturation of the mineral crystals could be decoupled 
from each other.  
The accumulation of AGEs has also been proposed as a mechanism by which 
bone tissue can be altered because of T2DM. AGEs are known to accumulate with 
normal aging, and they have been implicated in osteoporosis and T2DM as a 
mechanism by which the collagen crosslink profile can be altered.(54) Firstly, it is 
possible that AGEs can form on the collagen residues that are normally designated for 
enzymatic crosslinks. This would result in a tissue with decreased collagen maturity 
and increased AGE content. Secondly, AGE accumulation can change the charge 
profile of collagen fibrils,(56,57) thereby disrupting the otherwise highly controlled 
mineralization process.(58–60) Thirdly, high concentrations of AGEs can reduce the 
solubility of the collagen matrix,(54) which in turn could lead to lower resorption of 
AGE-heavy tissue. Finally, in vitro studies on AGE-modified collagen point to 
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decreased osteoblast(30–32,61) and osteoclast(62) function, thus AGEs can disrupt the 
remodeling processes. 
The main strength of this study is the inclusion of the IGT group which 
allowed for analysis of the intermediate stage of impaired glycemic control. The FTIR 
compositional parameters of the IGT group frequently fell between the values of the 
NGT and T2DM groups, though the differences between the NGT versus IGT and 
IGT versus T2DM groups were not always significant. Additionally, the availability of 
detailed participant information, including T2DM duration and bone turnover markers, 
and a large enough biopsy to spatially assess compositional parameters allowed for a 
deeper assessment of tissue composition changes with glucose derangement than in 
comparable studies that relied on opportunist collection of specimens during total hip 
arthroplasty.(44,63) A limitation of this study is that the iliac crest is not a clinically 
relevant fracture site, and it is currently unknown how tissue composition varies across 
site for people with and without T2DM. Another limitation of this study is that only 
serum pentosidine was available to measure AGE content. Tissue AGEs and serum 
pentosidine are only moderately, if at all, correlated,(63) thus serum pentosidine may 
not be a representative measure of tissue AGE content. Moreover, it is not known to 
what extent pentosidine, a single AGE, contributes to the total influence of AGEs 
because there are potentially hundreds of different types of AGEs in bone tissue.(64) 
Nevertheless, this study contributes to the broader understanding of how worsening 
glycemic derangement leads to alterations in bone tissue composition.  
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4.5 Conclusion 
In this work, we spatially assessed the composition of bone from post-menopausal 
women with varying degrees of glycemic derangement. Traditional clinical 
measurements of bone mass (i.e., BMD) underpredict bone fragility in people with 
T2DM; therefore, a broader approach that includes measures of bone quality is 
increasingly necessary to evaluate bone tissue to better prevent fragility fractures in 
people with T2DM. We found evidence of altered mineral and collagen properties 
between normal glucose tolerance, impaired glucose tolerance, and overt T2DM 
groups. In general, we observed that glycemic derangement was associated with 
increased mineral content, decreased collagen maturity, and non-conventional mineral 
maturation. While the precise underlying causes for these changes in tissue 
composition have yet to be elucidated, a more mineralized tissue and a less mature 
organic matrix can both deleteriously affect bone mechanics at the tissue level, and 
these compositional alterations at the micro-scale likely play a role in whole-bone 
mechanical integrity. In conclusion, these data are the first to offer evidence of 
progressive altering of bone tissue composition with worsening glycemic control in 
humans, and these findings can ultimately offer insight into when these changes occur.  
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CHAPTER 5 
ALTERED TISSUE COMPOSITION, MICROARCHITECTURE, AND 
MECHANICAL PERFORMANCE IN CANCELLOUS BONE FROM MEN WITH 
TYPE 2 DIABETES MELLITUS 
 
5.1 Introduction 
People with type 2 diabetes mellitus (T2DM) have normal to high bone mineral 
density (BMD), but counterintuitively, also have a greater fracture risk than people 
without diabetes.(1–4) Furthermore, clinical fracture risk assessments (e.g., FRAX) that 
account for hip BMD, age, body mass index (BMI), fracture history, neuropathy, 
retinopathy, and falls consistently underpredict fractures in people with T2DM.(1,5,6) 
Because these factors do not fully account for the increased fracture risk observed in 
patients with T2DM, additional factors, including bone quality,(7) may also contribute 
to the pathophysiology of T2DM-realted fractures. Aspects of bone quality that may 
contribute to decreased fracture resistance in T2DM include bone microarchitecture 
and tissue material properties, which can arise from changes in bone remodeling. 
Hyperglycemia and hyperinsulinemia, two conditions that typically characterize 
T2DM, alter bone remodeling and therefore are hypothesized to alter 
microarchitecture and tissue material properties.  
Hyperglycemia may alter bone tissue material properties through two primary 
mechanisms: 1) disruption of bone remodeling via osteoblasts and osteoclasts and 2) 
formation of advanced glycation endproducts. In T2DM, bone remodeling can be 
  
156 
 
altered by suppression of bone formation as well as bone resorption, as evidenced by 
in vitro studies,(8–10) reports of decreases in the bone formation markers (11–16) and bone 
resorption markers in patients,(14–16) and histomorphometric analyses.(17) Moreover, 
serum glucose correlates with a decrease in bone turnover markers,(18) and excess oral 
glucose intake is associated with decreased bone formation in otherwise healthy 
individuals.(19) In contrast to hyperglycemia, insulin is an anabolic agent, and 
hyperinsulinemia may help explain the greater BMD observed in people with 
T2DM.(20) Insulin signaling helps regulate osteoblastic proliferation and supports 
osteoclastogenesis.(21) Additionally, insulin levels post-oral glucose tolerance test are 
positively correlated with BMD at the hip and spine in men and women with and 
without T2DM.(22) Nevertheless, the extent to which bone remodeling and material 
properties are affected by the competing effects of hyperglycemia and 
hyperinsulinemia is not yet known. 
In addition to altered remodeling, excess glucose can lead to changes in bone 
tissue material properties through the accumulation of advanced glycation endproducts 
(AGEs). AGEs are the reaction products of reducing sugars with free amino groups in 
proteins and result in a diverse array of structures including crosslinking and non-
crosslinking products. Crosslinking AGEs have been implicated in embrittling the 
collagen matrix in rodent models of T2DM(23) and in in vitro 
ribosylation/glycosylation studies of human and bovine bone tissue.(24,25) Non-
crosslinking AGEs, like carboxymethyllysine (CML), can also be deleterious to bone 
tissue through interaction with the receptor for AGEs (RAGE), which induces 
oxidative stress and inflammation.(26) In a study of CML-modified collagen compared 
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to unmodified collagen, apoptosis of bone lining cells was increased in vivo and in 
osteoblast cell cultures.(27) Together, AGE accumulation and the downstream effects 
of AGE-RAGE interactions may compound the changes in tissue material properties 
with T2DM and worsen mechanical performance.  
Cross-sectional studies also indicate that bone microarchitecture may be 
altered in patients with T2DM compared to non-diabetic controls, though the precise 
mechanisms and relationships to hyperglycemia and hyperinsulinemia are unknown. 
Patients with T2DM had similar or greater trabecular volumetric BMD at the femoral 
neck(28) and tibia versus non-diabetic controls.(29) Observations of cortical bone 
microarchitecture are mixed; cortical porosity of T2DM versus non-DM tissue has 
been reported to decrease at the proximal femoral shaft,(18) to increase at the distal 
radius,(30) and to not significantly differ in the distal radius and distal tibia.(16,31) The 
divergent findings between trabecular and cortical microarchitecture highlight the 
need for compartment-specific analyses in T2DM bone tissue in humans. 
Although microarchitectural changes have been documented in patients with 
T2DM, the functional consequences of these changes are largely unknown. Just two 
studies have shown differences in T2DM versus non-DM tissue, and both have been in 
cortical tissue. One study reported decreased resistance to in vivo indention in cortical 
bone at the tibial diaphysis in patients with T2DM versus those without T2DM,(16) and 
the other found increased indentation distance and indentation distance increase in 
cyclic reference point indentation in cortical proximal femur tissue.(32) With the 
exception of these two studies, the majority of evidence that T2DM deleteriously 
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affects bone mechanical performance is from rodent models. In rodent models, 
strength(23,33,34) and work-to-failure(23,34,35) were consistently decreased in T2DM 
compared to non-DM controls(36) and were often accompanied by concomitant 
changes in bone quality including altered microarchitecture,(33–35,37) BMD,(34,35,37) 
osteoid surface and thickness,(35) and AGE content.(23)  
Similarly, the availability of data on tissue material properties in bone from 
humans with T2DM is limited. There are reports of greater concentrations of tissue 
AGEs(38) and greater mean calcium content in bone from people with T2DM 
compared to non-DM controls;(39) however, rodent models of T2DM provide the bulk 
of evidence that T2DM alters tissue material properties. Multiple rodent models of 
T2DM report increased mineral content (assessed by mineral:matrix ratio) in Zucker 
diabetic Sprague-Dawley (ZDSD) rats(40,41) and KK-Ay mice compared to controls.(42) 
The same studies report no differences in concentrations of mature enzymatic 
crosslinks (pyridinoline and deoxypyridinoline) or in the AGE pentosidine;(40–42) 
however, the collagen maturity (ratio of mature to immature enzymatic crosslinks) of 
the KK-Ay mice was increased compared to controls.(42) In contrast, a study of 
WBN/Kob rats that found a decrease in concentration of enzymatic crosslinks with a 
simultaneous increase in pentosidine concentration,(23) which suggests phenotype-
specific changes in tissue material properties with T2DM.  
In summary, although bone from people with T2DM may possess altered 
tissue material and microarchitecture properties , the effects of such changes on bone 
tissue mechanical properties have not been assessed, and the mechanism by which 
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T2DM affects bone fracture resistance is unknown. Moreover, most fragility fractures 
occur at cancellous sites, and the mechanical properties of cancellous bone from 
patients with T2DM have not yet been characterized.  
Therefore, the objectives of this study were to relate material properties and 
microarchitecture to the mechanical performance of cancellous bone from the femoral 
neck in men with and without T2DM. We focused on cancellous bone because it 
preferentially accumulates AGEs relative to cortical bone.(43) We hypothesized that 
cancellous bone specimens from men with T2DM would have increased AGE 
concentrations, have greater bone volume fraction, and would be more brittle relative 
to non-DM controls. 
5.2 Methods 
5.2.1 Study Cohort 
Men undergoing total hip arthroplasty for osteoarthritis were sequentially 
recruited at a single, metropolitan training hospital (Hospital for Special Surgery, New 
York, NY) where participating surgeons obtained informed consent. Prior to 
arthroplasty, HbA1c was measured in all subjects. All procedures were approved by 
the institutional review boards of the Hospital for Special Surgery and Cornell 
University.  
Initial power analyses to detect 20% differences in mean mechanical properties 
at 80% power and 5% level of significance indicated 17 specimens/group were 
needed. A total of 75 subjects were recruited and allocated to two groups based on 
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T2DM diagnosis at the time of surgery: men with a type 2 diabetes mellitus diagnosis 
(T2DM, n = 35) and men without a T2DM diagnosis (non-DM, n = 40). Four T2DM 
subjects and six non-DM subjects were excluded based on the following criteria: 
diagnosis of type 1 diabetes mellitus; a prior fragility fracture; any disease of bone 
such as osteogenesis imperfecta, fibrous dysplasia, or malignancy; renal or hepatic 
disorder involving the bone such as hyperparathyroidism or vitamin D deficiency; a 
history of avascular necrosis of the hip; treatment with medications that affect bone 
metabolism such as thiazolidinediones, teriparatide, glucocorticoids, bisphosphonates, 
or anticonvulsants; or pathological evidence of bone metastasis.  
In total, 31 T2DM subjects and 34 non-DM subjects were included in the 
analyses for this study.  
5.2.2 Specimen Retrieval and Preparation 
Femoral head and neck tissue retrieved from total hip arthroplasty was 
wrapped in saline-soaked gauze and stored at -20 ˚C prior to specimen preparation. 
For a subset of the specimens (T2DM: n = 20, non-DM: n = 25), 8-mm-diameter cores 
of cancellous bone from the femoral neck were excised for microarchitecture analysis 
and compression testing. The cortical tissue of the femoral head and neck specimens 
were retained for separate future analyses.  
The cancellous specimens were aligned along the principal trabecular axis 
which was determined from a radiograph. The specimens were then cut to 10 mm in 
length using a high-speed precision saw and a custom jig that ensured parallel ends. 
  
161 
 
The tissue removed from the ends of the original core (~3 mm total length removed 
per end) was retained for compositional analyses. Figure 5.2-1 shows the allocation of 
tissue for all analyses. For 20 specimens (T2DM: n = 11, non-DM: n = 9), a 10-mm 
uniform core could not be obtained because the size of the retrieved proximal femur 
specimen was too small or was otherwise damaged during retrieval or pathological 
analysis. For the 20 specimens that did not undergo mechanical testing, cancellous 
tissue along the principal trabecular axis was excised for compositional analyses.  
In all specimens, the tissue allocated for compositional testing was prepared as 
follows: Bone marrow from the excess tissue was removed with a dental water pick, 
defatted using three 15-minute soaks in isopropyl ether, and rinsed for 15 minutes in 
DI water. The tissue was then homogenized and allocated into two groups for 
compositional analysis: 1) FTIR and 2) HPLC and fluorescence spectroscopy.  
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Figure 5.2-1: Anatomical location, size of cancellous specimen excised, and 
allocation of tissue for each characterization technique. 
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5.2.3 Micro-computed Tomography 
Micro-computed tomography was used to assess the microarchitecture of the 
cancellous bone from the mechanical testing cohort. Specimens were scanned in saline 
at 55 kVp and a resolution of 10 µm (µCT 35, Scanco Medical, Brüttisellen, 
Switzerland). Trabecular microarchitecture, including bone volume fraction (BV/TV), 
bone surface to volume ratio (BS/BV), connective density (Conn.D), trabecular 
number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and 
degree of anisotropy (DA) was evaluated (µCT 40, Scanco Medical, Brüttisellen, 
Switzerland). 
5.2.4 Mechanical Testing 
Monotonic compression testing was performed to determine the apparent-level 
mechanical properties of the specimens. Specimens were thawed, press-fit into 
custom, shallow-welled, brass endcaps, and secured with cyanoacrylate glue. The glue 
was allowed to cure for at least 10 minutes while maintaining specimen hydration. The 
load regimen consisted of 10 preconditioning cycles from 0% to 0.1% strain at a rate 
of 0.5% s-1, followed by a single compressive load to 3% strain at a rate of 0.5% s-1 
before unloading to zero load (858 Mini Bionix, MTS, Eden Prairie, MN). Load was 
measured with a load cell (SSM-1000, Transducer Techniques, Temecula, CA), and 
strain was measured with an external extensometer (634.12 Axial Extensometer, MTS, 
Eden Prairie, MN) attached to the specimen endcaps.  
Stress-strain curves were used to evaluate apparent-level Young’s modulus, 
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yield strain, yield, stress, ultimate strain, ultimate stress, post-yield strain, post-yield 
toughness, toughness, and residual strain. Yield strain and stress were determined 
using the 0.2% strain offset method; ultimate strain and stress were determined from 
the maximum load; and post-yield strain was calculated as difference between ultimate 
strain and yield strain. Two different measures of toughness were determined: 1) 
toughness, which was defined as the toughness from zero strain to ultimate strain and 
2) post-yield toughness, which was defined as the toughness from yield strain to 
ultimate strain. In five non-DM specimens, failure was not observed before the end of 
the test at 3% strain; therefore, ultimate strain, ultimate stress, post-yield toughness, 
and toughness data were not available for those specimens. 
5.2.5 Fourier Transform Infrared Spectroscopy 
FTIR spectroscopy was used to evaluate the compositional properties of cancellous 
bone tissue. The demarrowed and defatted tissue was lyophilized in a vacuum drier 
then powdered using a cryomill (6770, SPEX SamplePrep, Metuchen, NJ). Two mg of 
tissue was added to 200 mg of dried KBr, then pressed into a pellet using a 13-mm-
diameter die. FTIR spectra were collected at a spectral resolution of 4 cm-1 over the 
spectral range of 800 to 2000 cm-1 using an FTIR spectrometer (Spotlight 400, Perkin-
Elmer Instruments, Waltham, MA).  
Using custom Matlab code (2014a, The MathWorks, Inc., Natick, MA), the 
spectra were baseline corrected (as detailed in (44)) and the following parameters were 
calculated: 1) the mineral:matrix ratio (area ratio of the phosphate 1-3 peak [916-
1180 cm-1] to amide I peak [1596-1712 cm-1]) which characterizes tissue mineral 
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content;(45,46) 2) the collagen maturity (intensity ratio of 1660 cm-1 to 1690 cm-1) which 
is related to the ratio of pyridinoline to divalent crosslinks;(47,48) 3) the mineral 
crystallinity (intensity ratio of 1030 cm-1 to 1020 cm-1) which is related to crystal size 
and stoichiometric perfection;(49) the carbonate:phosphate ratio (area ratio of the 
carbonate 2 peak [852-890 cm-1] to phosphate 1-3 peak [916-1180 cm-1]) which 
characterizes carbonate substitution into hydroxyapatite;(50) and the acid phosphate 
content (intensity ratio of 1127 cm-1 to 1096 cm-1) which characterizes acid phosphate 
substitution into stoichiometric hydroxyapatite.(51)  
Additionally, the sugar:matrix ratio, was examined to assess sugars bound to 
the collagen matrix. The sugar:matrix ratio (area ratio of  CO and  CC peaks [900-
1100 cm-1](52) to amide I peak [1596-1712 cm-1]) is related to the amount of sugars 
(including glucose and ribose) attached to the matrix.(53) The sugar:matrix ratio was 
evaluated following decalcification (see 5.8 S1) because the prominent 1 phosphate 
overlaps the sugar peaks. For a subset of the specimens, there was not enough tissue 
after demineralization to detect an infrared signal (T2DM: n = 5, non-DM: n = 5).  
5.2.6 High-Performance Liquid Chromatography 
The concentrations of pentosidine and two enzymatic crosslinks, pyridinoline (Pyd) 
and deoxypyridinoline (Dpd), were determined using HPLC and expressed normalized 
to collagen concentration (e.g., mol/mol collagen). The total content of mature 
enzymatic crosslinks (sum of Pyd and Dpd) was calculated, as well as the ratio of non-
enzymatic crosslinks (pentosidine) to mature enzymatic crosslinks, which indicates the 
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ratio of physiologically disadvantageous crosslinks to advantageous crosslinks (similar 
to (54)).  
Tissue allocated for HPLC and fluorescence spectroscopy analyses was 
lyophilized then hydrolyzed in 6 N HCl at 110 °C for 18 h. An aliquot of the 
hydrolysate was reserved for fluorescence spectroscopy, and the remainder was dried 
in a vacuum centrifuge (Speed Vac SC110A, Savant, Farmingdale, NY). The dried 
hydrolysate was re-suspended in an internal standard solution containing 10 nM 
pyridoxine and 2.4 µM homoarginine (30 µl internal standard per 1 mg dried bone) 
and filtered with a 0.45 µm membrane. The re-suspended samples were diluted 1:5 
with 10% acetonitrile (v/v) and 0.5% heptafluorobutyric acid (v/v).  
Pentosidine, Pyd, and Dpd were separated on a C-18 column (Gemini-NX C-
18, Phenomenex, Torrance, CA) using two isocratic steps(55) and a programmable 
HPLC system (Model 126, Beckman Coulter, Inc., Fullerton, CA) attached to a 
fluorescence detector (Model FP1520, Jasco, Easton, MD). The calibration standard 
containing pentosidine (Case Western Reserve University, Cleveland, OH), Pyd 
(8004, Quidel, Athens, OH), and Dpd (8004, Quidel, Athens, OH) was created through 
serial dilution. 
The concentrations of pentosidine, Pyd, and Dpd were normalized by collagen 
concentration determined by hydroxyproline concentration (assuming 300 mol 
hydroxyproline per mol collagen). To measure hydroxyproline, amino acid analysis 
was performed on an aliquot of the further diluted sample from the crosslink 
analysis.(56) Briefly, the crosslink sample used for separation was diluted 1:50 with 6 
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µM homoarginine (amino acid internal standard) in 0.1 M borate buffer (pH 11.4). For 
enhanced detection, the sample solution was derivatized using 6 mM 9-
fluorenylmethyl chloroformate for 40 minutes, and extracted three times with pentane. 
After derivatization, 25% (v/v) acetonitrile in 0.25 M boric acid (pH 5.5) was added. 
A calibration standard of purified hydroxyproline (Sigma-Aldrich, St. Louis, MO) and 
6 µM homoarginine in 0.1 M borate buffer (pH 11.4) was created through serial 
dilution. The separation of amino acids was run using the injection sequence described 
by Bank et al.(56) Data analysis for crosslink and hydroxyproline determination was 
performed using 32 Karat Workstation software (v. 5.0, Beckman Coulter, Inc., Brea, 
CA) and Matlab (2014a, The MathWorks, Inc., Natick, MA).  
5.2.7 Fluorescence Spectrometry  
Total fluorescent AGEs (fAGEs) were measured using fluorescence spectrometry and 
normalized to collagen concentration. The endogenous fluorescence of cancellous 
bone tissue was compared to the fluorescence of a quinine standard (149504, Sigma 
Aldrich, St. Louis, MO). The aliquot of hydrolysate, reserved from that used for the 
HPLC separations, was diluted with DI water to a concentration of 3 µg bone/ml 
solution. The fluorescence of diluted bone hydrolysate and the quinine standards were 
measured in a 96-well plate using a multi-mode microplate reader (Synergy H1, 
BioTek, Winooski, VT) at an excitation of 360 nm and an emission of 460 nm.  
 A colorimetric assay of hydroxyproline was used to determine collagen content 
and normalize the bulk fluorescence. For the bone tissue samples, the hydrolysate 
measured for bulk fluorescence was diluted with deionized water to 0.3 µg bone/ml. 
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To initiate the reaction, chloramine-T was added to the hydroxyproline standards and 
the diluted sample hydrolysates. The standards and samples were incubated for 20 
minutes at room temperature, then 3.15 M perchloric acid was added to stop the 
reaction. After sitting 5 minutes at room temperature, p-dimethylaminobenzaldehyde 
was added. The standards and samples were incubated at 60 °C in a water bath for 20 
minutes, then cooled in cold water in darkness to room temperature. The absorbance 
of the specimens and standards was measured at a wavelength of 570 nm in a 96-well 
plate a multi-mode microplate reader. Total fAGEs are reported in units of ng quinine 
fluorescence/mg collagen. 
5.2.8 Statistical Analyses 
Between-group differences in the compositional, microarchitectural, and mechanical 
outcomes were determined by a Student’s t-tests, Welch’s t-tests, Mann-Whitney U 
tests, or Kolmogorov-Smirnov tests were performed, as appropriate, after testing for 
normality and homogeneity of variances. Univariate linear regressions were performed 
with all mechanical, compositional, and microarchitectural outcomes as the dependent 
variable and pre-operative HbA1c as the independent variable to determine if recent 
glycemic control, a clinically available measure, is related to characteristics of bone 
tissue that are only measurable with biopsies. A significance level of p = 0.05 was 
used for all analyses.  
A principal component analysis (PCA) was used to determine whether 
variation in the large number of interrelated measured compositional variables could 
be explained in terms of a smaller number of independent variables (factors). Because 
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many of the primary compositional variables are interrelated (e.g., pentosidine and 
fAGEs; crystallinity and carbonate:phosphate ratio), we expected that PCA would 
yield a smaller number of independent compositional factors for use in regression 
modeling. Specifically, PCA was performed on mineral:matrix ratio, collagen 
maturity, crystallinity, carbonate:phosphate ratio, acid phosphate content, Pyd 
concentration, Dpd concentration, pentosidine concentration, and total fAGEs to 
detect underlying relationships in the compositional variables. A more detailed 
summary of the rationale for creating factors can be seen in 5.8 Section S4.  
Regression modeling was used to determine which compositional and 
microarchitectural factors were the most important explanatory variables of 
mechanical performance and how a single explanatory variable can influence a 
mechanical outcome when holding all other, highly influential factors (like BV/TV) 
constant. Four mechanical properties were modeled: 1) Young’s modulus, 2) ultimate 
stress, 3) post-yield strain, and 4) post-yield toughness. These properties respectively 
describe the bulk tissue stiffness, strength, ductility, and toughness, and together offer 
a comprehensive evaluation of the monotonic compressive properties of bulk 
cancellous tissue. First, stepwise selection regressions using the Akaike information 
criterion with the small sample size correction (AICc)(57,58) were used to determine 
which compositional (AGEs, enzymatic crosslinks, mineral properties) and 
microarchitectural parameters were the most important determinants of mechanical 
performance. Linear(59,60) and power law(61,62) relationships were assessed to determine 
the influence of BV/TV on mechanical properties (see 5.8 Section S2 and 
Supplemental Table S1), and a linear BV/TV term was elected for use in these models. 
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For highly collinear variables (e.g., Tb.Th, Tb.N, Tb.Sp), only one was included in the 
stepwise model. Patient age was included as a fixed effect, and the factor that emerged 
from the principal components analysis of the compositional outcomes was included 
as a potential model effects in place of the variables that constituted the factor. The 
interaction of Group with all potential compositional and microarchitecture predictors 
was also included. To ascertain whether or not the influence of T2DM-realted 
complications (e.g., CVD, CKD, Table 4.3-1) influenced the measured mechanical 
properties, dichotomous variables for these complications were also included as 
potential effects. To maintain power for the regression analyses (T2DM: n = 20, non-
DM: n = 25), the sugar:matrix ratio was not included as a potential effect.  
A visual representation that shows the direction and magnitude of each 
predictor in the post-yield toughness model was generated. The grand mean of all 
predictor variables was calculated for the non-DM and T2DM groups, and these 
values were entered into the model for post-yield toughness to ascertain the predicted 
average post-yield toughness. Next, the predicted post-yield toughness was calculated 
for a one standard deviation increase to the grand mean of each predictor variable 
while holding all other predictors at their respective grand means. Group was set to 
T2DM, and age was set to 63 years. This same method of adding one standard 
deviation to the grand mean was performed for all predictor variables, and the 
predicted post-yield toughnesses were plotted together on the same axis. The resulting 
figure shows the direction and magnitude of a one standard deviation unit increase 
from the grand mean for each predictor, thereby allowing for visual comparison of 
different compositional or microarchitectural effects. Low, medium, and high risk 
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scenarios were generated and plotted in the same manner.  
5.3 Results 
5.3.1 Group Characteristics  
In the full cohort, the T2DM group had a higher pre-operative HbA1c than the non-
DM group (+28%, p < 0.05), and hyperglycemia in the T2DM group and euglycemia 
in the non-DM group was confirmed (Table 5.3-1). Age, past surgical history, height, 
weight, and BMI did not differ across groups, and the T2DM group possessed a higher 
prevalence of coronary artery disease (p < 0.05) with a trend toward a higher 
prevalence of hypertension (p = 0.099) compared to the non-DM group (Table 5.3-1). 
Twenty-three percent of the T2DM group used insulin (n = 7/31), 74% used 
metformin (n = 25/31), and 45% used other antidiabetic medications (n = 13/31) 
(Table 5.3-1).  
The mechanical testing cohort differed slightly from the full cohort. First, 
although the mean ages of the T2DM and non-DM groups were not statistically 
different in the full cohort, the T2DM group was borderline older than the non-DM 
group in the mechanical testing cohort (+7%, p = 0.073) (Table 5.3-1). Accordingly, 
mechanical testing data were adjusted for age (see Statistical Analyses). Second, in the 
mechanical testing cohort, the T2DM group had a higher prevalence vitamin D 
supplementation than the non-DM group (p < 0.05) (Table 5.3-1).  
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5.3.2 Advanced Glycation Endproducts 
The concentration of the AGE pentosidine was 36% greater, and the sugar:matrix ratio 
was 42% greater in the T2DM group compared to the non-DM group (both p < 0.05) 
(Figure 5.3-1A). Concentration of total fAGEs did not differ across groups (Figure 
5.3-1A). Pentosidine, the sugar:matrix ratio, and total fAGEs were not correlated 
among each other.  
5.3.3 Enzymatic Crosslinks 
The concentration of the enzymatic crosslink Pyd trended towards being lower in the 
T2DM group than the non-DM group (-10%, p = 0.071) (Figure 5.3-1B), while the 
concentration of Dpd did not differ across groups (Figure 5.3-1B). The total content of 
mature/trivalent enzymatic crosslinks (sum of Pyd and Dpd) measured with HPLC and 
collagen maturity (XLR, Figure 5.3-1B) measured with FTIR did not differ across 
groups. 
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Table 5.3-1: Group characteristics of the full cohort and the mechanical testing 
cohort. Values are shown as means ± standard deviation, unless otherwise noted. 
Coexisting conditions were determined from medical records at the time of total hip 
arthroplasty. p values assessed by Student’s t-test, Welch’s t-test, Mann-Whitney U 
test, Kolmogorov-Smirnov test, or Pearson chi-square test, as appropriate. 
Abbreviations: non-DM: non-diabetic group, T2DM: type 2 diabetic group; THA: 
total hip arthroplasty; TKA: total knee arthroplasty. 1Antidiabetic medications include 
sulfonylureas (SUs): glyburide, glipizide, glimepiride; glinides: nateglinide; glucagon-
like peptide 1 (GLP-1) agonists: dulaglutide, liraglutide, exenatide; and depeptidyl 
peptidase 4 (DPP-4) inhibitor: sitagliptin.
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  Full Cohort Mechanical Testing Cohort 
Characteristic 
non-DM T2DM 
p 
non-DM T2DM 
p 
(n = 34) (n = 31) (n = 25) (n = 20) 
Demographic 
 
    
 
    
Age (years) 61.6 ± 8.6 64.8 ± 8.1 0.131 60.6 ± 8.0 64.8 ± 7.1 0.073 
Past surgical THA or TKA, n 
(%) 
10 (29.4) 6 (19.4) 0.347 9 (36.0) 4 (20.0) 0.239 
Biochemical 
 
    
 
    
Pre-operative HbA1c (%) 5.53 ± 0.39 7.07 ± 0.89 < 0.05 5.52 ± 0.40 7.21 ± 1.01 < 0.05 
Anthropometry  
 
    
 
    
Height (cm) 178.9 ± 6.9 177.2 ± 8.0 0.369 180.0 ± 6.9 176.4 ± 8.1 0.126 
Weight (kg) 93.7 ± 21.1 99.6 ± 17.7 0.222 97.7 ± 21.9 97.2 ± 18.6 0.945 
Body mass index (kg/m2) 29.8 ± 6.3 32.3 ± 5.3 0.084 30.9 ± 6.7 32.2 ± 6.0 0.508 
Coexisting conditions 
 
    
 
    
Hypertension, n (%) 15 (44.1) 20 (64.5) 0.099 11 (44.0) 14 (70.0) 0.081 
Hyperlipidemia, n (%) 15 (44.1) 18 (58.1) 0.261 11 (44.0) 14 (70.0) 0.081 
Chronic kidney disease, n (%)  1 (2.9) 2 (6.5) 0.501 1 (4.0) 2 (10.0) 0.427 
Coronary artery disease, n (%)  1 (2.9) 6 (19.4) < 0.05 1 (4.0) 2 (10.0) 0.427 
Current medications/supplements 
 
    
 
    
Insulin, n (%) 0 (0.0) 7 (22.6) < 0.05 0 (0.0) 4 (20.0) < 0.05 
Biguanides (Metformin), n (%) 0 (0.0) 23 (74.2) < 0.05 0 (0.0) 13 (65.0) < 0.05 
Other antidiabetic medications1, 
n (%) 
0 (0.0) 14 (45.2) < 0.05 0 (0.0) 7 (35.0) < 0.05 
Vitamin D, n (%) 3 (8.8) 8 (25.8) 0.068 2 (8.0) 8 (40.0) < 0.05 
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5.3.4 Ratio of Non-enzymatic to Enzymatic Crosslinks  
The ratio of non-enzymatic crosslinks to mature crosslinks (or disadvantageous 
crosslinks to advantageous crosslinks(54)), calculated as pentosidine/(Pyd+Dpd), was 
61% greater in the T2DM group compared to the non-DM group (T2DM: 9.94 ± 6.42, 
non-DM: 6.17 ± 2.42, p < 0.05).  
5.3.5 Mineral Properties 
The mineral:matrix ratio was 7% greater in the T2DM group versus the non-DM 
group (p < 0.05) (Figure 5.3-1C). The crystallinity, carbonate:phosphate ratio, and 
acid phosphate content did not differ across groups (Figure 5.3-1C). 
 
Figure 5.3-1: Compositional properties of the full cohort organized by (A) measures 
of advanced glycation endproducts, (B) measures of enzymatic crosslinks, and (C) 
measures of mineral properties. * p < 0.05 and # p < 0.10 assessed by Student’s t-test, 
Welch’s t-test, Mann-Whitney U test, or Kolmogorov-Smirnov test. Abbreviations: 
non-DM: non-diabetic group; T2DM: type 2 diabetic group; Total fAGEs: total 
fluorescent advanced glycation endproducts; Pyd: pyridinoline; Dpd: 
deoxypyridinoline; XST = crystallinity; C:P = carbonate:phosphate ratio; AP = acid 
phosphate content. 
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5.3.6 Microarchitecture 
In T2DM compared to non-DM specimens, Tb.Sp was lower (-13%, p < 0.05), Tb.N 
trended toward a greater value (+20%, p = 0.059), and Conn.D trended toward greater 
value (+96%, p = 0.061) (Table 5.3-2). All other microarchitectural parameters 
(BV/TV, BS/BV, Tb.Th, and DA) did not differ across groups (Table 5.3-2). Neither 
patient weight nor BMI were correlated with BV/TV suggesting that body mass did 
not increase bone volume.  
Table 5.3-2: Microarchitecture assessed with microCT of the mechanical cohort 
specimens. Values are shown as means ± standard deviation. p values assessed by 
Student’s t-test, Welch’s t-test, Mann-Whitney U test, or Kolmogorov-Smirnov test. 
Abbreviations: non-DM: non-diabetic group, T2DM: type 2 diabetic group; BV/TV: 
bone volume fraction; BS/BV: specific bone surface; Conn.D: connectivity density; 
Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; 
DA: degree of anisotropy. 
 
Microarchitecture 
Parameter 
non-DM T2DM T2DM vs. non-DM 
p 
(n = 25) (n = 20) (% difference) 
BV/TV (%) 15.81 ± 7.30 19.63 ± 8.69 24 0.125 
BS/BV (mm2/mm3) 19.01 ± 3.79 18.22 ± 4.24 -4 0.520 
Conn.D (1/mm3) 10.52 ± 9.19 20.65 ± 21.52 96 0.061 
Tb.N (1/mm) 1.27 ± 0.29 1.52 ± 0.49 20 0.059 
Tb.Th (mm) 0.15 ± 0.03 0.16 ± 0.07 7 0.534 
Tb.Sp (mm) 0.80 ± 0.15 0.71 ± 0.12 -13 < 0.05 
DA 1.77 ± 0.24 1.84 ± 0.23 4 0.394 
 
5.3.7 Mechanical Properties  
Compression testing revealed that Young’s modulus was 86% greater (p < 0.05) 
(Figure S1A), yield stress was 91% greater (p < 0.05) (Figure S1C), and ultimate 
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stress was 90% greater (p < 0.05) (Figure S1F) in the T2DM versus non-DM group. 
Yield strain, ultimate strain, post-yield strain, post-yield toughness, toughness, and 
residual strain did not differ across groups (Figure S1B, S1E, S1G, S1H, S1I, S1K).  
The mechanical property outcomes of Young’s modulus, yield stress, ultimate 
stress, and both measures of toughness were linearly normalized by each specimen’s 
respective BV/TV (mechanical property/BV/TV, see 5.8 S2 and Table S1). 
Normalized Young’s modulus (Figure 5.3-2A), normalized yield stress, and 
normalized ultimate stress (Figure 5.3-2B) remained 51%, 55%, 45% greater in the 
T2DM versus non-DM group, respectively (all p < 0.05). Normalized post-yield 
toughness (Figure 5.3-2C) and normalized toughness did not differ across groups. 
 
Figure 5.3-2: (A) Young’s modulus normalized by BV/TV, (B) Ultimate stress 
normalized by BV/TV, and (C) Post-yield toughness normalized by BV/TV. 
Horizontal lines indicate group means. * p < 0.05 by Student’s t-test. Abbreviations: 
non-DM: non-diabetic group, T2DM: type 2 diabetic group; BV/TV: bone volume 
fraction. A version of this figure that also shows the relationship of mineral content 
with the mechanical properties normalized by BV/TV can be seen in 5.8 Supplemental 
Figure S3. 
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5.3.8 Mineral Maturity Factor  
PCA was used to determine whether variation in the interrelated compositional 
variables could be explained in terms of a smaller number of independent variables 
(factors). Using PCA, we identified a factor (factor loadings > |0.8|, eigenvalue = 2.68) 
that we termed the mineral maturity factor (MMF) because it consisted of FTIR 
crystallinity, carbonate:phosphate ratio, and acid phosphate content, all variables that 
characterize the composition and size of bone mineral crystals. The original variables 
were standardized and coded such that higher MMF values indicate a more mature 
mineral crystal, with larger/more perfect crystals and lower carbonate and acid 
phosphate substitution. The MMF captured 89% of the variance of the three included 
parameters and was included in the subsequent regression analyses.  
The MMF was not statistically different across groups (T2DM: MMF = -0.172, 
non-DM: MMF = 0.129, p = 0.237); however, the lower T2DM group MMF value 
indicates that the T2DM specimens had a less mature mineral compared to the 
specimens in the non-DM group on average. 
5.3.9 Regression Analyses with Pre-operative HbA1c 
Correlations between pre-operative HbA1c and compositional parameters revealed 
that pre-operative HbA1c was weakly and positively correlated the mineral:matrix 
ratio (R2 = 0.182, p < 0.05). All other compositional parameters were not correlated 
with pre-operative HbA1c. 
Correlations between pre-operative HbA1c and microarchitectural parameters 
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revealed that pre-operative HbA1c weakly and positively correlated with Tb.N (R2 = 
0.077, p < 0.05) and weakly and negatively correlated with Tb.Sp (R2 = 0.091, p < 
0.05). No other microarchitectural parameters were correlated with pre-operative 
HbA1c. 
Correlations between pre-operative HbA1c and mechanical properties revealed 
that Young’s modulus was weakly and positively correlated with HbA1c (R2 = 0.088, 
p < 0.05). Pre-operative HbA1c was not correlated with any other mechanical 
outcomes.  
5.3.10 Predicted Regression Analyses for Mechanical Properties 
A combination of microarchitectural and compositional parameters explained between 
12% and 83% of the observed variation in Young’s modulus, ultimate stress, post-
yield strain, and post-yield toughness (Table 5.3-3). Age was included as a fixed effect 
for each model to control for variations in patient age (Table 5.3-1); however, age was 
not a significant explanatory variable in any of the models of mechanical properties.  
Eighty-three percent of the variation in Young’s modulus was explained by 
BV/TV, Tb.Th, mineral:matrix ratio, Group, and the interaction of Group with Tb.Th; 
70% of the variance in ultimate stress was explained by BV/TV and mineral:matrix 
ratio; 12% of the variance in post-yield strain was explained by the mineral maturity 
factor and pentosidine; and 74% of the variance in post-yield toughness was explained 
by BV/TV, the mineral maturity factor, pentosidine, total fAGEs, Group, and the 
interaction of Group with total fAGEs (Table 5.3-3).  
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Table 5.3-3: Final regression models of selected mechanical properties organized by parameter type (fixed effect, 
microarchitecture, or composition). Values are shown as parameter coefficients with standard error in parentheses. 
Regression coefficients were determined from forward stepwise regressions using the Akaike information criterion (AICc). 
Abbreviations: BV/TV: bone volume fraction; Tb.Th: trabecular thickness; Total fAGEs: total fluorescent AGEs. 
 
Parameter 
Young’s 
Modulus (MPa) 
Ultimate Stress 
(MPa) 
Post-yield 
Strain (%) 
Post-yield 
Toughness (kPa) 
Intercept  -1444.4 (676.1) -12.44 (7.45) 1.446 (0.485) -3.86 (38.60) 
Group -58.2 (36.4) --- --- -8.79 (4.68) 
Fixed Effect         
Age (years) 3.4 (4.1) 0.05 (0.06) -0.005 (0.008) -0.08 (0.58) 
Microarchitecture   
 
    
BV/TV (%) 43.8 (66.6) 0.51 (0.06) --- 5.57 (0.73) 
TbTh (mm) 2731.6 (1634.5) --- --- --- 
TbTh*Group -3039.4 (980.9) --- --- --- 
Composition   
 
    
Mineral:Matrix (unitless) 120.5 (100.6) 1.15 (1.20) --- --- 
Mineral Maturity Factor (unitless) --- --- -0.208 (0.070) -10.56 (5.62) 
Pentosidine (mmol/mol collagen) --- --- -0.038 (0.032) -6.10 (2.72) 
Total fAGEs (nq quinine/mg 
collagen) 
--- --- --- -0.10 (0.09) 
Total fAGEs*Group --- --- --- 0.17 (0.09) 
Adjusted R2 0.826 0.694 0.116 0.739 
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5.3.11 Magnitude and Direction of Model Predictors and Hypothetical Risk Scenarios 
The predicted post-yield toughness was calculated from the regression model (Table 
5.3-3) using the grand mean values for the non-DM and T2DM specimens combined 
and group set to T2DM (Figure 5.3-3, top gray box and corresponding vertical gray 
dashed line). Next, one parameter at a time was varied from the grand mean to the 
grand mean plus one standard deviation (Figure 5.3-3, gray boxes), or in the case of 
group, set to non-DM. As seen in Figure 5.3-3A, a one standard deviation increase in 
BV/TV from the grand mean increases predicted post-yield toughness by 68% (third 
gray box from the top), while a one standard deviation increase in MMF, pentosidine, 
or total fAGEs decreases predicted post-yield toughness by 14%, 16%, or 19%, 
respectively (bottom three gray boxes of Figure 5.3-3A). The direction of these 
changes match the signs of the predictor coefficients in Table 5.3-3.  
 Three different risk scenarios were hypothesized for post-yield toughness 
based on the regression model coefficients and Figure 5.3-3A. The low risk scenario 
for the T2DM group includes a high (grand mean + one standard deviation) BV/TV, 
but average (grand mean) MMF, pentosidine, and total fAGEs values (Figure 5.3-3B). 
The sum of all the effects was positive and equal to that of the effect of BV/TV, as 
shown on the bottom row of Figure 5.3-3B with the solid black box. The medium risk 
scenario for the T2DM group includes an average BV/TV, but high (grand mean + one 
standard deviation) values for MMF, pentosidine, and total fAGEs. The sum of all the 
effects was negative, as shown with the solid black box along the bottom row of 
Figure 5.3-3C. The high risk scenario for the T2DM group includes moderately-low 
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BV/TV (mean – one half of one standard deviation) and high (grand mean + one 
standard deviation) values for MMF, pentosidine, and total fAGEs. The sum of all the 
effects was more negative than the medium risk, as shown with the solid black box 
along the bottom row of Figure 5.3-3D. 
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Figure 5.3-3: The regression model for post-yield toughness (Table 5.3-3) was used 
to calculate predicted post-yield toughness under different circumstances. (A) The 
predicted post-yield toughness of a specimen with grand mean values of BV/TV, 
MMF, pentosidine, and total fAGEs is shown with the top gray box and the vertical 
black dashed line. The predicted post-yield toughness of each predictor parameter was 
varied one at a time from the grand mean to the grand mean plus one standard 
deviation to show the magnitude and direction of change and is indicated with a gray 
box. For (B-D), MMF, pentosidine, and total fAGEs were evaluated at the mean plus 
one standard deviation and BV/TV was evaluated at (B) the grand mean of BV/TV 
plus one standard deviation, which illustrates a low risk scenario; (C) the grand mean 
of BV/TV, which illustrates a medium risk scenario; and (D) the grand mean of 
BV/TV minus one half of one standard deviation, which illustrates a high risk 
scenario. The bottom black box in Panels B-D indicates the predicted post-yield 
toughness for that scenario, and it is also the cumulative effects of all predictor 
parameters compared to the predicted post-yield toughness evaluated with every 
parameter at the grand mean. The horizontal gray lines indicate the 95% CI. 
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5.4 Discussion 
In this work, we describe the compositional, microarchitectural, and mechanical 
properties of cancellous bone at the femoral neck in men with and without T2DM. As 
hypothesized, the concentration of AGEs was greater in cancellous tissue in the T2DM 
group. Contrary to our hypothesis, post-yield properties were similar across groups at 
the femoral neck; however, after accounting for the large influence of BV/TV, we 
observed that the altered tissue composition in the T2DM group decreases post-yield 
stain and post-yield toughness.  
Compositional characterization revealed a greater concentration of pentosidine 
and a greater sugar:matrix ratio in the T2DM specimens compared to the non-DM 
specimens. These results confirm increased accumulation of the AGE pentosidine and 
sugars bound to the collagen matrix in cancellous tissue with T2DM and are consistent 
with other reporting of bone tissue pentosidine in patients with and without T2DM.(38) 
In contrast, total fAGEs were not different between groups; nevertheless, this result is 
consistent in scope and magnitude with other reporting of fAGEs in proximal femoral 
cancellous bone in people with and without T2DM(32) and in non-DM femoral neck 
cadaveric tissue.(25) Although in vitro glycosylation/ribosylation studies of human and 
bovine tissue and collagen gels offer the ability to isolate the effects of AGE 
accumulation, the extent of glycosylation/ribosylation is two to ten times greater than 
the physiologic levels measured in the current study.(24,25,53) 
The apparent discrepancy between a highly specific measure of AGEs (i.e., 
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pentosidine), a global measure of sugars attached to the collagen matrix (i.e., 
sugar:matrix ratio), and a non-specific measure of AGEs that fluoresce at a specific 
wavelength (i.e., total fAGEs) underscores the current limitations of measuring AGE 
accumulation. For example, pentosidine is just one of hundreds of AGEs, so despite its 
ability to precisely characterize pentosidine concentration, its overall contribution to 
total AGE accumulation is unknown. Conversely, measurement of total fAGEs may 
capture a wider range of AGEs, but only fluorescent AGEs are measured, and all non-
fluorescent AGEs like CML are undetected. Finally, the ratio of non-enzymatic 
crosslinks to mature enzymatic crosslinks was 61% greater in the T2DM specimens 
compared to the non-DM specimens. Together, these findings provide clear evidence 
of detrimental crosslink accumulation in T2DM tissue and have translational relevance 
because crosslink accumulation stiffens the collagen matrix, which could in turn make 
bone in people with T2DM more brittle and less resistant to fracture.  
 In addition to a greater accumulation of AGEs in the T2DM specimens 
compared to the non-DM specimens, we observed additional evidence of altered 
collagen and mineral properties. The concentration of the trivalent enzymatic crosslink 
Pyd measured with HPLC trended towards being lower in the T2DM specimens 
compared to the non-DM specimens. This finding, though not statistically significant, 
may indicate a less mature collagen matrix and is consistent with a study of WBN/Kob 
rats that found reductions in enzymatic crosslinks with T2DM.(23) Reductions in 
mature crosslinks in tissue from patients with T2DM may similarly lead to decreased 
strength as evidenced by the association of mature pyridinoline crosslinks and tissue 
strength.(63,64)  
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 The mineral:matrix ratio, which characterizes tissue mineral content, was 7% 
greater in the T2DM specimens than the non-DM specimens. Our finding of increased 
mineral content with T2DM is consistent with findings of greater mean calcium 
content in the proximal femur of men and women with T2DM compared to non-
diabetic controls.(39) A more mineralized tissue is consistent with decreased 
ductility,(65) thus the greater mineral content observed in the tissue from the T2DM 
group likely contributes to the increased fracture risk in people with T2DM. The 
observed greater mineral content may indicate an increased tissue age (i.e., time since 
formation),(66) of the T2DM versus non-DM tissue. Alternatively, an increase in tissue 
mineral content may be due to an increase in mineralization nucleation sites.(67) FTIR-
assessed mineral properties and the mineral maturity factor (MMF), which combined 
mineral crystallinity with carbonate substitution and acid phosphate content, were not 
different across groups. This suggests that the overall maturity of the mineral in the 
T2DM group is similar to that of the non-DM group.  
 The simultaneous increase in mineral content without an increase in mineral 
maturity conveys complex effects of T2DM on mineralization, and it is likely that 
multiple processes responsible for the observed properties are occurring concurrently. 
One potential process is that hyperglycemia and AGE accumulation, which have been 
implicated in decreased osteoblastic function and proliferation in vitro, (8–10,27) may 
disrupt remodeling and could account for the increased bulk tissue mineral content. A 
second possible process is that AGE accumulation decreases mineralization rates and 
alters normal mineralization processes,(54) as evidenced by decreases in mineral 
apposition rates, bone formation rates, and the number of bone formation sites in 
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AGE-modified rat tissue.(68) A third possibility is that the formation of AGEs 
inherently alters the charge profile of the collagen fibers,(69,70) thereby disrupting cell-
matrix interactions that could cause downstream effects for collagen and mineral 
maturation.(67,71) The current study was not designed a priori to study these 
biochemical pathways; however, it is feasible that a simultaneous reduction in 
remodeling rates and disruption of mineralization and collagen maturation with T2DM 
via these proposed processes would culminate in the tissue properties observed here. 
 In the microarchitectural analyses, the T2DM specimens had smaller 
separation distances between trabecula than the non-DM specimens. Additionally, the 
T2DM specimens had a borderline greater number of trabecula (+20%, p = 0.059) and 
borderline greater connective density (+96%, p = 0.061) than the non-DM specimens. 
The BV/TV of the T2DM specimens was not different than the non-DM specimens 
(+23%, p = 0.125). Even though not all of the differences in microarchitecture 
outcomes met the 0.05 threshold for statistical significance, overall, the T2DM 
specimens had more numerous, more connected, and closer trabeculae, which are 
known to contribute to a greater BV/TV. Therefore, the 23% greater BV/TV observed 
in the T2DM group versus non-DM group, though not significant, is consistent with 
these other measured microarchitectural parameters. Furthermore, the 23% difference 
in BV/TV is similar to significant differences reported in larger studies of trabecular 
microarchitecture in patients with T2DM(72) and is consistent with prior observations 
of greater trabecular hip vBMD in patients with T2DM compared to those without.(28) 
Interestingly, cancellous microarchitecture may vary between the hip and the spine. 
Using DXA images to calculate trabecular bone score (TBS), the TBS of the lumbar 
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spine was lower in people with T2DM compared to those without T2DM,(73,74) 
indicating a poor-quality microarchitecture.(75) 
The Young’s modulus and ultimate stress of specimens from the T2DM group 
were greater than those from the non-DM group, indicating that the T2DM specimens 
were stiffer and stronger. The post-yield properties, including post-yield strain and 
post-yield toughness, however, did not differ across groups. Because the apparent 
stiffness, strength, and toughness of bulk cancellous tissue are all strongly influenced 
by the quantity of bone in the tested specimen (i.e., BV/TV),(62,76,77) we normalized 
these apparent properties by each specimen’s BV/TV. Contrary to our hypothesis, the 
stiffness and strength remained greater in the T2DM specimens after normalization, 
though to a lesser magnitude (Figure 5.3-2). The post-yield properties remained 
similar across groups after normalization by BV/TV. Thus, the decreased resistance to 
fracture at the whole-bone level observed clinically in T2DM patients was not 
mirrored in the monotonic compressive behavior of cancellous explants. 
The increased mineral content of the T2DM specimens compared to the non-
DM specimens is largely responsible for the greater stiffness and strength of the 
specimens in the T2DM group observed after normalization by BV/TV. The 
specimens with higher mineral content (as measured by the FTIR mineral:matrix ratio) 
had consistently greater moduli, ultimate stresses, and post-yield toughnesses before 
and after accounting for BV/TV (see 5.8 Supplemental Figure S3).  
The importance of bone volume fraction and the mineral content on the bulk 
cancellous bone behavior is further exemplified by the regression models (Table 3), 
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which show the strong contribution of these two parameters on Young’s modulus and 
ultimate stress. These results demonstrate that tissue mineral content is consistently 
important for elastic behavior (which has been previously documented).(65) 
In the regression model of post-yield strain, which modeled the tissue’s 
ductility or ability to deform plastically prior to failure, measures of bone quality (i.e., 
the Mineral Maturity Factor [MMF] and pentosidine) were significant explanatory 
variables (Table 3). Similarly, the predictive factors for post-yield toughness, a 
quantity that characterizes the tissue’s ability to absorb energy prior to failure and 
depends on the product of strength and ductility, were the combination of the 
predictive factors observed in strength (BV/TV) and in post-yield strain (MMF, 
pentosidine). The MMF and AGE outcomes had distinctly opposite effects as BV/TV 
and the mineral:matrix ratio. For example, greater values of BV/TV increased post-
yield toughness, while greater values of AGEs, like pentosidine, decreased post-yield 
toughness (Table 3). Our regression models of post-yield properties clearly 
demonstrate the important role of tissue composition after controlling for the greater 
bone volume fraction of cancellous bone in patients with T2DM. One limitation of our 
regression models, however, is the large confidence interval for each parameter as a 
result of our limited sample size (n = 40-45) and the inherent variability in human 
data.  
The regression modeling is essential to elucidating the relative contributions of 
microarchitecture and tissue material properties to contributions of tissue-level 
material properties with T2DM that occur concurrent with changes in BV/TV. Here, 
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the between-group differences in the quantity of bone (measured as BV/TV) were so 
large that they dominated the monotonic mechanical properties and essentially masked 
any other, lower-magnitude differences in material properties with T2DM. By 
performing regression modeling, we were able to elucidate compositional and 
microarchitectural changes in T2DM tissue that can be observed after controlling for 
BV/TV. For example, post-yield toughness was not different by group, but was 
strongly influenced by BV/TV (as shown in Table 5.3-3). Using stepwise regression 
models to isolate the effect of BV/TV, we were able to see that the mineral maturity 
factor, pentosidine, and total fAGEs, had an effect on post-yield toughness, albeit a 
smaller effect than that of BV/TV (Figure 5.3-3). Of the mineral maturity factor, 
pentosidine, and total fAGEs, only pentosidine was significantly different by group 
(Figure 5.3-1); however, the presence of the mineral maturity factor and total fAGEs 
in the predicted models indicates that these two predictors capture aspects of post-
yield toughness that are not necessarily as heavily influence by group.  
The different scenarios hypothesized in Figure 5.3-3B-D for low, medium, and 
high risks further exemplify the large influence of BV/TV; however the influence of 
tissue AGEs and mineral maturity can also be appreciated. For example, a one 
standard deviation increase from the mean in mineral maturity, pentosidine, or total 
fAGEs decreases the predicted post-yield toughness compared to the predicted post-
yield toughness for an average specimen (Figure 5.3-3A). The scenarios proposed in 
Figure 5.3-3B, Figure 5.3-3C, and Figure 5.3-3D demonstrate how deleterious effects 
in tissue composition can affect bone toughness, especially in the absence of the 
compensatory effect of BV/TV. Specifically, in the low risk scenario, the high BV/TV 
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improves post-yield toughness to a greater extent than the deleterious effects due to 
compositional changes (Figure 5.3-3B). In the medium risk scenario, BV/TV still 
compensates for the negative influences of the compositional changes, but to a lesser 
extent, and there is a cumulative decrease in post-yield toughness (Figure 5.3-3C). 
Finally, in the high risk scenario where BV/TV is moderately lower than the grand 
mean, BV/TV no longer compensates for the compositional changes, and there is a 
drastic reduction in predicted post-yield toughness (Figure 5.3-3D). While the 
regression model presented here is only representative of this study cohort, our models 
demonstrate how there can be various stages of skeletal fragility risk associated with 
changes in microarchitecture or tissue composition.  
The variable Group modulated trabecular thickness in the model of modulus 
and on total fAGEs in the model of post-yield toughness (Table 5.3-3). Neither 
trabecular thickness nor total fAGEs alone were statistically different between groups 
(Figure 5.3-1); nevertheless, the significant effect of group in these two models 
indicates that there are important characteristics relating to trabecular thickness and 
total fAGEs that were not captured by the models. 
Tying together the differences in material properties in T2DM versus non-DM 
specimens and the regression model results, it is evident that T2DM has both 
beneficial and adverse effects on the mechanical performance of bone. First, T2DM 
patients had a greater bone volume fraction at the femoral neck, though not 
statistically significant, which is consistent with clinical assessments of BMD at the 
femoral neck(1,2) and hip.(3) Furthermore, the greater quantity of bone had a large and 
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favorable influence on the monotonic apparent stiffness, strength, and toughness. 
Second, the greater mineral content in the T2DM specimens compared to the non-DM 
specimens resulted in greater apparent-level strength; however, greater strength 
typically comes at the expense of ductility and results in more brittle tissue. While we 
did not detect a group-wise difference in post-yield strain or post-yield toughness, the 
tradeoff between strength and toughness is well documented.(65,78) It is possible that 
the large effect of BV/TV overshadowed any smaller effects of T2DM on post-yield 
properties and inhibited our ability to detect such differences in group comparisons.  
One key benefit of our regression models is that they allowed us to estimate 
the potential effect of material properties separate from the compensatory effects of 
increased BV/TV with T2DM. For example, our data show greater concentrations of 
AGEs (e.g., pentosidine) in cancellous tissue from patients with T2DM than those 
without T2DM, and after accounting for differences in BV/TV, our models revealed 
the adverse effect of pentosidine accumulation on the post-yield properties. This 
indicates that if a patient with T2DM has very large accumulation of tissue AGEs, like 
pentosidine, but does not have a concurrent increase in BV/TV, the adverse effects of 
T2DM can outweigh any potential compensating effects of increased BV/TV with 
T2DM. Because post-yield toughness is indicative of the amount of energy that can be 
absorbed before failure, our model demonstrates how poor bone quality without an 
advantageous increase in bone mass can lead to decreased fracture resistance in 
patients with T2DM.  
Although the mechanical testing (which showed that bulk cancellous tissue 
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from the T2DM group was stronger than that from non-DM controls) appear in 
conflict with clinical observations of reduced whole-bone fracture resistance, they 
highlight the complexity of identifying the key factors that contribute to fracture 
behavior across multiple levels of structural hierarchy. Our study focused on the 
cancellous tissue properties at the millimeter-scale, and our results suggest that 
patients with T2DM have a greater quantity of bone that is more highly mineralized. 
While these changes will ultimately increase cancellous bone strength at the 
millimeter-scale, a more highly mineralized bone will be inherently more brittle and 
less capable of plastic deformation and thus potentially less fracture resistant.(65,79) In 
addition, our models of post-yield strain and post-yield toughness demonstrate an 
adverse effect of AGE accumulation on energy absorption once the large influence of 
BV/TV is controlled for. Finally, it is important to note that both cancellous and 
cortical bone contribute to structural performance at the whole-bone level, and cortical 
bone is more critical for load bearing in the hip.(80) Because growing evidence 
indicates that T2DM compromises cortical tissue integrity,(16,29,31) it is possible that 
adverse changes due to T2DM in the cortical compartment may outweigh any 
beneficial changes in the cancellous compartment, and this may help to explain whole-
bone fragility observed clinically at the hip. Future work includes analysis of the 
accompanying cortical tissue in these specimens. 
Our study design has several important limitations and advantages. The main 
shortcoming of this study was the limited availability of patient information related to 
T2DM. Even though the pre-operative HbA1c and diagnosis of T2DM were recorded 
at the time of total hip arthroplasty, the patients’ long-term HbA1c history or duration 
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of T2DM were not available. Therefore, our information on the patients’ glycemic 
control was only on the order of months, which is much shorter than the years required 
for skeletal changes due to T2DM to fully manifest. Furthermore, the severity and 
duration of T2DM are known to greatly affect fracture risk,(31,81) and therefore may 
also affect the degree of compositional changes due to T2DM. Thus, the single time 
point for HbA1c level limits our ability to relate clinical measures of glycemic control 
to the tissue properties that may govern fracture behavior and likely influenced our 
ability to detect stronger correlations between HbA1c and tissue material properties. 
Similarly, we were not able to directly account for any T2DM-related complications 
that may affect bone, such as cardiovascular disease, renal osteodystrophy, 
retinopathy, or systemic inflammation. Similarly, although we accounted for the 
presence of CVD and CKD in our model, our ability to directly account for other 
T2DM-related complications that may affect bone, such as renal osteodystrophy, 
retinopathy, or systemic inflammation(82) was limited by the lack of detailed 
information on these comorbidities collected prior to surgery. We also could not assess 
whether bone remodeling was altered in the T2DM group via serum biomarkers or 
dynamic bone labeling. Lastly, although we collected and characterized femoral neck 
tissue at the farthest distance possible from the joint surface, all subjects in our study 
had osteoarthritis. A recently published study with a similar cohort of patients 
undergoing total hip arthroplasty for osteoarthritis did not report differential effects of 
osteoarthritis in patients with and without T2DM on the trabecular tissue; however, it 
is possible that osteoarthritis may have altered the joint tissue properties in our 
specimens.(83) The medical management of patients with T2DM, as well as OA, may 
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affect the results and may also help explain some of the apparent discrepancies 
between our findings and the findings of T2DM animal models. Our study did not 
include women because female age-matched specimens accrued much more slowly; 
however, future analyses should include women participants. While the surgical 
setting of our specimen collection imposed several limitations, one major benefit of 
our study is that the explants characterized here are from the femoral neck, a highly 
clinically relevant fracture site with a large volume of cancellous bone. Moreover, 
tissue from the femoral neck allows for tissue characterization at the bulk level and for 
compartment-specific analysis of cancellous and cortical bone. Finally, our study is 
among the first to characterize changes in bone quality and mechanical properties in 
cancellous bone from a clinical population of men with T2DM. 
5.5 Conclusion 
In this study, we quantified the accumulation of AGEs, characterized the mineral and 
matrix composition, assessed the microarchitecture, and mechanically assessed 
cancellous bone from men with and without T2DM. Our findings showed clear 
evidence, for the first time, of AGE accumulation and altered tissue material 
properties in a clinical population with T2DM. Additionally, we used statistical 
models to predict and compare the mechanical performance of hypothetical low, 
medium, and high risk scenarios based on the observed changes in tissue composition 
and microarchitecture with T2DM. Our regression models showed, as expected, that 
bone volume fraction was by far the greatest determinant of compressive mechanical 
properties. Furthermore, the T2DM group had a greater tissue mineral content than the 
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non-DM group which increased strength. After accounting for the greater bone 
volume fraction in the T2DM group, our analyses revealed the deleterious effects of 
T2DM such AGE accumulation and altered mineral maturity. Specifically, we 
illustrated that poor bone quality (e.g., high AGE concentrations) in the absence of 
increased bone volume fraction can drastically reduce the ability of cancellous bone to 
absorb energy prior to failure in patients with T2DM. Our findings echo 
epidemiological evidence that the quantity of bone alone does not explain fracture 
risk, and our results provide a foundation for future investigations of changes in bone 
quality with T2DM. Although our methods are not available in a typical diabetes 
clinic, our findings are clinically relevant because they demonstrate that different 
populations of T2DM patients may have distinctly different bone fragilities as a result 
of varying tissue composition and microarchitecture.  
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5.8 Supplemental 
S1: Decalcification of Cancellous Tissue for FTIR Analyses 
The cancellous tissue allocated for analysis of the sugar:matrix ratio was 
demineralized using a 9.5% ethylene diamine tetra-acetic acid (EDTA) solution in 
phosphate-buffered saline. The tissue was submerged in the EDTA solution for five 
days at 4 ˚C, with a solution change every 24 hours. After five days, the demineralized 
tissue was rinsed twice with acetone for 10 minutes, then rinsed twice with deionized 
water for 10 minutes. The demineralized tissue was lyophilized, powdered using a 
cryomill, and pressed into a pellet with a tissue:KBr ratio of 1:100.  
S2: Normalization of Mechanical Properties by Bone Volume Fraction 
Linear(59,60) and power law(61,62) relationships were assessed to determine, and 
ultimately account for, the influence of BV/TV on mechanical properties. Linear 
relationships were determined by performing univariate linear regressions between the 
mechanical properties (Young’s modulus, yield stress, post-yield toughness, 
toughness) as the dependent variable and BV/TV as the independent variable. Power 
law relationships were assessed by performing univariate linear regressions on 
logarithmically transformed mechanical properties and BV/TV. The resulting 
coefficients of determination (R2) were compared for the linear and the log 
transformed regressions. The interaction of group and BV/TV was also evaluated for 
the linear and power law relationships to ascertain if there was a group-dependent 
effect of BV/TV on mechanical properties. 
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The power law relationships between BV/TV and yield stress, ultimate stress, 
post-yield toughness, and toughness had higher coefficient of determinations 
compared to the linear relationships; however, using a power law relationship only 
explained up to 7% more of the observed variation in the aforementioned mechanical 
properties with BV/TV. Moreover, a power law relationship decreased the explained 
variance of BV/TV with Young’s modulus compared to a linear relationship. We 
opted to use a linear normalization of mechanical properties with BV/TV because of 
the marginal difference in explanatory power between linear and power law 
relationships and for simplicity. 
 There was a group-dependent effect of BV/TV on Young’s modulus, yield 
stress, and ultimate stress (BV/TV*Group: all p < 0.05); however, this group different 
became insignificant when other compositional variables were included in the models 
(i.e., mineral:matrix ratio).  
Supplemental Table S1: Coefficients for linear and power law regressions of 
mechanical properties with BV/TV. The coefficient of determination (R2) is shown.  
Regressed on BV/TV  
Linear Relationship to 
BV/TV 
Power Law Relationship to 
BV/TV 
  Slope Intercept  R2 Slope Intercept  R2 
Young’s Modulus (MPa) 58.20 -390.74 0.796 1.91 0.77 0.731 
Yield Stress (MPa) 0.41 -2.98 0.702 2.01 -4.54 0.727 
Ultimate Stress (MPa) 0.61 -4.77 0.748 1.89 -3.87 0.766 
Post-yield Toughness (kPa) 6.98 -60.62 0.591 2.01 -1.95 0.664 
Toughness to (kPa) 9.29 -77.79 0.634 1.96 -1.46 0.696 
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S3: Tertiles of Mineral:Matrix Ratio 
Mineral:matrix ratio had a large influence on stress, which also affects toughness. To 
show the effect of mineral content on mechanical properties after the normalization by 
BV/TV, we created tertiles of the mineral:matrix ratio to designate groups in the 
lower, middle, and upper thirds of mineral content. There were more specimens in the 
lower tertile from the non-DM group than the T2DM group (non-DM: 88%; T2DM: 
12%), and there were more specimens in the upper tertile from the T2DM group than 
the non-DM group (T2DM: 75%; non-DM: 25%) as determined by Chi-squared test (p 
< 0.05). 
Tertiles of mineral:matrix are shown in Figure S3 to 1) show that specimens 
with high mineral:matrix values also had greater stiffness, strength, and toughness; 
and 2) that most of the specimens with high mineral:matrix values were in the T2DM 
group.  
S4: Rationale for PCA and Description of MMF 
The rationale for performing PCA on compositional variables was to reduce the 
collinearity of variables used in the stepwise regression modeling. Thus, we performed 
PCA out of mathematical necessity rather than to propose a new metric to describe 
bone quality. 
To simplify related variables to explain how mineral maturity influences 
mechanical properties, we developed the Mineral Maturity Factor (MMF). The MMF 
consists of three closely related, independently validated constituent variables 
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(crystallinity,(49) carbonate:phosphate ratio,(50) acid phosphate content(51)). Moreover, 
all three variables are strongly and linearly correlated with each other, and all three 
variables indicate the maturity of the mineral crystals in bone in slightly different 
ways. To avoid a high collinearity of predictor variables and overfitting, we could not 
include all three variables in the stepwise linear regression models. Therefore, our 
options were to 1) make a factor with all three variables, or 2) choose a single mineral 
characteristic to include. We chose to use a factor to describe these three related 
mineral characteristics.  
Importantly, the constituent variables in the MMF have also been reported as 
evidence of changes in bone quality with T2DM (crystallinity, type 2 diabetic mouse 
model(42)) and other pathologies that affect bone fragility (carbonate:phosphate ratio 
and acid phosphate content, low and high turnover bone(84)). 
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Supplemental Figure S1: Mechanical properties from monotonic compression testing 
of cancellous specimens by group. The T2DM group include two specimens from men 
who were on TZDs and were excluded from the analysis in the main manuscript. 
Abbreviations: non-DM: non-diabetic group; T2DM: type 2 diabetic group. 
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Supplemental Figure S2: Methods overview. 
 
 
 
Supplemental Figure S3: (A) Young’s modulus normalized by BV/TV, (B) Ultimate 
stress normalized by BV/TV, and (C) Post-yield toughness normalized by BV/TV. 
Horizontal lines indicate group means. Mineral:matrix data (Figure 5.3-1C) were used 
to divide the 65 FTIR samples (both DM and non-DM groups) into tertiles of lower 
(white squares), middle (light grey squares), and upper (dark grey squares) (see 
Supplemental S3). Abbreviations: non-DM: non-diabetic group, T2DM: type 2 
diabetic group; BV/TV: bone volume fraction. 
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CHAPTER 6 
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS FOR FURTHER 
STUDY 
 
6.1 Summary of Key Results 
The main objectives of this research were 1) to elucidate the material factors that may 
contribute to whole-bone fragility with T2DM by characterizing the material 
properties, microarchitecture, and bulk-tissue mechanical properties of bone from 
subjects with and without T2DM, and 2) to relate material changes to the 
pathophysiology of T2DM. The properties of bone tissue from a rodent model and two 
clinical populations of T2DM were evaluated. 
In Chapter 2, measurement techniques available to assess the geometric, 
compositional, and mechanical properties of tissue were discussed, as well as how the 
technique is currently being used or can be used in the near future. Several of the 
techniques discussed were used to evaluate bone tissue in Chapters 3-5, including 
FTIR in Chapters 3, 4, and 5, and apparent-level mechanical testing, micro-CT, and 
HPLC in Chapter 5.  
 In Chapter 3, the compositional characteristics of bone in the KK-Ay mouse 
were characterized. Overt T2DM manifests in KK-Ay mice around eight weeks of age 
as a result of insulin resistance; therefore, the KK-Ay mouse exhibits an essential 
feature of T2DM in humans. In the KK-Ay mice with overt T2DM, we observed 
changes in tissue-level material properties, including increased mean collagen 
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maturity and mineral content in the KK-Ay mice compared to littermate non-DM 
controls. Greater mean collagen maturity and greater mean mineral content are both 
consistent with older tissue and with previous documentation of reduced bone turnover 
with T2DM.  
 In Chapter 4, the composition of iliac crest bone from post-menopausal women 
with varying degrees of glycemic derangement was characterized using FTIR imaging. 
We found evidence of altered mineral and collagen properties between normal glucose 
tolerance, impaired glucose tolerance, and overt T2DM groups. In general, glycemic 
derangement was associated with increased mineral content, decreased collagen 
maturity, and atypical mineral maturation. A more mineralized tissue and a less 
mature organic matrix can both deleteriously affect bone mechanics at the tissue level; 
however, the precise underlying causes for these changes in tissue composition and the 
resulting macro-scale consequences to bone fragility are unknown. We also observed 
progressive changes in tissue composition from normal glucose tolerance to impaired 
glucose tolerance to overt T2DM, though these differences were not always 
statistically significant. Serum analyses indicated that the T2DM group had lower 
markers of bone turnover than the normal glucose tolerance group. 
 In Chapter 5, the structure, composition, and mechanical properties of bulk 
cancellous tissue from the femoral neck of men were assessed. These results were 
subsequently used in statistical models to better understand how changes in the 
structure and composition of bone due to T2DM impact bulk tissue-level mechanical 
performance. We found clear evidence of AGE accumulation, increased mineral 
content, and atypical mineral maturation in the specimens from the T2DM group 
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compared to the non-DM group. Our regression models indicated that bone volume 
fraction was by far the greatest determinant of compressive mechanical properties, as 
expected. After accounting for the greater bone volume fraction in the T2DM group, 
the models demonstrated how AGE accumulation and altered mineral maturity can 
drastically reduce the ability of cancellous bone to absorb energy prior to failure in 
patients with T2DM.  
6.2 Conclusions  
The compositional assessment of tissue from the KK-Ay mouse model and from both 
clinical populations confirmed increased mineral content with T2DM. Greater mineral 
content is indicative of older tissue (i.e., time since formation)(1) and is associated with 
a stronger, but more brittle material.(2,3) Furthermore, the lower bone turnover rates 
that are observed with T2DM(4–9) may help explain our observations of more 
mineralized tissue across these populations. 
Conversely, the rodent model tissue and the clinical tissue showed different 
effects of T2DM on collagen maturity and mineral maturity. In general, more mature 
collagen has a higher ratio of divalent to trivalent enzymatic crosslinks, and more 
mature mineral typically has larger, more perfect crystal, and these maturations 
processes are contemporaneous. The whole proximal femora of the KK-Ay mice had 
7% more mature collagen and a 24% narrower distribution of crystallinity, both of 
which are consistent with a more mature, or older, tissue. In contrast, tissue from the 
iliac crest of post-menopausal women with T2DM versus those with normal glucose 
tolerance had similar collagen maturities, but a 16% wider distribution of crystallinity, 
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which indicates a less mature mineral, but unchanged collagen maturity, with T2DM. 
The distributions of compositional properties were not assessed in the tissue from 
Chapter 5 (cancellous femoral neck tissue from men with and without T2DM) because 
this tissue was homogenized; however, the T2DM specimens in this cohort had a 
lower mineral maturity factor (factor that includes crystallinity, carbonate:phosphate 
ratio, and acid phosphate content) than the non-DM specimens. In summary, the 
mineral was more mature in the KK-Ay mouse model of T2DM versus controls, but 
less mature in the clinical human tissue from people with T2DM versus those without 
T2DM, and collagen maturity was different in the tissue of the KK-Ay mice vs. 
controls, but similar across groups in the human tissue. These discrepancies point to 
different effects of T2DM on the mineral and matrix components of bone. 
The discrepancy of greater mineral content without an increase in mineral 
maturity in the human tissue is particularly surprising, and it is likely that multiple 
pathological factors are responsible. One potential factor is that hyperglycemia leads 
to greater AGE accumulation.(10) Hyperglycemic conditions and AGE accumulation 
have been shown to decrease osteoblast and osteoclast function;(11–14) therefore, 
hyperglycemia and AGE accumulation may work in concert to disrupt bone turnover. 
Slower turnover may account for the increased tissue mineral content because older 
tissue that is not remodeled will be more mineralized than younger tissue. In addition 
to lower turnover caused by AGE-cell interactions, AGE accumulation may also 
inherently alter the mineralization process and rates(15)(16) by changing the charge 
profile of the collagen fibers,(17,18) thereby disrupting cell-matrix interactions that 
control mineral maturation.(19,20)  
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 On the other hand, the differences in the effects of T2DM on rodent tissue 
compared to human tissue may lie in the different mechanisms by which bone grows 
and is turned over. Mice continue to grow after sexual maturity (~ 6-8 weeks of age) 
and they reach peak bone mass around 4-6 months of age, which is markedly different 
than human bone growth which ceases with sexual maturity.(21) In addition, mice do 
not have osteons; therefore, the osteonal remodeling observed in human cortical bone 
is not possible. Turnover in cancellous bone occurs similarly in both mice and 
humans; however, the rate at which murine cancellous bone remodels is roughly 10 
times faster than that of humans.(21) In this light, the differences observed in collagen 
maturity between the KK-Ay murine tissue and human tissue may be due to the 
variations in turnover. Specifically, it takes weeks to months for AGEs to fully 
form;(22) therefore, murine bone may not age long enough for high concentrations of 
AGEs to accumulate. While the time formation of AGEs in different species has not 
been fully explored, the anecdotal evidence that AGEs accumulate in rat and human 
tissue, but not in murine tissue, may indicate that tissue lifetime matters. 
 The precise pathological mechanism by which T2DM disrupts mineral and 
matrix maturation is presently unknown; however, the consequences of these changes 
are evidenced in Chapter 5 with the evaluation of mechanical performance of T2DM 
and non-DM human cancellous bone. The main finding of the Chapter 5 study was 
that bone volume fraction can compensate for suboptimal tissue material properties to 
a certain extent; however, in the absence of greater bone mass, the deleterious effects 
of T2DM on bone tissue can result in increased bone fragility. While the models 
generated in Chapter 5 with a small sample size are unlikely to be universally 
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applicable to all people with T2DM, this study was the first to comprehensively 
evaluate tissue mineral and matrix properties, including tissue AGE accumulation, in 
clinical specimens from people with T2DM. Moreover, it one of only two studies of 
clinical T2DM specimens that relates the compositional and microarchitectural 
changes to measured mechanical properties (the other was performed by Karim et. al. 
(23)).  
 The study presented in Chapter 4 regarding iliac crest tissue from post-
menopausal women with varying degrees of glycemic control is also a novel 
contribution to the understanding of how the pathophysiology of T2DM changes the 
composition of bone. Specifically, the inclusion of three groups with progressive 
glucose intolerance allows for the determination of which compositional properties are 
affected between the normal glucose tolerance phase to the impaired glucose tolerance 
phase and then from the impaired glucose tolerance phase to the overt T2DM phase. 
Moreover, the measurement of bone turnover markers allows for the direct assessment 
of the hypothesis that altered bone turnover affects tissue composition. 
6.3 Statement of Impact 
Taken together, Chapters 3-5 contribute to the growing body of evidence that T2DM 
has deleterious consequences for the skeletal integrity of bone. The study of 
spontaneously diabetic KK-Ay mice compared to littermate controls (Chapter 3) is the 
first to characterize tissue composition in this particular mouse model of T2DM, 
which contributes to the evolving understanding of T2DM rodent model selection and 
T2DM tissue composition in general. The characterization of tissue composition from 
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three groups of women with varying degrees of glycemic control (normal glucose 
tolerance, impaired glucose tolerance, and overt T2DM) (Chapter 4) is the first to 
explicitly characterize tissue properties in an intermediate and pre-T2DM stage, which 
allows us to link glycemic control/the duration of T2Dm to changes in tissue 
properties. Also, this study is the first to characterize tissue composition in a spatially-
resolved fashion from a clinical T2DM population. Finally, the collective 
compositional, microarchitectural, and mechanical assessment of bulk cancellous 
tissue from men with and without T2DM (Chapter 5) is the first study to directly 
correlate changes in tissue composition, including AGE accumulation, with 
mechanical performance in a clinical population with T2DM.  
In summary, it is vital to assess tissue from populations with T2DM to 1) better 
understand how T2DM is detrimental to skeletal integrity, 2) better predict 
populations that are at a higher risk of experiencing fragility fractures based on their 
bone tissue characteristics, and 3) use these findings to eventually prevent T2DM-
related fragility fractures.  
6.4 Strengths and Limitations 
One major strength of translational research is the ability to relate the results of 
laboratory experiments to clinical practice; however, research on clinical specimens 
has several unique limitations.  
To begin, there is often a tradeoff in the extent of controllable cohort 
characteristics (e.g., the ability to age match between groups) and the usefulness of 
tissue available to study from the study participants. The tradeoffs between knowable 
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patient information and the traits of the excised tissue specimen is particularly 
exemplified in Chapters 4 and 5: The women in the clinical study detailed in Chapter 4 
were specifically recruited such that a wide range of glycemic control (HbA1c ranged 
from 4.9 to 13.3%) was captured while maintaining an otherwise homogeneous 
population; however, the iliac crest biopsies were too small to perform many 
mechanical characterization assays, and the tissue was not from a clinically-relevant 
fracture site. On the other hand, little to no diabetic history was known for the men 
recruited for the study detailed in Chapter 5, who had better glycemic control (HbA1c 
ranged from 5.0 to 9.3%); however, the excised specimens were from a highly-
relevant fracture site and there was a large quantity of tissue for a comprehensive 
characterization of compositional, structural, and mechanical properties.  
Nevertheless, the study designs of Chapters 4 and 5 are complementary and 1) 
allow for a more comprehensive understanding of how T2DM affects bone tissue at 
different length scales and different sites, and 2) provide a framework for identifying 
factors that can mitigated the negative effects of T2DM on skeletal integrity. 
Moreover, the clinical studies described in Chapter 4 and 5 are two of five published 
studies that directly characterize tissue from people with T2DM (the other studies are: 
Pritchard. J. Bone Miner. Res. 2014; Farr. J. Bone Miner. Res. 2016; and Karim Bone 
2018).  
6.5 Recommendations for Further Study 
Because many aspects of the research discussed in this dissertation were the first steps 
of their kind towards understanding how T2DM affects bone tissue, there are many 
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potential avenues for future research that can build off these foundational results. In 
the succeeding section, I have outlined potential future studies that further explore the 
effects of T2DM on bone tissue, specifically regarding microdamage accumulation 
and the complex observations of mineral and matrix maturation. 
The ability of bone to resist fracture is dependent upon the dissipation of 
energy throughout the bone matrix, and one key mechanism by which energy is 
dissipated is the formation and propagation of microdamage. Microdamage 
accumulates in both the cortical and cancellous compartments with age as a result of 
normal daily loads;(24) however, extensive damage induced through fatigue or a single 
overload events can also occur. Microdamage is categorized as either crack-like or 
diffuse from damage morphology, which is typically evaluated through staining. 
Crack-like microdamage appears with distinct edges and is associated with more 
brittle tissue that requires lower energies for damage to propagate, whereas diffuse 
microdamage has more of a pooled or muddled morphology (sometimes described as 
cross-hatched(25,26)) and is associated with a more ductile material that requires higher 
energies for damage to propagate.(27) In cancellous bone for example, crack-like 
microdamage accumulates along the more mineralized, stiffer, and older cores of 
trabeculae where the tissue is most brittle, and diffuse microdamage localizes along 
the less mineralized, less stiff, and younger trabecular edges.(28) 
The presence of microdamage catalyzes the remodeling process to remove the 
old, damaged tissue and replace it with new, more structurally sound tissue.(29,30) The 
main trigger for microdamage removal is osteocyte apoptosis, and definitive casual 
links between osteocyte apoptosis and osteoclast recruitment to remove the damaged 
  
226 
 
tissue have been demonstrated.(31–33) Interestingly, osteocytes immediately 
surrounding the microdamaged tissue do not undergo apoptosis and instead express 
anti-apoptotic responses, such as the upregulation of RANKL and Bcl-2, to quickly 
recruit osteoclast precursors to the damaged area.(34) After the osteoclasts are recruited 
to the damaged site, the bone remodeling process continues with the subsequent 
recruitment of osteoblasts which then lay down new organic matrix.(29) From these 
processes, it is evident how excessive microdamage accumulation and/or disrupted 
microdamage removal can lead to a tissue with reduced mechanical integrity.  
Under T2DM disease state conditions, it is possible that lower bone turnover 
(see Chapter 4 and references (4–9)) and AGE accumulation(11–14) can lead to more 
microdamage accumulation because the damaged tissue is not removed in a timely 
manner. Because the extent of microdamage is associated with reductions in stiffness 
and strength,(25,26,35,36) it is possible that the greater skeletal fragility observed in 
people with T2DM compared to those without(37–44) is a macro-scale mechanical 
consequence of micro-scale damage accumulation. In this framework, there are 
several avenues for the continuation of the work described in Chapters 4 and 5 to 
further elucidate the effects of T2DM on skeletal integrity, and they are briefly 
outlined here.  
6.5.1 Proposed Study #1: Microdamage assessment in cancellous tissue from people 
with and without T2DM 
Microdamage accumulation in cancellous bone from people with T2DM compared to 
those without has not yet been reported. Therefore, the main goals for this proposed 
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study are to evaluate the extent and type of microdamage in specimens from people 
with T2DM compared to those without T2DM, and if possible, to relate microdamage 
accumulation to the severity of T2DM. I hypothesize that there will more 
microdamage per unit volume of tissue in specimens from people with T2DM 
compared to those without T2DM, that worsening glycemic control will be associated 
with more microdamage, and that the microdamage in the T2DM specimens will 
exhibit more crack-like than diffuse microdamage.  
In preparation for future microdamage quantification, the cancellous cores 
from both the T2DM and non-DM groups were stained with lead uranyl acetate (LUA) 
immediately after mechanical compression to 3% strain, then underwent secondary 
micro-CT scanning (see Appendix B for LUA staining methods). LUA is a bulk, 
double contrast, and heavy metal stain that infiltrates the void spaces in bone tissue 
and attaches to damaged areas.(36,45) When scanned with x-rays in micro-CT, the LUA 
complexes appears as bright white regions which distinctly indicates damage tissue 
along the contours of the native tissue. LUA staining and subsequent micro-CT 
assessment allows for 3-D quantification of microdamage that is not possible with 
most other microdamage staining assays.(36,46) Because existing damage prior to 
mechanical testing is not distinguishable from damaged induced during compression, 
T2DM and non-DM controls that were not mechanically tested, but were stained with 
LUA, should be used as a baseline value for pre-existing damage.  
Post-processing of the micro-CT image stacks (currently ongoing) allows for 
assessment of the following outcome variables: damage volume per bone volume 
(DV/BV), which is the summation of volumetric damaged pixels over volumetric bone 
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pixels and therefore independent of bone volume fraction; damaged surface area per 
damaged volume (DS/DV), which is a surface-to-volume ratio of damage where 
higher DS/DV values indicate more crack-like damage and lower DS/DV values 
indicate more diffuse damage; and the distribution of DS/DV values across each 
damaged region, such that a wide distribution indicates a mix of crack-like and diffuse 
damage and a narrow distribution indicates more crack-like than diffuse character or 
vice versa.  
In summary, the outcomes of this Proposed Study #1 will indicate whether or 
not tissue from people with T2DM have more microdamage than tissue from people 
without T2DM and the overall morphology of the microdamage (crack-like or diffuse) 
under single overload conditions. Preliminary results of the DV/BV for the T2DM and 
non-DM group specimens are provided in Appendix C.  
6.5.2 Proposed Study #2: Trabecular morphology, microdamage, and mechanical 
performance 
In addition to the quantification of BV/DV, BS/BV, and the distribution of BS/BV, 
another key question is whether or not microdamage is more likely to form on specific 
morphologies of trabeculae. In general for compressive loading, the plate-like 
trabeculae support the bulk of mechanical loads and are axially aligned with the 
principal stress, especially in the femur, whereas the rod-like trabeculae are oriented 
transverse to the principal stress and contribute less to stiffness and strength.(47,48) 
Thus, trabecular morphology, which plays a key role in mechanical performance and 
differs in cancellous bone from T2DM subjects vs. non-DM subjects,(49–52) may also 
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influence the location and extent of microdamage with T2DM. Therefore, the goals of 
this proposed study are to ascertain if microdamage outcomes (DV/BV, DS/DV) are 
related to trabecular morphology (plate vs. rod, orientation) and to deduce whether or 
not the location and type of microdamage are associated with mechanical outcomes in 
specimens from people with and without T2DM. I hypothesize that the rod-like 
trabeculae will accumulate more damage than plate-like trabeculae, especially in 
transversely- and obliquely-oriented rods, and that the thicker plates and rods 
(observed in tissue from people with T2DM vs. without T2DM, Chapter 5)(52) will 
have greater DV/BV in the T2DM vs. non-DM specimens.  
The conventional measure to assess the rod-like or plate-like character of 
cancellous bone is the structure model index (SMI)(53) which ranges from a value of 0 
to 3 indicating completely plate-like or rod-like, respectively, in an idealized 
structure.(54) SMI provides a simple, single value for how plate-like or rod-like a 
structure is; however, the algorithm for SMI assumes all trabecular surfaces are 
convex, which is almost certainly untrue for most cancellous bone specimens.(55) 
While many studies have reported associations between SMI and mechanical 
properties, it is likely that SMI is more of a surrogate for BV/TV than an indicator of 
rod-like or plate-like character.(55) Thus, a more detailed characterization of trabecular 
morphology is desired.  
To this end, analysis using the Individual Trabecular Segmentation (ITS) 
software developed at Columbia University(56) has been begun on the specimens from 
Chapter 5. The ITS software is specifically designed for the isolation and classification 
of trabeculae into rod-like or plate-like and longitudinally-, horizontally-, or obliquely-
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oriented and can be run on the same micro-CT image stacks of LUA-stained 
specimens. The ITS outcomes for each trabecula (i.e., plate or rod; longitudinal, 
transverse, or oblique; and all possible combinations thereof [e.g. longitudinal plates, 
oblique rods]) can then be correlated pixel by pixel to the microdamage determined 
through LUA staining. Figure 6.5-1 shows damaged tissue vs. undamaged tissue, 
plate-like vs. rod-like trabeculae, and longitudinal vs. transverse vs. oblique trabecular 
orientations on the same specimen.  
 
 
Essentially, the 3-D structure that depicts microdamage with LUA stain can be 
superimposed on the 3-D structure derived from ITS-assessed trabecular morphology 
to ultimately determine if there are differences in microdamage location between 
specimens from people with and without T2DM. Additionally, and arguably more 
importantly, this analysis will help determine if the confluence of microdamage 
Figure 6.5-1: Left: Damaged pixels are denoted by bright green coloring. Center: 
Blue pixels denote plate-like trabeculae and magenta pixels denote rod-like trabeculae.  
Right: Yellow pixels denote longitudinal trabeculae, teal pixels denote transverse 
trabeculae, and purple pixels denote oblique trabeculae. 
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location and trabecular morphology better explains the compressive, monotonic 
mechanical properties than traditional microarchitecture outcomes alone in a 
population with T2DM. 
Appendix C details the methods for ITS analysis on previously mechanically 
tested and LUA stained cancellous cores.  A checklist detailing the ITS preparation 
steps that have already been performed on the Chapter 5 samples is in Appendix D. 
Preliminary ITS and microdamage results for a subset of specimens from the non-DM 
and T2DM groups are reported in Appendix E.  
6.5.3 Proposed Study #3: Colocalization of AGEs, composition, mechanical 
properties, and tissue age with varying degrees of glycemic control 
While the cancellous specimens described in Chapter 5 offer the ability to further 
study bulk cancellous tissue properties, the iliac crest specimens described in Chapter 
4 will allow for further assessment of direct spatial comparison of AGE content, tissue 
composition, and mechanical properties at the micro-scale. Moreover, the study design 
of Chapter 4 included comprehensive characterization of the participant population, 
including T2DM severity and biomarkers of bone turnover, and double-labeling for 
bone formation. The main goals of this proposed study are to determine 1) if local 
regions of altered tissue composition are associated with diminished mechanical 
properties, and 2) if the former outcome is associated with T2DM severity. I 
hypothesize that regions of high AGE content will be associated with older tissue 
(determined bone formation double-labels), with regions of greater mineral content 
and greater collagen maturity (determined by FTIR imaging), and with greater 
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stiffness and hardness, but lower energy absorption (determined by mechanical 
testing). Furthermore, I hypothesize that the aforementioned associations between 
AGEs, tissue composition, and mechanical properties will be more pronounced with 
worsening glycemic control.  
 The FTIR image collection and analysis of specimens from women with NGT 
(n = 32, age = 65±7, HbA1c = 5.8±0.3), IGT (n = 25, age = 64±5, HbA1c = 6.0±0.4), 
and overt T2DM on insulin (n = 25, age = 64±6, HbA1c = 9.13±0.6) is complete 
(Chapter 4) and the biopsies have already been double-labeled for bone formation; 
therefore, the key remaining tasks are AGE assessment and mechanical testing. The 
locations of AGE accumulation on the same sections used for FTIR imaging can be 
determined by auto-fluorescence using a confocal microscope using 405/488 nm 
excitation/emission and an exposure time of 150 ms;(57) however, the sections may 
need to be demineralized beforehand to generate a strong enough fAGE signal.  
The remainder of the biopsies that were not section for FTIR image analysis 
are currently embedded in PMMA, which makes nano-indentation the logical choice 
for mechanical assessment. The outcomes for nano-indentation are hardness; which is 
the average pressure under load and is calculated as the maximum load divided by the 
indentation contact area; reduced modulus, which includes contributions from both the 
specimen and the indenter and is calculated from the slope of the unloading portion of 
the force-displacement curve; and elastic modulus, which can be calculated from the 
reduced modulus, the Poisson’s ratio of the specimen, and the material properties of 
the indenter.(58) Moreover, the capability for dynamic load- and displacement-control 
during nanoindentation allow acquisition of full force-displacement curves at the 
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micron scale. By performing multiple nano-indents in a gridded pattern along the same 
region of interest as the FTIR imaging, a 2-D map of mechanical properties across the 
specimen can be generated(59,60) and subsequently compared to the composition 
outcomes.  
Finally, the FTIR imaging maps, the fAGE maps, and the nanoindentation 
maps can be compiled to assess the extent to which fAGEs and tissue compositional 
properties influence the mechanical properties in regions of new bone formation vs. 
older bone tissue as well as across NGT, IGT, and T2DM groups.  
6.6 Final Remarks 
In conclusion, this dissertation provides a foundation for studying the effects of T2DM 
on bone tissue in terms of compositional, microarchitectural, and mechanical 
properties and offers several opportunities for further investigation using available 
valuable clinical specimens. 
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APPENDIX A 
PROTOCOL FOR MICRODAMAGE STAINING USING LEAD URANYL 
ACETATE 
 
Summary: This protocol describes how to stain for microdamage in human cancellous 
bone using lead uranyl acetate. For cancellous bone cores, this staining should be 
performed after the pre-mechanical testing microCT scan and after mechanical testing.  
 
Chemical List:  
 
Chemical Supplier Catalog Number 
Uranyl acetate dihydrate Electron Microscopy 
Sciences 
22400 (25 g) 
Lead(II) acetate trihydrate Sigma-Aldrich 467863-250G 
Ammonium sulfide 20% aq 
solution 
Sigma-Aldrich A1952-500ML 
Acetone, 99.5% Acros (Fisher) 67-64-1 
 
I. Before you begin… 
1) Everything must be performed in the hood, even weighing chemicals.  
2) Read attached Appendix I to familiarize yourself with the specific hazards 
of this process.  
3) A description of how each solution is made is given in Appendix II.  
4) Typically, 10-15 mL of lead uranyl acetate stain is needed to cover an 8 
mm diameter x 10 mm length cancellous bone core.  
 
II. Sample Preparation 
1) Remove marrow from cancellous bone cores using DI water and water 
pick. 
2) Place sample in 70% acetone to fix. See Appendix II for notes on how to 
make 70% acetone. 
3) Put on shake table at a low speed for at least one day. 
 
III. Preparing Lead Uranyl Acetate Solutions 
Uranyl Acetate  
1) Prepare solution of 8% uranyl acetate in 70% acetone in an amber glass 
bottle. See Appendix II for notes on how to make the uranyl acetate 
solution.  
2) Wrap bottle in aluminum foil to prevent light exposure.  
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3) Place small magnetic stir bar in solution and let stir on stir plate in fume 
hood for at least one day.  
Lead Acetate 
4) Prepare solution of 20% lead (II) acetate in 70% acetone in a glass bottle. 
See Appendix II for notes on how to make the lead acetate solution. 
5) Place small magnetic stir bar in solution and let stir on stir plate in fume 
hood for at least two hours, but preferably longer.  
Lead Uranyl Acetate 
6) Combine uranyl acetate and lead acetate (of equal volumes) into an amber 
glass bottle. You can use the same bottle from the uranyl acetate step and 
just add the lead acetate to your uranyl acetate solution. The final solution 
will have a yellowish-orange milky color (it looks like a mango smoothie).  
7) Wrap with foil.  
8) Continue to stir on stir plate in fume hood for at least one hour.  
 
IV. Staining Samples 
LUA Staining  
1) Add solution to bone samples. Typically if using the wide-mouth glass 
vials, 10-15 mL of lead uranyl acetate is enough to submerge an 8 mm 
diameter x 10 mm length cancellous bone core. See Figure 6.7-1below.  
 
 
Figure 6.7-1: Samples in LUA Stain 
2) Wrap each vial with foil.  
3) Place on shake table in fume hood at a speed of 120 rpm. This is an 
adequate speed to prevent the stain from settling, but not so fast as to 
damage the samples.  
4) If staining many samples at a time, you can combine the foil-wrapped-vials 
in a secondary container, like an old micropipette tip box. Make sure vials 
are secure on the shake table and make sure there is no light penetration of 
staining solution.  
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5) Let samples shake in stain for 14 days.  
Fixing LUA Stain with Ammonium Sulfide 
6) Note: This step is very smelly!! Warn people in the lab.  
7) Remove bone sample from LUA stain and rinse with 70% acetone.  
8) Create 1% ammonium sulfide in 70% acetone solution. See Appendix II 
for this recipe.  
9) Place bone sample in ammonium sulfide solution for one week, changing 
the solution after three days. Sample will turn black immediately, this is 
normal. 
10) Keep sample vials wrapped in foil and on shake table. 
11) After one week of soaking in ammonium sulfide, rinse samples with 70% 
acetone.  
12) Place samples back in 70% acetone for up to 1 week. This will help remove 
smell. 
Sonicate 
13) Rinse samples again with 70% acetone. 
14) Sonicate for 10 minutes in 70% acetone to remove solution from the pores. 
 
V. Waste Removal and Cleanup 
1) Note: Lead uranyl acetate is both toxic and radioactive, so it needs a 
special radioactive waste removal. Appendix III is the email conversation 
between Heather and an EHS employee specifying the waste removal 
procedure. Keep this email as a record (just in case)! 
2) All liquid waste solutions should be placed in a glass waste container. You 
can usually use the amber glass bottle from the uranyl acetate solution step. 
Label properly! 
3) All solid waste, including sample vials, beakers, weigh boats, etc., needs to 
be placed in a ziplock bag clearly labeled “Radioactive Waste”.  
4) You will need to call and order a radioactive waste pickup from EHS, 
which is separate from the usual waste pickup.  
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APPENDIX B 
 
WORK IN PROGRESS: SUMMARY OF DV/BV RESULTS 
 
The following tables and figure are preliminary results of the microdamage assessment 
of the femoral neck cancellous specimens from Chapter 5 that were compressed to 3% 
strain. 
 
Notes: These damage volume calculations are not ready for publication. Many of the 
samples need to be further cleaned before doing a damage analysis (see final column 
on Table 2). The cleaning process involves removing globs of stain by subtracting the 
initial, unstained microCT image stacks from the stained microCT image stacks. Also, 
many of these specimens were later cleaned through the ITS analysis procedures, so 
the DV/BV from those calculations (when done) should most likely be used instead of 
these values.  
 
Table 1 and Figure 1 summarize the preliminary results. There was no difference 
between DV/BV between groups. DV/BV also did not correlate with patient age or 
HbA1c 
 
Table 1: N, mean, and standard deviation by group. Student’s t-test used to assess 
group-wise difference. 
  Age HbA1c DV/BV 
Non-DM count 36 36 22 
T2DM count 33 33 22 
        
Non-DM average 61.4 5.55 0.056 
Non-DM stdev 9.0 0.41 0.044 
        
T2DM average 64.9 7.11 0.047 
T2DM stdev 8.8 0.91 0.044 
        
% difference 5.7 28.01 -15.012 
        
Student’s t-test 0.109 0.000 0.532 
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Figure 1: Preliminary microdamage results for cancellous specimens mechanically 
compressed to 3% strain (see Chapter 5).  
  
247 
 
Table 2: Notes on DV/BV calculations. 
 
Group 
Core 
Number 
Age HbA1c DV/BV 
Further cleaning 
required? 
Non-DM 52 44 6.44 0.039 maybe 
Non-DM 33 47 5.20 0.057 maybe 
Non-DM 165 47 5.00 0.201 no 
Non-DM 80B 50 5.16 0.075 no 
Non-DM 40 51 5.78   not stained 
Non-DM 128 51 5.56 0.053 no 
Non-DM 22B 52 5.67 0.045 no 
Non-DM 72 55 6.04     
Non-DM 152 55 5.10 0.152 no 
Non-DM 116 56 5.57   yes 
Non-DM 122B 56 5.92 0.058 maybe 
Non-DM 48 57 5.88   not stained 
Non-DM 37 58 6.17   not stained 
Non-DM 62B 58 5.59 0.018 maybe 
Non-DM 159 58 5.10 0.020 no 
Non-DM 6 60 5.21   not stained 
Non-DM 154 60 5.40 0.030 no 
Non-DM 12 62 5.37 0.066 no 
Non-DM 39B 62 5.67 0.048 no 
Non-DM 157 62 5.30   not stained 
Non-DM 17 63 5.51 0.039 maybe 
Non-DM 121 63 5.37 0.025 no 
Non-DM 161 63 7.00   yes 
Non-DM 84 65 5.42   not stained 
Non-DM 23 66 5.49 0.012 maybe 
Non-DM 123B 66 5.65 0.041 no 
Non-DM 13 67 4.97   not stained 
Non-DM 151 67 5.80 0.078 no 
Non-DM 9B 68 5.45 0.046 no 
Non-DM 75 70 5.64   yes 
Non-DM 5 72 5.21     
Non-DM 149 73 5.20 0.071 no 
Non-DM 38B 74 5.37 0.023 no 
Non-DM 44 75 5.62 0.030 maybe 
Non-DM 36 78 5.50   not stained 
Non-DM 16 81 5.58   not stained 
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Group 
Core 
Number 
Age HbA1c DV/BV 
Further cleaning 
required? 
T2DM 29 52 8.64 0.005 maybe 
T2DM 24 53 6.34     
T2DM 27 54 6.98   not stained 
T2DM 170 54 9.30 0.033 no 
T2DM 32 56 6.62   not stained 
T2DM 145 56 7.00   not stained 
T2DM 156 56 5.70 0.052 no 
T2DM 160 56 6.80 0.069 maybe 
T2DM 146 58 6.50   not stained 
T2DM 155 58 6.30 0.126 maybe 
T2DM 166B 58 8.70 0.028 no 
T2DM 169 58 7.50 0.034 maybe 
T2DM 51B 61 6.12 0.016 maybe 
T2DM 162 61 6.00 0.028 no 
T2DM 31 63 6.60     
T2DM 164 63 6.80 0.193 no 
T2DM 163 64 8.80   not stained 
T2DM 167 64 6.50 0.034 redone already 
T2DM 168 65 7.30 0.035 redone already 
T2DM 76B 66 7.28   yes 
T2DM 88 68 7.08 0.033 no 
T2DM 35B 69 6.98 0.042 no 
T2DM 96 70 7.54 0.021 maybe 
T2DM 19 73 5.93     
T2DM 64 73 6.60 0.034 maybe 
T2DM 112 74 7.08 0.034 maybe 
T2DM 41B 75 8.83 0.027 no 
T2DM 46 75 7.65   not stained 
T2DM 153 75 7.50 0.120  maybe 
T2DM 70B 76 6.51 0.038 no 
T2DM 43B 77 7.34     
T2DM 59 77 7.60 0.015 no 
T2DM 34B 85 6.16 0.025 no 
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APPENDIX C 
PROTOCOL FOR ITS ANALYSIS ON CANCELLOUS CORES 
 
Notes: This protocol describes the steps I used to perform ITS analysis on the 
cancellous cores from Chapter 5. The ITS software stopped working around June 
2018, and I was not able to finish running all of my specimens. In theory, once the ITS 
software bugs have been fixed, the following steps will work perfectly. All of the 
specimens I prepped for ITS analysis have a .raw and .aim file on the “Heather 
Cancellous” hard drive (so you can skip to step 6 for these). All of the referenced 
Matlab codes are in the Donnelly Lab archive folder under /Heather Hunt/ITS. 
 
1) Output LUA scan into stack of tiffs using Scanco and Filezilla. 
2) Clean LUA images with Matlab 
a. Crop to 8-9 mm (outer core) 
b. Clean (threshold, Gaussian blur, etc.) 
c. Make binary 
d. Convert binary and clean to 21 um resolution 
e. Save all of these steps in the sample folder 
3) Save 21 um clean binary tiffs as .raw file 
a. Use Biomech 10 
b. Import -> Binary -> Despecle -> Purify -> Save as .raw 
4) Transfer to Biomechanics Lab Scanco 
a. Filezilla into folder [MICROCT.DATA.00000773] 
5) Convert .raw to .aim 
a. @rawaim3.com;12 
6) Transfer .aim file back to hard drive using Filezilla 
7) Run ITS software on Biomech 10 
a. Processing -> Batch Processing -> select all .aim files you want to run 
8) Run ITS_BoneMatrix_Aim4_HH.m 
a. Makes .seg files for orientation and type 
9) Import .seg files into ImageJ and save as stack of tiffs into relevant folder (folder 
7) 
a. 16 bit signed integer 
b. 0 header 
c. 0 spaces between slices 
d. x, y, z from image stack 
10) Make inner core mask using ImageJ (to exclude the damaged edges) 
a. Save as sample#_inner core_mask.tif 
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11) Run ITS_DamageTypeOri_Analysis_July172018.m 
a. Makes all flavors of trabecula images (e.g. longitudinal plate, oblique rod) 
and saves them in the appropriate folder 
b. Multiplies all relevant things by the inner core mask 
c. Overlaps stain from folder 4.5 with each flavor of trabecula and saves in 
step 8 folder 
d. Runs analysis on inner 286 slices of inner core masked images (so final 
analysis is on 6 mm diameter by 6 mm in length core) 
e. Output excel file sample#_IC Short – ITS Analysis Pixel Counts. 
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APPENDIX D 
ITS PROGRESS CHECKLIST 
 
Notes: This checklist describes the step I was at with the ITS analysis as of August 1, 
2018. The designation of _Kelsie or _Jesse indicates that either Kelsie or Jesse 
performed pre-ITS analysis “cleaning” to remove stain chunks. The designation of B 
or C indicates the second or third core, respectively, obtained from a specimen. 
 
Sample Name Notes 
Convert 
to .raw 
Convert 
to .aim 
Run ITS 
software 
9B Stained good, ends just ok yes yes yes 
96 Stained scraggly, needs extra attention yes     
96 Kelsie Stained         
9 Stained fine, ends not great yes yes yes 
88 Stained slightly slanted, but probably ok yes yes yes 
80B Stained almost good, minor chunks yes yes yes 
80B Kelsie 
Stained         
80 Stained almost good, minor chunks yes yes yes 
76C Stained fine yes yes yes 
76B Stained 
slightly slanted, stain on edges 
but may be ok yes yes yes 
75 Stained 
very messy - needs special 
attention       
75 Kelsie Stained         
72B Stained ??       
70B Stained mostly good, but some chunks yes yes yes 
70B Kelsie 
Stained         
64 Stained fine ac K yes yes yes 
64 Jesse Stained good yes yes yes 
62B Stained almost good, minor chunks yes yes yes 
62B Kelsie 
Stained         
59A Stained slightly slanted, ends not great yes yes yes 
58B Stained fine ac K yes yes yes 
58B Jesse 
Stained redo yes yes yes 
53B Stained use redo by Kelsie yes yes yes 
53B Jesse use redo by Kelsie yes yes yes 
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Stained 
52 Stained check with K yes yes yes 
52 Jesse Stained use redo by Kelsie yes yes yes 
51B Stained slightly slanted, may be ok yes yes yes 
51B Kelsie 
Stained         
51 Stained stain on edges, may be ok yes yes yes 
46 Stained ??       
44 Stained 
slanted, maybe messy stain, 
could be ok yes yes yes 
41B Stained use redo by Kelsie yes yes yes 
41B Kelsie 
Stained         
41B Jesse 
Stained maybe ok, maybe use K's yes yes yes 
39B Stained redo yes yes yes 
39B Kelsie 
Stained         
38B Stained good yes yes yes 
38 Stained ??       
38 Kelsie Stained         
35B Stained use redo by Kelsie       
35B Kelsie 
Stained         
35B Jesse 
Stained use redo by Kelsie yes yes yes 
34B Stained fine, some chunks yes yes yes 
33 Stained use redo by Kelsie yes yes yes 
33 Kelsie Stained         
33 Jesse Stained use redo by Kelsie yes yes yes 
29 Stained 
scraggly edges, slanted, needs 
extra attention yes     
23 Stained 
scraggly edges, needs extra 
attention yes     
22B Stained good yes yes yes 
170 Stained slightly slanted, but probably ok yes yes yes 
17 Stained messy, needs extra attention yes     
169 Stained too thick, needs extra attention yes     
169 Kelsie 
Stained         
168 Stained stain on edges yes yes yes 
167 Stained 
slanted, ends chunked, lots of 
stain chunks yes     
167 Kelsie         
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Stained 
166B Stained good, edges just meh yes yes yes 
165 Stained slanted and ends chunked yes yes yes 
164 Stained good, but slanted yes yes yes 
162 Stained a little messy, but may be ok? yes yes yes 
161 Stained good, but slanted yes yes yes 
160A Stained 
stain on edges, maybe have K 
redo yes yes yes 
159 Stained stain on edges, but probably ok yes yes yes 
158 Stained 
good, but slightly slanted, may 
be ok yes yes yes 
156 Stained good yes yes yes 
155 Stained 
random splotches, should be 
easy to fix yes     
154 Stained 
stain chunks, maybe only on 
edges yes     
154 Kelsie 
Stained         
153 Stained too thick, needs extra attention yes     
153 Kelsie 
Stained         
152 Stained square, but ok, ends not great yes yes yes 
151 Stained good, ends are just meh yes yes yes 
149 Stained slanted, missing pieces? yes     
134 Stained 
big chunks of bone missing and 
weird stain yes     
128 Stained good, but slanted yes yes yes 
123B Stained good, but slightly slanted yes yes yes 
122B Stained slanted, scraggly, but not terrible yes yes yes 
122A Stained too thick, needs extra attention yes     
122A Kelsie 
Stained         
121 Stained slightly slanted, thick?? yes     
12 Stained fine yes yes yes 
118 Stained good yes yes yes 
116 Stained 
stain chunks in middle, needs 
extra attention yes     
116 Kelsie 
Stained         
113 Stained good yes yes yes 
112 Stained too thick, needs extra attention yes     
112 Kelsie 
Stained         
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APPENDIX E 
PRELIMINARY ITS AND MICRODAMAGE RESULTS 
 
Notes: The protocol outlined in Appendix C was followed to obtain the following 
results. Briefly, the femoral neck cancellous cores from Chapter 5 were compressed to 
3% strain, stained with LUA for microdamage, and analyzed using ITS software. The 
results detailed here are on the inner 6 mm diameter and 6 mm length core which 
minimizes damage due to specimen prep (coring and cutting) and mounting for 
mechanical testing (gluing ends).  
 
The following specimens were successfully analyzed for microdamage and trabecular 
morphology with the ITS software, but they are not age-matched or otherwise paired: 
 
 
Group 
Core 
Number 
Age A1C 
Non-DM 9 68 5.45 
Non-DM 12 62 5.37 
Non-DM 123B 66 5.65 
Non-DM 128 51 5.56 
Non-DM 151 67 5.80 
Non-DM 152 55 5.10 
Non-DM 159 58 5.10 
T2DM 34B 85 6.16 
T2DM 88 68 7.08 
T2DM 156 56 5.70 
T2DM 162 61 6.00 
T2DM 164 63 6.80 
T2DM 166B 58 8.70 
T2DM 170 54 9.30 
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Figure 1: Damaged volume per bone volume categorized by ITS by (B) plate vs. rod, 
(C) longitudinal vs. transverse vs. oblique, and (D) plate/rod and orientation for each 
specimen. Non-DM group specimens are to the left of the vertical dashed line and 
T2DM group specimens are to the right. There were no significant differences 
between groups for the above classifications of damage. 
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Figure 2: (A) Plate and rod volume per bone volume. (B) Longitudinal, transverse, or 
oblique orientation per bone volume. Non-DM group specimens are to the left of the 
vertical dashed line and T2DM group specimens are to the right. There were no 
significant differences between groups for the above classifications of trabeculae. 
